0.9649519354	matrix metalloproteinase
0.9647068551	portal vein
0.9621351554	bone marrow
0.9604580222	signal transduction
0.9603878938	cyclin d1
0.9601639947	ionizing radiation
0.9597938990	autosomal dominant
0.9592959673	histone deacetylase
0.9587897980	vitamin b6
0.9587123615	quinone oxidoreductase
0.9586838912	amino acids
0.9583584848	benign prostatic hyperplasia
0.9581278219	histone h3
0.9579217292	nadph oxidase
0.9579068885	mesenchymal stem cells
0.9577418998	smooth muscle
0.9571039107	monoclonal antibody
0.9568329368	rheumatoid arthritis
0.9567514933	alkaline phosphatase
0.9566097933	cytochrome p450
0.9559283561	caffeic acid
0.9555275392	fatty acids
0.9555205804	polycyclic aromatic hydrocarbons
0.9553556184	phospholipase a2
0.9553152930	eicosapentaenoic acid
0.9552199848	mass spectrometry
0.9549817817	monoamine oxidase
0.9547948869	neuropathic pain
0.9547266905	valproic acid
0.9543973254	myocardial infarction
0.9541722840	hepatocellular carcinoma
0.9541341426	open reading frame
0.9541259691	monoclonal antibodies
0.9540272809	frontal cortex
0.9538657358	diabetes mellitus
0.9533368690	organic anion transporting polypeptide
0.9532602749	glutathione peroxidase
0.9530593053	retinoic acid
0.9528411666	cerebrospinal fluid
0.9522339499	sciatic nerve
0.9517995242	glomerular filtration rate
0.9517329654	adenylyl cyclase
0.9515774005	skeletal muscle
0.9510423905	allergic rhinitis
0.9509712961	adipose tissue
0.9507520062	adenylate cyclase
0.9504910938	qt interval
0.9503141982	thymidylate synthase
0.9502697049	nicotinic acetylcholine receptor
0.9501664548	aspartate aminotransferase
0.9500095322	naturally occurring
0.9499735901	adverse event
0.9498425071	chronic obstructive pulmonary disease
0.9497708495	body mass index
0.9496874564	lipid peroxidation
0.9495378489	medroxyprogesterone acetate
0.9493428404	heparan sulfate
0.9491655220	tandem mass spectrometry
0.9488956780	polyethylene glycol
0.9488584400	green tea
0.9487763692	inflammatory bowel disease
0.9486414293	reactive oxygen species
0.9482127103	tyrosine hydroxylase
0.9482043940	positron emission tomography
0.9479095538	coronary artery
0.9478342956	gastric emptying
0.9477462968	spinal cord
0.9476885781	voltage clamp
0.9476651860	hypoxia inducible factor
0.9476592670	arachidonic acid
0.9475615398	drinking water
0.9474754529	hydrogen bond
0.9473663084	alternative splicing
0.9470914275	single nucleotide polymorphisms
0.9470252172	hydrogen peroxide
0.9470230465	colorectal cancer
0.9468223835	gel electrophoresis
0.9467144471	heart failure
0.9462861637	prefrontal cortex
0.9462217616	poorly understood
0.9459516986	acute liver failure
0.9458152013	carbon nanotubes
0.9457758102	tyrosine kinase
0.9453838125	bone mineral density
0.9453435041	multidrug resistance
0.9452959967	mesenteric arteries
0.9447728580	propidium iodide
0.9444868166	adverse events
0.9442789180	rhesus monkey
0.9442499106	chromatin immunoprecipitation
0.9440796517	dna damage
0.9440677730	acetic acid
0.9439423983	fluticasone propionate
0.9434269578	liquid chromatography
0.9433285894	bone resorption
0.9432314387	nucleus accumbens
0.9426749597	wound healing
0.9426309296	prostate cancer
0.9423428838	basilar artery
0.9423246023	voltage gated
0.9423188798	vas deferens
0.9421635758	hydrogen bonds
0.9421296888	argininosuccinate synthetase
0.9418806102	cyclic amp
0.9416547814	weight gain
0.9415400123	major depressive disorder
0.9412719700	mm hg
0.9411602950	aryl hydrocarbon receptor
0.9411563868	blood pressure
0.9411007745	site directed mutagenesis
0.9410741202	sulindac sulfide
0.9409531736	hpa axis
0.9408690814	malonyl coa
0.9407934792	surface plasmon resonance
0.9407933322	brugada syndrome
0.9407833263	transforming growth factor
0.9406406313	tumor necrosis factor
0.9406388236	fatty acid
0.9405619690	gap junction
0.9403990680	northern blot
0.9402711069	vascular endothelial growth factor
0.9401965381	superoxide dismutase
0.9401682245	polymerase chain reaction
0.9401598817	small interfering rna
0.9401237299	nerve injury
0.9400981279	steady state
0.9399448171	dihydrofolate reductase
0.9399276963	congestive heart failure
0.9398085837	medicinal chemistry
0.9397349859	epidermal growth factor
0.9395828967	erectile dysfunction
0.9393402447	prostaglandin e2
0.9392082466	luciferase reporter
0.9391044496	middle cerebral artery occlusion
0.9390128724	cysteinyl leukotriene
0.9389931331	unfractionated heparin
0.9389263513	vitamin b12
0.9389249142	triamcinolone acetonide
0.9386079228	carbonic anhydrase
0.9385139237	reverse transcription polymerase chain reaction
0.9382737324	dorsal root ganglion
0.9382442426	western blotting
0.9381993837	left atria
0.9381918638	hmg coa reductase
0.9380667158	phenylalanine hydroxylase
0.9380325094	neurite outgrowth
0.9380101996	endoplasmic reticulum
0.9379593883	splice variants
0.9379540793	insulin sensitivity
0.9379500595	long term
0.9379170982	alanine aminotransferase
0.9378443489	angiotensin converting enzyme
0.9378221722	pertussis toxin
0.9377753022	mesenteric artery
0.9375898839	object recognition
0.9372152810	patch clamp
0.9370790802	oxidative stress
0.9369885259	body weight
0.9366531058	ascorbic acid
0.9365961403	mammary gland
0.9364300357	clinical trials
0.9363650111	pyridoxal phosphate
0.9362967814	mg dl
0.9360984565	golgi apparatus
0.9359810066	polyunsaturated fatty acids
0.9359154814	lymph node
0.9359092661	diabetic retinopathy
0.9359006251	bcr abl
0.9356641002	tranexamic acid
0.9355835923	tricyclic antidepressants
0.9353392727	hydrogen sulfide
0.9351436519	saccharomyces cerevisiae
0.9349177042	methionine adenosyltransferase
0.9348567459	genome wide
0.9347051066	fibroblast growth factor
0.9345825678	bundle branch block
0.9343370129	luteinizing hormone
0.9342022008	folic acid
0.9340063174	glutamic acid
0.9339972056	bile acids
0.9339574242	base pair
0.9338130408	heart rate
0.9336296111	ulcerative colitis
0.9333422141	guinea pigs
0.9331104006	odds ratio
0.9331042944	dissociation constant
0.9330467769	ornithine decarboxylase
0.9326842565	confocal microscopy
0.9322698190	nicotinic acetylcholine receptors
0.9322464109	gallic acid
0.9322054662	insulin resistance
0.9318584606	positive allosteric modulator
0.9318403692	thromboxane a2
0.9316294339	acute myeloid leukemia
0.9315890651	factor xa
0.9315095040	mecasermin rinfabate
0.9313490138	left ventricular
0.9311994258	docosahexaenoic acid
0.9311269927	low density lipoprotein
0.9310051146	western blot
0.9306975140	bronchoalveolar lavage fluid
0.9305347281	guinea pig
0.9304160694	united states
0.9304090161	flow cytometry
0.9302963196	bovine serum albumin
0.9302108355	breast cancer
0.9301705424	ubiquinone oxidoreductase
0.9300593127	strand breaks
0.9300047718	western blots
0.9299196258	platelet aggregation
0.9297325607	escherichia coli
0.9296354338	messenger rna
0.9292163952	epigallocatechin gallate
0.9290587791	ng ml
0.9290032783	nicotinamide adenine dinucleotide
0.9287948075	diastolic blood pressure
0.9284380709	coronary heart disease
0.9283216124	bile acid
0.9282854736	glucose tolerance
0.9279741795	100mg kg
0.9279565879	transcription factor
0.9277471827	rate constants
0.9276855491	cell line
0.9276036635	lactate dehydrogenase
0.9274160733	nucleic acid
0.9273029737	constitutive androstane receptor
0.9272199178	tumor suppressor
0.9271554131	125i icyp
0.9270845752	caenorhabditis elegans
0.9270686963	attention deficit hyperactivity disorder
0.9269681909	mitogen activated protein kinase
0.9265662887	reverse transcriptase polymerase chain reaction
0.9265224674	okadaic acid
0.9264862175	hydrogen bonding
0.9262365895	double blind
0.9260650119	cgp 12177a
0.9260585649	essential oils
0.9258784468	amino acid
0.9256135677	oic acid
0.9255792925	radical scavenging
0.9254345874	p38 mapk
0.9254260826	helicobacter pylori
0.9252913602	glial fibrillary acidic protein
0.9252517432	cyclic adenosine monophosphate
0.9248760364	ethylene glycol
0.9248543986	µg ml
0.9248041883	weight loss
0.9245946896	multiple sclerosis
0.9245938137	bcl xl
0.9244347725	food intake
0.9242779981	cerebral ischemia
0.9241509602	synaptic transmission
0.9240871629	medial prefrontal cortex
0.9239491563	nick end labeling
0.9238457034	cell cycle
0.9236191195	glycemic control
0.9235911232	carboxylic acids
0.9233871314	reverse transcriptase
0.9233568087	rating scale
0.9233303891	tyrosine kinases
0.9232443103	ferulic acid
0.9232085007	public health
0.9231064588	dna methylation
0.9230916878	trna synthetase
0.9230075481	carbon tetrachloride
0.9229619313	nitric oxide
0.9225848933	amyotrophic lateral sclerosis
0.9224903309	angiotensin ii
0.9222984549	cell death
0.9221520272	superior cervical ganglion
0.9221129120	proximal tubules
0.9219592045	sinapic acid
0.9217093621	abdominal aorta
0.9215876527	systolic blood pressure
0.9215107153	dynamic light scattering
0.9214016325	thyroid hormone
0.9213257155	nasal mucosa
0.9211248240	substantia nigra
0.9209457054	ventral tegmental area
0.9208618702	orally bioavailable
0.9207583216	platelet derived growth factor
0.9207543197	white matter
0.9205719138	extracellular signal regulated kinase
0.9205148717	factor viii
0.9205072193	oatp1a 1b
0.9204419465	serine hydroxymethyltransferase
0.9202435015	cell cycle arrest
0.9202180518	acetyl coa carboxylase
0.9200134673	glutamic acid decarboxylase
0.9198571032	ibritumomab tiuxetan
0.9197983454	confidence intervals
0.9197142043	arsenic trioxide
0.9196710692	ribonucleotide reductase
0.9196542153	inducible nitric oxide synthase
0.9196425170	adrenal gland
0.9195821558	niflumic acid
0.9195573746	olmesartan medoxomil
0.9191445360	cigarette smoke
0.9189498239	artemisinic acid
0.9186298550	lipoic acid
0.9186280309	copyright ©
0.9184698824	nitric oxide synthase
0.9183058673	carboxylic acid
0.9181429653	organic anion transporting polypeptides
0.9181377964	ovarian cancer
0.9180692960	short term
0.9180539943	aspidin pb
0.9178989786	mast cell
0.9178620786	proximal tubule
0.9173583512	ischemia reperfusion
0.9173542069	green fluorescent protein
0.9172308862	autosomal recessive
0.9168276364	body weight gain
0.9167221694	atrial natriuretic peptide
0.9165787963	topoisomerase iialpha
0.9164586347	adenosine triphosphate
0.9164566786	electrospray ionization
0.9162811816	amyloid precursor protein
0.9161100701	thiobarbituric acid reactive
0.9160187452	carnitine palmitoyltransferase
0.9157581592	nuclear factor kappab
0.9157097452	chronic myeloid leukemia
0.9156533801	proinflammatory cytokines
0.9156237750	takes place
0.9153540898	progression free survival
0.9153165643	cell lines
0.9151918155	high density lipoprotein
0.9150203365	leydig cell
0.9149831094	sudden death
0.9147325360	circular dichroism
0.9146994307	factor ix
0.9146276870	microg kg
0.9144538836	paw edema
0.9140705426	sialic acid
0.9139639167	glutamine synthetase
0.9139186971	nonsteroidal anti inflammatory drugs
0.9135144362	room temperature
0.9133384199	35s gtpgammas
0.9131492026	advance online publication
0.9129991762	gas chromatography
0.9127325360	choroid plexus
0.9127254651	growth hormone
0.9127167544	memory consolidation
0.9125697238	qtc interval
0.9124100084	dihydroorotate dehydrogenase
0.9122329697	dried blood spots
0.9117969072	salicylic acid
0.9117443940	nitrosative stress
0.9116802560	missense mutations
0.9116507027	muromonab cd3
0.9116044628	nmr spectroscopy
0.9115227306	biliary excretion
0.9112969548	nuclear factor κb
0.9112312918	oleanolic acid
0.9111945254	renal cell carcinoma
0.9108012177	anterior pituitary
0.9107494865	methionine synthase
0.9106448909	ccaat enhancer binding protein
0.9106409796	gastric mucosa
0.9105977237	dentate gyrus
0.9103049765	thymidine incorporation
0.9099316602	structure activity relationships
0.9098537475	dna fragmentation
0.9095532615	lymph nodes
0.9095511794	statistically significant
0.9092105277	flow cytometric
0.9091385300	db db mice
0.9089761082	prostate specific antigen
0.9085224215	cardiac hypertrophy
0.9084551864	negatively charged
0.9084172591	lipid rafts
0.9080686121	electrophoretic mobility
0.9078657086	mitogen activated protein kinases
0.9075448376	ventricular myocytes
0.9071110385	transcription factors
0.9070549629	gram negative
0.9067699168	rna interference
0.9067007694	neutral endopeptidase
0.9066527045	infarct size
0.9066378565	long acting
0.9065421862	50mg kg
0.9062767321	topoisomerase ii
0.9060121967	nicotinic acid
0.9057281760	dna repair
0.9057182248	endometrial cancer
0.9056217051	candesartan cilexetil
0.9055005895	vascular smooth muscle
0.9054560111	penile erection
0.9054250278	mast cells
0.9052586888	life threatening
0.9052120773	nedocromil sodium
0.9050747726	widely distributed
0.9047924128	oral glucose tolerance test
0.9046335305	high fat diet
0.9046242685	amp activated protein kinase
0.9043648127	molecular weight
0.9042660639	healthy volunteers
0.9040531552	lower urinary tract symptoms
0.9039218693	cell viability
0.9038308260	oxidative damage
0.9038052878	ethnopharmacological relevance
0.9035340401	ellagic acid
0.9032793260	imatinib mesylate
0.9032488914	squalene epoxidase
0.9031746313	synaptic plasticity
0.9031675434	heavy chain
0.9031030233	cystic fibrosis
0.9030267484	inhibitory potency
0.9029498177	colon cancer
0.9029238731	freely moving
0.9028828137	splice variant
0.9023470766	nuclear translocation
0.9022503945	estramustine phosphate
0.9021961741	cross linking
0.9020370484	cell cycle progression
0.9019612740	chlorogenic acid
0.9018383035	nonsteroidal antiinflammatory
0.9017359784	arabidopsis thaliana
0.9016474351	nf κb
0.9014969360	pgh synthase
0.9014964491	serine threonine
0.9012155148	lu af21934
0.9010604634	benzoic acid
0.9008575037	neuromuscular junction
0.9007395994	local anesthetics
0.9006714846	intraocular pressure
0.9005095359	aldo keto
0.9004084909	acyl coa
0.9003859582	matrix metalloproteinases
0.9001703204	chinese hamster ovary
0.9001011777	bronchoalveolar lavage
0.8998839819	dose dependently
0.8997529618	renal failure
0.8997234357	udp glucuronosyltransferase
0.8997021578	neurodegenerative diseases
0.8996114440	computed tomography
0.8995029902	parathyroid hormone
0.8994856774	tricyclic antidepressant
0.8992955488	ursolic acid
0.8991181392	kcnq2 q3
0.8990504955	sr 141716a
0.8989999878	cardiovascular risk
0.8988407842	virtual screening
0.8983953842	brush border
0.8982427340	essential oil
0.8981446786	cardiovascular disease
0.8980452323	electron microscopy
0.8977480137	dna polymerase
0.8975757493	gonadotropin releasing hormone
0.8973683403	endocrine disrupting
0.8971336395	nervous systems
0.8969861555	energy balance
0.8968810639	immune responses
0.8968570538	gonadotrophin releasing hormone
0.8968109556	aerial parts
0.8966732925	cyclo oxygenase
0.8965999875	map kinase
0.8963036042	wild type
0.8961773820	ifn gamma
0.8961766112	anti inflammatory
0.8961002805	low molecular weight heparins
0.8960969392	nerve terminals
0.8959338844	blood flow
0.8958546858	working memory
0.8958269017	sprague dawley rats
0.8958014119	tumor growth
0.8957051036	factor xiif
0.8956918740	peptidylarginine deiminase
0.8956116971	serine racemase
0.8954484197	pc12 cells
0.8951359126	allosteric modulators
0.8949873428	tnf α
0.8947435425	long lasting
0.8944910325	insulin secretion
0.8944288143	blood glucose
0.8941775137	tumour necrosis factor
0.8940596368	gastric mucosal
0.8934288966	μg ml
0.8930299324	zinc finger
0.8929646056	risk assessment
0.8929021597	pulmonary fibrosis
0.8927738452	active site
0.8926053243	voltage dependence
0.8921843879	st segment elevation
0.8921453876	liver microsomes
0.8920121382	phenolic acids
0.8918200732	intercellular adhesion molecule
0.8918057629	tnf alpha
0.8917424588	pi3k akt
0.8917172793	norepinephrine transporter
0.8916339164	transient receptor potential
0.8915759659	advanced glycation end products
0.8914885334	half life
0.8912726274	rt pcr
0.8912247571	nmda receptor
0.8911742357	zebrafish embryos
0.8911656975	delayed rectifier
0.8909634961	uvb irradiation
0.8908925685	knockout mice
0.8908029917	aldehyde dehydrogenase
0.8905213131	clinically relevant
0.8904592842	gamma glutamyl
0.8904549649	glur5 kainate
0.8903504080	gamma aminobutyric acid
0.8898844802	null mice
0.8898214674	10mg kg
0.8897988984	inverse agonists
0.8896202048	xenopus laevis oocytes
0.8894269514	airway smooth muscle
0.8892726876	extracellular matrix
0.8892209373	aldehyde oxidase
0.8890192762	mu opioid receptor
0.8887731646	light chain
0.8886593274	hydroxysteroid dehydrogenase
0.8886559326	micrograms kg
0.8886556897	pancreatic cancer
0.8884462048	alanine transaminase
0.8881677114	cognitive enhancers
0.8880040022	consecutive days
0.8879346399	heat shock protein
0.8877639300	cdna library
0.8876257531	phase ii
0.8876133886	lipid metabolism
0.8873546363	linoleic acid
0.8871842534	streptozotocin induced diabetic
0.8870584691	histamine h2 receptor
0.8868734699	nf kappab
0.8868595438	ang ii
0.8866452397	anaplastic thyroid
0.8865765526	glycaemic control
0.8862703139	biologically active
0.8862217626	vesicular monoamine transporter
0.8862210460	thymidine kinase
0.8862033557	transition state
0.8861461776	high throughput screening
0.8860512657	tgf β1
0.8859056956	peroxisome proliferator
0.8855569434	sds page
0.8853997066	gm csf
0.8852769399	radioligand binding
0.8851894099	constitutively active
0.8848799620	interleukin 1beta
0.8846951978	small molecule
0.8845413069	metabotropic glutamate receptors
0.8841392667	drug discovery
0.8841370366	organic cation
0.8840323780	glycogen synthase kinase 3β
0.8837710988	microg bid
0.8837708840	amino acid residues
0.8837128457	antioxidant defense
0.8834054215	free radical
0.8832627244	β catenin
0.8830227265	nr1 nr2a
0.8828414403	white adipose tissue
0.8826001529	serotonin transporter
0.8821067008	beta endorphin
0.8820747756	pulmonary hypertension
0.8820524603	natural product
0.8820521787	gastrointestinal stromal
0.8819900677	animal models
0.8819713538	adrenoceptor subtype
0.8818819741	inverse agonist
0.8818301101	base pairs
0.8818102760	cyclin dependent kinase
0.8816511806	kg bw
0.8816242649	estrogen receptor
0.8814608108	dopamine d1
0.8814348975	sergliflozin etabonate
0.8813810557	cross talk
0.8813723077	organic anions
0.8810150287	mc3t3 e1
0.8810024401	sprague dawley
0.8807939393	er stress
0.8807751588	postprandial hyperglycemia
0.8801124297	enzyme linked immunosorbent assay
0.8800916395	fmol mg
0.8800413065	ko mice
0.8798766676	optic cup
0.8798679749	p450 2a13
0.8795744734	michaelis menten
0.8793874162	binding sites
0.8792389952	androgen receptor
0.8792244445	chloride channel
0.8788917323	udp glucuronosyltransferases
0.8787241270	pituitary gland
0.8786138815	broad spectrum
0.8785140925	adrenergic receptors
0.8781390590	signaling pathways
0.8781036081	steroid hormone
0.8773903020	epidermal growth factor receptor
0.8773584465	dipeptidyl peptidase
0.8773473684	leydig cells
0.8770252920	aggressive behavior
0.8770202692	mechanical allodynia
0.8767768842	electron transfer
0.8767426678	placebo controlled
0.8766807866	special issue entitled
0.8766680917	dim dim
0.8766508658	adrenergic receptor
0.8765323066	adipocyte differentiation
0.8763899402	hyp ·
0.8762245433	negatively regulates
0.8761097556	mineralocorticoid receptor
0.8760477259	transmission electron microscopy
0.8758955847	serine protease
0.8758405670	mass spectrometric
0.8758144890	odds ratios
0.8757092919	alcohol consumption
0.8755562758	tgf beta1
0.8755407557	il 1beta
0.8754155852	glutathione reductase
0.8751974839	basal ganglia
0.8751022184	mg kg
0.8750217687	recent advances
0.8748807087	combination therapy
0.8748351031	diabetic nephropathy
0.8747172194	phase iii trials
0.8747152339	proximal tubular
0.8746050169	structure activity relationship
0.8744910931	sterol regulatory element binding protein
0.8743826060	actin remodeling
0.8742099591	fatty acid synthase
0.8741743376	microg ml
0.8741431699	xenopus laevis
0.8741346702	channel opener
0.8740083178	alpha 2a adrenoceptor
0.8738098365	c57bl 6j
0.8735805058	arginine vasopressin
0.8735768231	tgf β
0.8733204077	cytokine production
0.8732977809	signaling pathway
0.8728986320	inflammatory mediators
0.8728327953	essential hypertension
0.8725563107	nuclear magnetic resonance
0.8724132426	cognitive deficits
0.8722473861	glucose uptake
0.8721843455	partial agonist
0.8719841778	aqueous solution
0.8719194006	selective serotonin reuptake inhibitors
0.8717244644	iib iiia
0.8714059776	physiologically relevant
0.8711542691	solid tumors
0.8710889558	gpiib iiia
0.8710346465	small intestine
0.8710250952	real time polymerase chain reaction
0.8708936527	translation initiation
0.8700917268	blood brain barrier
0.8699179976	glutathione s transferase
0.8699130837	adp ribose
0.8699082854	anticancer agents
0.8698977549	organic anion
0.8698579318	discriminative stimulus
0.8697803919	mixed micelles
0.8697228391	pain relief
0.8694793876	fc gamma
0.8692955648	ig module
0.8690458742	factor vii
0.8688498221	hif 1α
0.8688413811	motor coordination
0.8687751422	qrt pcr
0.8687635566	raas blockade
0.8686582414	major depression
0.8686315696	pulmonary artery
0.8683284018	gp iib iiia
0.8679764400	hif 1alpha
0.8676192046	il 1β
0.8675500321	promyelocytic leukemia
0.8669730828	glutamate decarboxylase
0.8669276208	stem cell
0.8667794500	blood samples
0.8666299364	longer term
0.8663508333	inactivated state
0.8662021009	high performance liquid chromatography
0.8659211790	multidrug resistant
0.8656063096	inversely correlated
0.8653371389	cell adhesion
0.8652846245	⁻ ¹
0.8651877175	adenosine monophosphate
0.8650338659	mda mb 231
0.8649959470	active metabolite
0.8648421767	atherosclerotic lesions
0.8643241011	creatine kinase
0.8643226598	epithelial cells
0.8643149454	apoptotic cell death
0.8641548764	apo ciii
0.8639744137	pressor response
0.8638802181	endothelial dysfunction
0.8638099449	long qt syndrome
0.8631462055	bone mass
0.8628839698	qt syndrome
0.8623441957	cross linked
0.8623280157	glucose homeostasis
0.8622868531	real time pcr
0.8618450783	atypical antipsychotic
0.8613298946	molecular modeling
0.8607584247	potassium channel
0.8606603761	peroxisome proliferator activated receptor
0.8605637404	molecular dynamics simulations
0.8600227357	glucose stimulated insulin secretion
0.8599611557	western blot analysis
0.8598010326	reading frame
0.8597593044	mammary glands
0.8596288864	natriuretic peptide
0.8591960144	releasing hormone
0.8591430456	particle size
0.8590845592	glucose intolerance
0.8588107559	small molecules
0.8583331077	channel blockers
0.8583215287	atypical antipsychotics
0.8582254643	mitochondrial dysfunction
0.8582029057	thromboxane b2
0.8581235238	gsh px
0.8581072123	family members
0.8580877731	pyruvate kinase
0.8580369569	drg neurons
0.8579296353	pancreatic islets
0.8579106477	tumor necrosis factor alpha
0.8578477945	catalytic efficiency
0.8576553212	micromol kg
0.8575784988	tertiary amine
0.8572350388	nerve agents
0.8568364656	myo inositol
0.8567110146	male rats
0.8565108758	ion channels
0.8564927402	nmda receptors
0.8564612746	vascular permeability
0.8564578670	human embryonic kidney
0.8564246001	radix glycyrrhizae
0.8563024004	gsk 3β
0.8560303277	outcome measures
0.8558730310	antioxidant capacity
0.8557518443	osteoblast differentiation
0.8557020702	esi ms
0.8555122494	aqueous extract
0.8555121013	cyclic nucleotide
0.8553340367	tissue engineering
0.8549682173	thioredoxin reductase
0.8548528375	brain derived neurotrophic factor
0.8546365261	inflammatory diseases
0.8544547044	john wiley & sons
0.8544195376	exposed workers
0.8538282040	serine dehydratase
0.8537302833	hepg2 cells
0.8536173577	β ionone
0.8535973102	coronary arteries
0.8535435297	blood vessels
0.8534579841	tumor necrosis factor α
0.8533773857	nuclear factor
0.8532756770	hepatic steatosis
0.8531652337	cell proliferation
0.8528975257	myosin light chain
0.8527923296	linolenic acid
0.8526444132	cross sectional
0.8523896746	beta blockers
0.8523109701	single nucleotide polymorphism
0.8522269552	lipid raft
0.8520856637	excision repair
0.8515096509	water maze
0.8513141882	acquired resistance
0.8511885160	red blood cells
0.8510289010	breast cancer resistance protein
0.8507715436	fish oil
0.8504152359	beta adrenergic
0.8503327323	electrical stimulation
0.8500945258	review summarizes
0.8499880396	pdgf bb
0.8498454775	progenitor cells
0.8498410620	catechol o methyltransferase
0.8497909122	methylenetetrahydrofolate reductase
0.8497090185	alpha 1a adrenoceptor
0.8495057572	binding affinities
0.8494882369	pro inflammatory cytokines
0.8494336366	glucagon secretion
0.8493551248	sodium iodide
0.8493184991	11beta hsd
0.8492432448	allergic asthma
0.8490999274	dietary supplements
0.8490177708	mg bid
0.8489640293	pro inflammatory
0.8489285106	phase iii
0.8489144499	hmg coa
0.8488184210	voltage dependent
0.8487499498	xenopus oocytes
0.8486691042	steroid hormones
0.8484920776	binding site
0.8483992165	coronary artery disease
0.8483544273	dna methyltransferase
0.8483036975	actin rings
0.8482685998	mitochondrial membrane potential
0.8477344683	total cholesterol
0.8476555261	3beta adiol
0.8476542449	sk n sh
0.8473522902	aortic rings
0.8473175557	glucocorticoid receptor
0.8471190641	wistar rats
0.8470452402	targeted therapies
0.8468787384	remain unclear
0.8467625616	calcitonin gene related peptide
0.8467339953	vagal control
0.8467332767	crystal structures
0.8466652919	sertoli cells
0.8465883954	blood coagulation
0.8464098976	ca3 region
0.8463606928	physico chemical
0.8462473175	fluorescence microscopy
0.8462424933	dna topoisomerase ii
0.8461968871	low dose
0.8461766357	plasminogen activator
0.8461582502	topical ocular
0.8458954563	remains unclear
0.8457480550	double strand
0.8455130147	bovine tracheal smooth muscle
0.8455102036	carbetocin metabolite
0.8454832524	drug delivery
0.8453443478	sh sy5y
0.8450898971	type plasminogen activator
0.8446916422	arterial pressure
0.8445882644	fasting glucose
0.8445702076	water soluble
0.8444217550	avoidance task
0.8444115154	silica nanoparticles
0.8443755527	pregnane x receptor
0.8439455330	niemann pick
0.8438832026	positive inotropic effect
0.8436186336	hdl cholesterol
0.8435255564	α glucosidase
0.8434840361	peroxisome proliferator activated receptor gamma
0.8433184760	mucin secretion
0.8431665520	ic50 values
0.8430803856	mir 193a 3p
0.8430578602	ras dva
0.8430228515	low density lipoprotein cholesterol
0.8429581110	aminobutyric acid
0.8428907732	hydroxamic acid
0.8427411075	family member
0.8426761464	clinical trial
0.8426583983	colon carcinoma
0.8426430407	deficient mice
0.8425157750	ubiquitin ligase
0.8420008691	transmembrane domain
0.8419215437	c57bl 6j mice
0.8417996705	nf kb
0.8414507196	transplant recipients
0.8414497438	differentially expressed
0.8411012895	pyramidal neurons
0.8409808080	mek erk
0.8409473648	topo iialpha
0.8407894356	ischemic stroke
0.8407322978	neurodegenerative disorders
0.8405734554	active site gorge
0.8405332284	cardiac output
0.8403617531	conditioned medium
0.8402933936	clinical relevance
0.8401420639	amino acid sequence
0.8399911035	granulosa cells
0.8397498353	disease progression
0.8396680105	rat hepatocytes
0.8396212452	pharmacokinetic pharmacodynamic
0.8395851838	insulin like growth factor
0.8395504955	nh2 terminal
0.8395233427	norepinephrine reuptake
0.8392386500	phasic da
0.8392088558	transiently transfected
0.8386565981	mtt assay
0.8385772643	ethyl acetate
0.8384361050	glp 1r
0.8384140633	breast carcinoma
0.8383939829	diabetic rats
0.8383122810	splice site
0.8380598507	transient transfection
0.8378640314	fxi pka4
0.8375881446	calcium channels
0.8372826278	pharmacokinetic profiles
0.8371248600	confidence interval
0.8369887876	spatial memory
0.8368482816	muscarinic m2
0.8365850308	metal ions
0.8365162170	percutaneous coronary
0.8361956476	lipid lowering
0.8356592366	microarray analysis
0.8355577597	lactic acid
0.8355277920	innate immune
0.8353655123	a549 cells
0.8352736799	drug drug interactions
0.8352408579	risk factors
0.8351119296	17β estradiol
0.8350304990	tissue plasminogen activator
0.8346791131	pro apoptotic
0.8346663144	cell migration
0.8344099372	newly synthesized
0.8343831160	gold nanoparticles
0.8342289855	genetic variation
0.8337343429	transgenic mice
0.8331501305	pgc 1α
0.8329055529	prepulse inhibition
0.8320199178	mg kg body weight
0.8319752582	bone formation
0.8319554724	fasting plasma glucose
0.8318918049	endothelial cells
0.8317364297	previously reported
0.8317192400	dopamine d2 receptor
0.8315167311	adrenoceptor subtypes
0.8309229105	alpha ketoglutarate
0.8308976675	growth factor
0.8307182077	type ii
0.8306333346	inflammatory pain
0.8305485359	progesterone receptor
0.8301025320	metabotropic glutamate
0.8300950347	3t3 l1 adipocytes
0.8299059008	comet assay
0.8298449436	mld stz
0.8297289287	type 2 diabetes mellitus
0.8296690556	aortic endothelial
0.8295042823	lps stimulated
0.8292444421	protective effect
0.8290735633	hypothalamic pituitary adrenal
0.8288828852	human liver microsomes
0.8288393226	response element
0.8287275787	hela cells
0.8283190479	histamine h3 receptor
0.8283086782	class iii
0.8282760755	ifn α2a
0.8280859395	hs crp
0.8280471677	gram positive
0.8279071438	ceftazidime avibactam
0.8278789898	jio gan
0.8278198355	nr1 nr2b
0.8278018772	substrate specificity
0.8276043356	sr bi
0.8275985687	high density lipoprotein cholesterol
0.8275918009	camp response element binding protein
0.8270135822	positively charged
0.8269866215	adrenoceptor antagonist
0.8268936787	cognitive impairment
0.8266272401	cell survival
0.8266074872	crystal structure
0.8265121746	mammary epithelial cells
0.8264638123	homa ir
0.8264633043	ifn γ
0.8263149676	cell types
0.8260664322	mrna abundance
0.8259517440	sphingosine 1 phosphate
0.8259243971	beta lactamase
0.8259030190	canonical wnt signaling
0.8258764154	male wistar rats
0.8257892089	multivariate analysis
0.8255973691	insulin detemir
0.8254915609	multiple myeloma
0.8251443172	dominant negative
0.8249691241	5alpha reductase
0.8249187082	gaba transaminase
0.8246906943	renal tubular
0.8246767344	safety profile
0.8245550408	dissociation constants
0.8245494728	clinical significance
0.8244680748	glutathione s transferases
0.8244299017	molecular docking
0.8244212215	renin angiotensin aldosterone
0.8244148968	high risk
0.8243476904	adverse effects
0.8242813692	tolerability profile
0.8241231663	injected intraperitoneally
0.8240493999	interferon gamma
0.8239432381	micromolar range
0.8239390408	ampa receptor
0.8236174774	aromatase inhibitors
0.8235599664	nonselective cox
0.8235463584	17beta estradiol
0.8234307469	interleukin 1β
0.8230766633	rodent models
0.8230450193	neurological disorders
0.8229890635	molecular mass
0.8226884793	neuronal death
0.8226466900	iron overload
0.8223788640	phosphoinositide 3 kinase
0.8222871339	pg ml
0.8221781686	heme oxygenase
0.8219116802	concentration response curves
0.8216425864	histamine h1
0.8211913820	lipid mediators
0.8211269863	rbl 2h3
0.8209903698	review article
0.8209117160	alcohol dependence
0.8208329955	active ingredient
0.8206149708	chain length
0.8205681557	cdna encoding
0.8204805064	monoamine transporters
0.8204070034	accumulating evidence
0.8200993503	healthy subjects
0.8195982748	endothelium dependent
0.8194208955	nerve growth factor
0.8193043484	colony stimulating factor
0.8192603591	beta lactamases
0.8192435834	drug metabolizing enzymes
0.8189668914	traditional chinese
0.8188327651	female rats
0.8186635776	enzymatically active
0.8183449307	db db
0.8183041459	adhesion molecules
0.8182334890	endothelial cell
0.8178387303	mcf 7
0.8175315047	protein tyrosine phosphatase 1b
0.8171224755	synthetic progestins
0.8169820293	al 4943a
0.8166255175	5mg kg
0.8163478006	betaine homocysteine
0.8162898260	bone turnover
0.8161014466	thyroid cancer
0.8159490291	g1 phase
0.8157706857	voltage gated sodium
0.8157451413	cortical neurons
0.8153720591	hek293 cells
0.8152391002	therapeutic window
0.8152221422	tgf beta
0.8149416956	half maximal
0.8149411789	physicochemical properties
0.8148916930	maximum tolerated
0.8146198851	human bronchial epithelial
0.8145060570	nanomolar range
0.8140047504	anti proliferative
0.8136158423	critical roles
0.8135475110	endothelial nitric oxide synthase
0.8132021813	cerebral cortex
0.8131204149	srebp 1c
0.8128581310	dopamine transporter
0.8127937206	single stranded
0.8125177409	anti diabetic
0.8123470261	brain regions
0.8120870004	gene transcription
0.8118080128	spontaneously hypertensive
0.8115726184	dna adducts
0.8115421502	histamine h1 receptor
0.8114642703	growth plate
0.8112757456	cardiovascular events
0.8112423101	growth factors
0.8108627124	adenosine a2a receptor
0.8106966358	methionine synthase reductase
0.8102292398	freshly isolated
0.8101735463	remained unchanged
0.8101191854	at1 receptor
0.8098671180	methyl ester
0.8098544315	underlying mechanisms
0.8095914136	acute pancreatitis
0.8095546352	late onset
0.8093853093	c2 domain
0.8092497278	guanine nucleotide
0.8092201185	α tocopherol
0.8092081354	kat ii
0.8091931682	alcohol dehydrogenase
0.8091695322	point mutations
0.8091290415	free fatty acids
0.8091017571	high resolution
0.8090773551	long chain fatty
0.8089497735	cerebral ischemic
0.8089460073	dorsal root
0.8087202772	control subjects
0.8086366336	highly conserved
0.8080714000	dna synthesis
0.8076543463	mismatch repair
0.8072639027	atp sensitive potassium
0.8072131363	flt3 itd
0.8071789328	aromatic l amino acid decarboxylase
0.8069674124	autoimmune diseases
0.8068990265	ifn alpha
0.8067742599	metabotropic glutamate receptor
0.8062795793	wnt signaling
0.8060655783	chemical warfare
0.8059287392	firing rate
0.8058624745	ay mice
0.8057880616	hormonal therapy
0.8057293477	high affinity
0.8057195685	nuclear import
0.8056994489	oral bioavailability
0.8056017894	hazard ratio
0.8055735602	retinal ganglion
0.8055023639	metabolic syndrome
0.8054040742	previous studies
0.8050571190	mammalian target of rapamycin
0.8047836394	glucose lowering
0.8047219694	locomotor activity
0.8045487571	dendritic cells
0.8044701193	mda mb
0.8043724838	fusion protein
0.8042609001	neural tube
0.8039254122	remain unknown
0.8037184515	abstract truncated at 250 words
0.8036931291	insulin sensitizing
0.8033242267	dissociation rate
0.8031562038	gastric acid secretion
0.8030792846	binding pocket
0.8029319843	type iii
0.8028542227	large scale
0.8028414912	ser sec
0.8026664692	tumor xenografts
0.8025801198	rapidly absorbed
0.8025638072	benign prostatic
0.8025493538	colony formation
0.8021312631	membrane vesicles
0.8017676351	head and neck
0.8016739891	genes encoding
0.8015789373	structural determinants
0.8014513648	mu opioid receptors
0.8011355668	beta2 adrenergic
0.8010908554	extracellular loop
0.8010164075	plasma renin activity
0.8008109761	gas phase
0.8007751526	advanced breast cancer
0.8005905739	bone loss
0.8003025340	mtorc1 signaling
0.8001805979	met camo
0.8001205559	amiloride sensitive
0.7999201403	cardiovascular diseases
0.7997964265	gamma secretase
0.7996724086	respiratory chain
0.7993056093	breast cancers
0.7988483634	largely unknown
0.7987392277	xenograft models
0.7986667953	anxiety disorders
0.7985790363	cationic amino acid
0.7985628470	current knowledge
0.7985025222	thiazide sensitive
0.7984453992	structurally diverse
0.7983988735	negative regulator
0.7982219945	opioid receptors
0.7981470359	preclinical studies
0.7980484891	myocardial ischemia reperfusion
0.7980153529	responsive element
0.7979518207	histamine h1 receptor antagonists
0.7978809962	end point
0.7977694207	dried blood
0.7973986048	permeability transition
0.7971668925	brush border membrane
0.7970403026	hyp * ·
0.7969627230	dependent manner
0.7968682400	pmol mg
0.7967327786	flanking region
0.7965769159	orders of magnitude
0.7965505247	mmol kg
0.7963506625	cognitive function
0.7963147394	alpha glucosidase
0.7959042366	ternary complex
0.7957442653	conformational change
0.7957061887	organic anion transporter
0.7956931961	alpha tocopherol
0.7953661983	bcl 2
0.7952524623	atrial natriuretic
0.7951768157	completely abolished
0.7951192632	beneficial effect
0.7949388152	alpha 1b adrenoceptors
0.7948940396	insulin granules
0.7946678759	stably expressing
0.7944478656	cancer cell lines
0.7944102890	p38 mitogen activated protein kinase
0.7943134116	aryl hydrocarbon
0.7940948686	reporter gene
0.7940755486	mouse embryonic fibroblasts
0.7940268184	previous reports
0.7940112646	kinetic parameters
0.7938722393	rate constant
0.7938367419	inflammatory cytokines
0.7938108628	protein phosphatase
0.7935176964	trp channels
0.7935030718	advanced glycation end
0.7934094739	α sma
0.7933775984	extracellular signal regulated
0.7931606833	β d glucuronide
0.7930938021	sodium salicylate
0.7930907777	pharmacokinetic profile
0.7930400403	healthy individuals
0.7929920625	remains unknown
0.7928815679	ppar γ
0.7928472606	tgf alpha
0.7927605948	tumor regression
0.7924044105	bronchial epithelial cells
0.7922796203	heterologously expressed
0.7921212590	fructose fed
0.7919201767	crossover study
0.7918575713	tracheal smooth muscle
0.7918438635	long qt
0.7917499232	immune response
0.7916543794	chromaffin cells
0.7912442602	alpha synuclein
0.7909635577	open field
0.7906993494	3t3 l1
0.7905780059	orally administered
0.7904635600	postmenopausal women
0.7902012059	energy homeostasis
0.7900293090	nonselective nsaids
0.7900133738	molar ratio
0.7898133861	liver damage
0.7895824582	fda approved
0.7894654503	structural similarity
0.7892344333	pituitary adrenal axis
0.7891479233	discriminative stimulus effects
0.7886723999	receptor antagonist
0.7884103619	airway epithelial cells
0.7881854460	cyslt1 receptor
0.7880373450	subjective effects
0.7868999743	plant extracts
0.7866789274	cisplatin induced nephrotoxicity
0.7861205910	orally active
0.7853042055	protein tyrosine phosphatase
0.7851778861	cell culture
0.7851316552	epidemiological studies
0.7850885655	protective role
0.7850647155	monophosphate dehydrogenase
0.7848785155	meta analysis
0.7844709121	cell surface
0.7841067509	drug drug interaction
0.7838786402	squamous cell
0.7836637102	peripheral blood
0.7835031282	inflammasome activation
0.7830159109	spontaneously hypertensive rats
0.7828440202	igf 1r
0.7826557783	phosphatidylinositol 3 kinase
0.7824926451	organic anion transport
0.7823041126	cross resistance
0.7820617120	lung injury
0.7819778528	myocardial ischemia
0.7819138035	channel blocker
0.7818045135	glycogen synthase
0.7816152754	heat shock
0.7814430284	peripheral blood mononuclear cells
0.7813495327	mild to moderate
0.7809766467	adrenoceptor agonist
0.7803274718	hl60 cells
0.7802231157	hydroxysteroid dehydrogenase type
0.7796553100	anti angiogenic
0.7794600311	gamma carboxylase
0.7793924036	imidazoline receptors
0.7791176632	open label
0.7789981016	binding mode
0.7789011584	pge2 production
0.7786486717	cell growth
0.7784082244	subtype selective
0.7782506698	dorsal raphe
0.7782080729	rank order
0.7777377711	3h paroxetine binding
0.7776908935	binding affinity
0.7776207239	receptor occupancy
0.7776141654	long chain
0.7771336873	single strand
0.7767970857	high throughput
0.7767294005	male sprague dawley rats
0.7767028418	glp 1
0.7757953267	fatty liver disease
0.7757206706	phenolic compounds
0.7756288610	il 6
0.7751684543	primary endpoint
0.7749020490	dopamine d3
0.7748597220	receptor subtypes
0.7745828756	receptor tyrosine kinases
0.7745739472	vp 16
0.7745601713	tissue factor
0.7743503901	elimination half life
0.7741825819	ion channel
0.7741110205	toxic effects
0.7737837654	stably transfected
0.7737209428	muscarinic receptor
0.7736685142	structurally related
0.7736084576	adenosine a1
0.7735412309	molecular cloning
0.7730627053	impaired glucose tolerance
0.7727279122	sequence identity
0.7722846670	opioid receptor
0.7722779357	healthy controls
0.7722484308	forskolin stimulated
0.7720880680	lc ms ms
0.7720868569	gene expression
0.7720114976	tight binding
0.7718077034	sr b1
0.7712610702	spontaneous locomotor activity
0.7711809710	findings suggest
0.7709600136	blood pressure and heart rate
0.7709319966	anti apoptotic
0.7705319283	gnrh ii
0.7705071342	mk 801
0.7703632920	ht 29
0.7700759692	corticotropin releasing
0.7699955152	ethanol consumption
0.7699455193	akt phosphorylation
0.7696931778	nucleoside transporters
0.7693333673	alzheimer disease
0.7692764914	acetyl coa
0.7690386258	alpha2 adrenoceptor
0.7688851472	ach release
0.7688168385	dopamine d2
0.7687459334	μg kg
0.7683443486	highly potent
0.7677977092	3β diol
0.7676793098	rat aorta
0.7676311299	nerve agent
0.7675427511	patients receiving
0.7674748318	μ opioid
0.7674267305	antitumor activity
0.7671724373	small interfering
0.7669605960	action potentials
0.7666148851	ppar gamma
0.7664060575	significantly attenuated
0.7651286816	endothelium derived
0.7649877129	treated rats
0.7649169241	genomic dna
0.7648529101	northern blot analysis
0.7647390434	treatment options
0.7643067234	metastatic breast cancer
0.7639334914	quality of life
0.7637666505	neurotransmitter release
0.7637512176	pi3k akt pathway
0.7633500814	β cell function
0.7630923311	low molecular weight
0.7628070587	ns 398
0.7626698344	phospho akt
0.7626185985	hl 60
0.7619344707	beta adrenoceptor antagonists
0.7618194697	derived neurotrophic factor
0.7617264634	dopaminergic neurons
0.7612454666	protected by copyright
0.7612076719	structural features
0.7610381146	tsg 6
0.7608217590	randomly assigned
0.7600776333	peroxisome proliferator activated receptor alpha
0.7600029729	insulin dependent diabetes
0.7596797863	nucleotide sequence
0.7596034572	morbidity and mortality
0.7596015497	ros production
0.7595038933	fold higher
0.7591033592	adult onset
0.7589704147	biological evaluation
0.7587973473	kd values
0.7586882576	cognitive performance
0.7586690713	nonsteroidal anti inflammatory drug
0.7584756531	emission tomography
0.7584111080	cd1 mice
0.7584098338	natural products
0.7583438520	food and drug administration
0.7581467803	small cell lung
0.7577076353	long term potentiation
0.7577075952	functional role
0.7570030879	dna replication
0.7567539979	tas 102
0.7567392534	tyrosine kinase inhibitor
0.7566646478	anticancer activity
0.7566498986	oocytes expressing
0.7562363206	type 2 diabetes
0.7560785012	reuptake inhibitors
0.7559120883	ampa receptors
0.7559090645	peroxisome proliferator activated
0.7553377074	clinical practice
0.7551503800	amino terminal
0.7545980826	mrna expressions
0.7545390619	da uptake
0.7543509801	type ii collagen
0.7541563477	creb phosphorylation
0.7541286657	body fat
0.7540429446	serine threonine kinase
0.7539184360	peroxisome proliferator activated receptor γ
0.7538386458	ph responsive
0.7537993788	ribosomal protein
0.7536806397	lung cancer
0.7535692932	zeta potential
0.7534838951	promoter region
0.7532353300	bde 47
0.7530716914	higher doses
0.7528077965	catalytic subunit
0.7526020745	adiponectin levels
0.7525447845	induced neurotoxicity
0.7524078618	fat mass
0.7523979213	mmp 9
0.7521645453	arginase ii
0.7520882789	lung carcinoma
0.7519812556	mechanisms underlying
0.7517652586	primary hepatocytes
0.7505903082	ca ii
0.7505863311	neuroprotective effects
0.7505786213	phenyl ring
0.7504583919	caspase 3
0.7504294874	mobility shift
0.7504095831	acth and corticosterone
0.7500865207	therapeutic targets
0.7497621716	pai 1
0.7496911120	chinese hamster
0.7496408650	response rate
0.7491177196	il 2r
0.7490431169	generally well tolerated
0.7486695799	chemotherapeutic agents
0.7485334352	surface area
0.7485019620	kappa opioid receptors
0.7484100604	rat cerebral cortex
0.7483203819	hippocampal slices
0.7483113583	hfd fed
0.7482532031	point mutation
0.7482311167	administered orally
0.7481285773	renal interstitial
0.7479425204	x ray crystallography
0.7477760065	short acting
0.7477207345	ligand binding
0.7476828147	exendin 4
0.7474550849	completely reversed
0.7468836150	glucagon like peptide
0.7466786683	molecular dynamics
0.7466734843	high fat
0.7466052540	celecoxib and rofecoxib
0.7464583340	β cell mass
0.7463414496	serum testosterone
0.7462945675	hql 79
0.7461899755	hct 116
0.7459248163	mice lacking
0.7458572110	post translational
0.7457485225	positron emission
0.7456646701	diabetic mice
0.7452167616	structure based design
0.7451951940	human serum albumin
0.7451171144	amyloid β
0.7450922785	fold higher affinity
0.7450747665	learning and memory
0.7449399758	middle cerebral artery
0.7448084536	recent studies
0.7446742734	serum creatinine
0.7445313607	vascular endothelial cells
0.7444068185	human umbilical vein endothelial cells
0.7442667271	plasma membrane
0.7438664126	clinical efficacy
0.7436161308	drug resistance
0.7433264816	drug interactions
0.7429607204	dopamine d2 receptors
0.7429137542	recent findings
0.7428528680	ganglion cell
0.7428301277	hippocampal neurons
0.7422324544	clinical signs
0.7420763176	treated animals
0.7419918473	deleterious effects
0.7419890898	heparin binding
0.7414287329	cholesterol lowering
0.7410995029	se deficiency
0.7410044238	completely blocked
0.7408013330	concentration time curve
0.7406519356	glycogen synthase kinase
0.7406415577	catalytic domain
0.7404778261	d2 receptor
0.7403967202	enzyme activities
0.7402889762	clinical utility
0.7398468965	ace inhibitor
0.7394772782	lesser extent
0.7394477830	c jun
0.7393352945	acyl coa synthetase
0.7392747955	binding cassette
0.7391614558	antioxidant activities
0.7391268317	abt 384
0.7388525378	cell membranes
0.7383352365	calcitonin gene related
0.7381047692	serum albumin
0.7380673246	alpha 1a adrenoceptors
0.7377960196	real time rt pcr
0.7377178030	intracellular calcium
0.7375481625	data suggest
0.7372902946	rank order of potency
0.7372367592	patients undergoing
0.7370027956	drug metabolism
0.7368927875	5 meo dmt
0.7368195674	clinical benefit
0.7367183777	women with pcos
0.7366615120	hydroxyl group
0.7366143642	lavage fluid
0.7364404929	liver cytosol
0.7363392816	gestational diabetes
0.7361413305	early stage
0.7361041353	intercellular adhesion
0.7359907400	renal fibrosis
0.7357966499	free energy
0.7357437527	liver injury
0.7355067552	dipeptidyl peptidase 4
0.7349232029	brain natriuretic peptide
0.7347672162	il 10
0.7347005033	amino acid transporter
0.7345437719	physiological role
0.7345124315	lncap cells
0.7343939428	histamine h1 receptor antagonist
0.7341031491	lung tissue
0.7340488739	hormone receptor positive
0.7338974836	lung fibroblasts
0.7334502802	peripheral blood mononuclear
0.7334300264	nude mice
0.7333321058	disease modifying
0.7333144166	recombinant human
0.7332431144	abt 288
0.7330496686	control group
0.7329986010	glucose transporter
0.7328203841	female mice
0.7327593062	rate limiting
0.7324410243	group ii
0.7320991845	heme oxygenase 1
0.7319766401	arginine transport
0.7319686614	recently approved
0.7319601992	1h pyrazole
0.7319438195	cardiac remodeling
0.7319318287	testosterone to estradiol
0.7315532650	kappa opioid receptor
0.7315064557	95 confidence interval
0.7314977353	ici 182
0.7311555734	mir 663
0.7309202152	stem cells
0.7309147976	nf kappab activation
0.7307673521	pde4 inhibitors
0.7305298459	fat body
0.7301231804	ros generation
0.7300164352	spatial learning
0.7297165220	treated groups
0.7281600686	anticancer drug
0.7276077764	add on therapy
0.7275733227	transcriptional regulation
0.7274096996	pharmacokinetic and pharmacodynamic
0.7271635723	sh sy5y cells
0.7270299093	highly homologous
0.7269253170	signalling pathway
0.7267313941	glial cells
0.7267245127	nmda receptor antagonists
0.7265433708	metabolizing enzymes
0.7264941220	d2 dopamine
0.7262923781	breast tumors
0.7260172945	platelet activation
0.7257922657	fp receptor
0.7257644624	chronic heart failure
0.7257585271	beta adrenoceptor
0.7257298746	acinar cells
0.7256934761	cytotoxic effect
0.7256681911	antiproliferative effects
0.7255581503	human umbilical vein endothelial
0.7254988939	oxidized glutathione
0.7254954611	response curve
0.7254485749	tnf α and il
0.7254451369	ho 1
0.7253505890	lead compound
0.7251754451	calcitonin receptor
0.7250949677	male mice
0.7250368361	type ii diabetes
0.7245864606	e2 related factor 2
0.7243595457	gastrointestinal tract
0.7241636940	element binding protein
0.7238929855	inhibitory activity
0.7237345190	hepatic fibrosis
0.7236121355	calcium channel
0.7235317116	3 methylglutaconic aciduria
0.7234770364	endothelial function
0.7232897250	cp 778 875
0.7232473463	apoptosis inducing
0.7231355865	mrna expression
0.7230401857	case control study
0.7228909268	ace inhibitors
0.7228229461	cysteine residues
0.7227900184	white adipose
0.7226093060	dopamine d4
0.7225356049	order of magnitude
0.7221595974	central nervous
0.7220983677	mrna level
0.7219438247	tumor progression
0.7219157355	flow rate
0.7218541786	ici 118
0.7215521193	higher risk
0.7212801041	dna topoisomerase
0.7212553472	inhibitory activities
0.7209678623	ache and bche
0.7207647432	alpha 1 adrenoceptor
0.7206305857	amino acid sequences
0.7205689736	antioxidant status
0.7205437910	5 methyl urapidil
0.7203882373	17 beta hsdxi
0.7203775971	immune cell
0.7203607433	copyright © 2013 john wiley &
0.7201006922	5 ht2a
0.7200133164	cultured rat hepatocytes
0.7195473376	raw 264
0.7193147563	efflux transporters
0.7193027232	neurotrophic factor
0.7189712222	recognition site
0.7184018118	protein kinase
0.7183374250	3h rs 15385 197
0.7183125381	antiepileptic drug
0.7181374458	target genes
0.7181227522	cell invasion
0.7181083398	signal transducer and activator of transcription
0.7180251064	endocrine therapy
0.7171682259	concentration dependently
0.7170407935	insulin signaling
0.7170041905	adrenoceptor stimulation
0.7169806875	x ray diffraction
0.7169201598	trep 132
0.7165796361	rs 17053
0.7165595485	thyroid cancers
0.7163251401	n acetylglucosamine
0.7160104070	breast cancer risk
0.7158911108	l bmaa
0.7158531082	mrna levels
0.7158126707	il 8
0.7156021184	5 ht1b
0.7155861597	neurotoxic effects
0.7150967224	jth 601
0.7150130501	liver glycogen
0.7149804955	controlled trials
0.7147094096	safe and effective
0.7146623469	nuclear factor kappa
0.7146265070	plasma membranes
0.7145784249	mouse model
0.7145335740	cho cells
0.7145051829	antidepressant drugs
0.7144371906	therapeutic doses
0.7143902868	mammary epithelial
0.7143861245	potently inhibits
0.7143675943	da release
0.7143671391	vcam 1
0.7138544838	cardiac dysfunction
0.7138418035	mouse hepatocytes
0.7137748002	myeloma cells
0.7135816997	non small cell lung cancer
0.7135443974	hek 293 cells
0.7134808087	nuclear accumulation
0.7134087947	pathological conditions
0.7133390197	antioxidant enzymes
0.7132416194	partial agonists
0.7132266445	male and female
0.7131096996	invasion and metastasis
0.7123119991	covalent binding
0.7119665563	cdb 2914
0.7117564344	delta opioid receptor
0.7116165202	all rights reserved
0.7114641878	atpase activity
0.7113319273	dependent protein kinase
0.7112042136	potassium channels
0.7111379074	materials and methods
0.7109721463	drug candidates
0.7105627316	binding modes
0.7105109229	concentration response curve
0.7105069115	tunel positive
0.7104151570	phosphodiesterase type
0.7103940451	kim 1
0.7103597195	competitive inhibition
0.7103378453	platelet derived growth factor receptor
0.7099988655	migration and invasion
0.7098620181	lateral sclerosis
0.7097251336	nmda receptor antagonist
0.7096495855	protein protein interactions
0.7095561573	lc ms
0.7092245743	beta subunit
0.7090752726	selective agonist
0.7090376687	inflammatory bowel
0.7089934879	inflammatory responses
0.7088287147	ampk activation
0.7087579347	ppar alpha
0.7084179794	placebo controlled trials
0.7082140486	adhesion molecule
0.7081321315	solid state
0.7080180577	underlying mechanism
0.7078390393	drf 2655
0.7075460430	high glucose
0.7072651258	cox 2
0.7071781526	caspase activation
0.7071531778	jnk and p38
0.7069179653	newly developed
0.7067808543	adverse effect
0.7067644699	© 2013
0.7067594414	rna polymerase
0.7065454518	rat stomach
0.7064676239	transfected cells
0.7063104137	body wt
0.7062273783	colon cancer cells
0.7061614556	contractile response
0.7060606411	at1 receptor antagonist
0.7058500002	mglu receptor
0.7058184098	vehicle treated
0.7057992361	purkinje cells
0.7054665563	cdb 4124
0.7053751840	dld 1
0.7052150890	evidence suggests
0.7051994286	antiproliferative effect
0.7050632923	age and sex
0.7050471301	thyroid carcinoma
0.7049156765	atypical antipsychotic drugs
0.7047555734	bms 690514
0.7045033694	retinoid x receptor
0.7044019204	bms 354825
0.7041526205	human hepatoma
0.7040475550	significantly higher
0.7040366814	aimed to investigate
0.7036111061	lps induced
0.7035999769	neuronal damage
0.7035643480	anticancer drugs
0.7034925574	highest dose
0.7034769145	agonistic activity
0.7034436129	versus placebo
0.7033501013	n ethylmaleimide
0.7033409097	docking studies
0.7033366930	glutamate release
0.7032811904	ethanol withdrawal
0.7031464694	active metabolites
0.7030617843	muscarinic receptors
0.7029100304	wb 4101
0.7028956247	coa carboxylase
0.7026498620	e cadherin
0.7026483000	plasma glucose
0.7025633392	reduced glutathione
0.7023909995	energy metabolism
0.7022832356	ms ms
0.7022005197	clinical outcome
0.7021053023	liver fibrosis
0.7020199048	promoter activity
0.7020113978	significantly lowered
0.7019913148	insulin resistant
0.7019377956	therapeutic approaches
0.7017992935	vascular smooth muscle cells
0.7017745597	igf 1
0.7017678755	aminosalicylic acid
0.7015360605	epithelial na
0.7012104000	selectively inhibit
0.7009001412	c fos
0.7008069407	luciferase reporter gene
0.7005723314	glutathione conjugates
0.7005419666	chain acyl
0.7004904235	sodium channel
0.7003540006	immunohistochemical analysis
0.7001159403	significantly decreased
0.7001077103	apoptosis induction
0.7000351722	cholesterol efflux
0.6999888646	beta2 adrenoceptor
0.6995502369	therapeutic approach
0.6995362404	cultured rat
0.6993959808	reporter assay
0.6992563705	lipid profile
0.6991777958	sulfonylurea receptor
0.6990655663	reperfusion injury
0.6990333355	methyl group
0.6987584012	species differences
0.6985966233	β cell dysfunction
0.6985817343	blot analyses
0.6985022041	ml kg
0.6982527882	sms 201 995
0.6982273343	c57bl 6 mice
0.6979349916	receptor subtype
0.6979180996	significant improvement
0.6976823192	histamine release
0.6976152660	renin angiotensin
0.6974357004	5 ht1a
0.6972941434	receptor tyrosine kinase
0.6967721871	binding domain
0.6966992628	alpha 1d adrenoceptors
0.6966632851	3h oxotremorine m
0.6966597978	collagen type
0.6965439287	pcr and western blot
0.6965126010	transcriptional activity
0.6963395021	5 hydroxytryptamine
0.6961771682	beta blocker
0.6960976995	ca2 + entry
0.6960787998	renal function
0.6960558108	clinical pharmacology
0.6956479680	beta hsd
0.6952373352	beneficial effects
0.6952179514	multidrug resistance associated protein
0.6949569402	competition binding
0.6948407426	sensory neurons
0.6948116466	extended release
0.6946033964	p gp
0.6945627823	mouse models
0.6945514512	rat liver
0.6940797996	treated mice
0.6940135249	converting enzyme
0.6939939264	experimental design
0.6938650281	sgc 7901
0.6938287325	6 ohda
0.6935792028	evn 50
0.6935619476	short chain
0.6931824753	airway inflammation
0.6930727023	islet cell
0.6930530745	mcp 1
0.6928417006	metabolic pathways
0.6926584735	l oddc
0.6926263809	response rates
0.6925710313	lipocalin 2
0.6925224040	physiological processes
0.6923360600	alpha 1a and alpha
0.6921957449	antiviral activity
0.6920121933	tissue distribution
0.6919745211	kinase inhibitor
0.6917963035	cl l arg
0.6915955177	drug release
0.6915324813	all trans retinoic acid
0.6911537451	kinetic analysis
0.6910754008	high mobility
0.6906709997	non steroidal anti inflammatory drugs
0.6906498562	alpha 1b
0.6904451056	calmodulin dependent
0.6899182790	pi3k akt signaling
0.6899034164	neuroblastoma cells
0.6898133029	therapeutic strategy
0.6897277272	epithelial cell line
0.6896544210	efficacy and tolerability
0.6894544914	receptor antagonists
0.6892350027	enzymatic activity
0.6892291677	selective antagonist
0.6890580553	baseline values
0.6888370261	snap 25
0.6887004917	behavioral effects
0.6886078459	cannabinoid receptor
0.6883340950	acetylcholinesterase inhibitors
0.6882775799	analysis revealed
0.6882156076	antitumor agents
0.6881410618	5 ht1d
0.6877814126	5 ht1
0.6874593821	nitro l arginine
0.6871908637	5 ht2
0.6871246776	g protein coupled receptor
0.6869203943	x ray
0.6867516670	ischemia reperfusion injury
0.6867306711	amino groups
0.6865855206	clinically significant
0.6864186539	allosteric site
0.6863415110	post transcriptional
0.6862540382	heart disease
0.6859552121	twik 2
0.6856243378	nf κb activation
0.6855896545	dependently inhibited
0.6855643405	wt mice
0.6853884483	pharmacokinetic properties
0.6852409971	beta 1 adrenoceptor
0.6850656267	therapeutic strategies
0.6849959192	catalytic site
0.6847947706	beta amyloid
0.6847425594	muscarinic m2 receptor
0.6846987081	il 11
0.6846552980	depressed patients
0.6846533620	cholinesterase inhibitors
0.6845961146	dna damage response
0.6844124023	significantly increased
0.6843961511	cytochrome p450 enzymes
0.6843804481	glucose metabolism
0.6843364083	wild type and mutant
0.6841058911	norepinephrine transporters
0.6836203991	5 ht7
0.6835764583	animal model
0.6834780626	herg channels
0.6834525949	membrane potential
0.6833175066	clinical development
0.6832540522	gnrh receptor
0.6832267101	antipsychotic drugs
0.6830128816	solution structure
0.6829308000	adult male
0.6828669661	opposite effects
0.6828308929	stromal cells
0.6827966040	high performance liquid
0.6827400805	t bet
0.6823492129	nuclear receptors
0.6821917108	randomly divided into
0.6821171695	mode of action
0.6820104812	muller cells
0.6817255958	gain of function
0.6816963764	lipid accumulation
0.6814992138	lipid homeostasis
0.6814761543	obese women
0.6814272283	ns 49
0.6813252005	nuclear receptor
0.6813036834	background and purpose
0.6808454783	late stage
0.6808406793	lysine residues
0.6806474591	aromatase inhibitor
0.6802705047	erk1 2
0.6800986063	murine model
0.6800985628	protective effects
0.6800596271	pharmacokinetic parameters
0.6799963316	reactive oxygen
0.6799296468	l dopa
0.6798250735	energy transfer
0.6797362409	adrenoceptor antagonists
0.6796461590	in situ hybridization
0.6795905362	mice fed
0.6793305840	tnf alpha production
0.6792745780	nuclear factor kappa b
0.6792690522	striatal neurons
0.6789966242	replacement therapy
0.6788102245	human umbilical
0.6784896368	organophosphorus compounds
0.6784684857	tyrosine kinase inhibitors
0.6784337165	american society for
0.6783111864	high dose
0.6782590691	class ii
0.6781381269	vascular endothelial growth factor receptor
0.6779337415	3 hydroxy 3 methylglutaryl coenzyme
0.6778868508	hepatic uptake
0.6778782890	twik 1
0.6778123596	real time quantitative
0.6776608606	synovial cells
0.6773590118	egf receptor
0.6773165305	activating mutations
0.6772049520	bone marrow derived
0.6771153117	human hepatocytes
0.6768089088	5 ht3
0.6765852249	dose dependent
0.6764400435	p450 enzymes
0.6762435147	treated group
0.6761599406	gene therapy
0.6760166895	ec50 values
0.6760157900	functional characterization
0.6759012173	ml min
0.6757268559	glioma cells
0.6757264656	hd patients
0.6756644847	markedly reduced
0.6744787024	experimental approach
0.6742971963	dose dependent fashion
0.6738901057	rat brain
0.6738373661	recently discovered
0.6738151678	nuclear localization
0.6735767825	calcium dependent
0.6734668892	anti obesity
0.6733700458	p glycoprotein
0.6731949726	physiological functions
0.6731466455	canonical wnt
0.6731450003	kg body weight
0.6731267529	gender specific
0.6730550958	anti inflammatory properties
0.6727725266	mg daily
0.6727218811	kappa opioid
0.6723219432	rar beta
0.6721664795	beta 2 adrenoceptor
0.6720703739	induced tachycardia
0.6720300836	therapeutic intervention
0.6719311359	magnetic resonance
0.6718069901	gsh levels
0.6717954898	main outcome
0.6716951735	free medium
0.6716489641	retinoic acid receptor
0.6711970881	fas ligand
0.6710209402	inhibitory effects
0.6710092279	strongly suggest
0.6708815140	diet induced obesity
0.6708725855	9 hydroxyrisperidone
0.6707084028	antioxidant properties
0.6706958033	caspase 9
0.6706870075	differential effects
0.6699886826	human lung
0.6699745330	calcium homeostasis
0.6699689370	dna binding
0.6697956726	reverse transcription
0.6696719353	drug interaction
0.6695252544	designed and synthesized
0.6694193676	significantly greater
0.6693578675	biological functions
0.6693129909	gsk 3
0.6692967294	single doses
0.6692651357	volume of distribution
0.6691183013	oral administration
0.6689855454	major metabolite
0.6689320681	experimental models
0.6688466477	inos induction
0.6688154242	phase iii clinical trials
0.6686822384	interleukin 6
0.6685356426	human placental
0.6685162976	estrogen receptor alpha
0.6683720705	u937 cells
0.6682870658	5 ht6
0.6678510077	serotonin reuptake
0.6676627831	dpp 4
0.6676067767	cancer cells
0.6672615890	signal transduction pathways
0.6671300034	significantly improved
0.6670795898	cos 7 cells
0.6670780120	obese mice
0.6670000390	cell cultures
0.6668636736	pharmacological profile
0.6666881952	endothelial no synthase
0.6665253403	sensitive potassium
0.6664926031	crucial role
0.6664910640	8 oxog
0.6664373221	g2 m phase
0.6662121397	expression pattern
0.6661257482	extensively studied
0.6660504072	closely related
0.6655755008	limiting step
0.6654444356	gene promoter
0.6653040401	interfering rna
0.6652628785	signalling pathways
0.6652087503	alpha 1 adrenoceptors
0.6648956414	population based
0.6648288476	reuptake inhibitor
0.6645417632	mir 21
0.6644072497	peripheral tissues
0.6642582831	nf kappa b
0.6642263454	targeted agents
0.6640478767	animal studies
0.6637289626	h9c2 cells
0.6634721913	thiobarbituric acid
0.6634192418	metabolic disorders
0.6633689241	antioxidant activity
0.6631789479	cells expressing
0.6629762336	recent evidence
0.6621733141	significantly reduced
0.6618830206	acth secretion
0.6618553637	tyrosine phosphorylation
0.6618421278	potently inhibited
0.6617608671	mcl 1
0.6617049102	beta hydroxysteroid dehydrogenase
0.6616142369	molecular mechanisms
0.6613320660	intracellular camp
0.6611663335	action potential
0.6610783674	beta 2 adrenergic
0.6608954357	light scattering
0.6608861864	response curves
0.6608801747	human platelets
0.6605239748	molecular targets
0.6602426230	adaptive response
0.6600467821	central and peripheral
0.6599505245	caco 2
0.6598590002	therapeutic agents
0.6597505733	renal injury
0.6596817174	cytochrome c release
0.6595904665	drugs of abuse
0.6595805739	oxidative stress and apoptosis
0.6595589554	inotropic effects
0.6595180265	© 2013 john wiley & sons
0.6592168787	adjuvant therapy
0.6591200010	tissue damage
0.6590608548	voltage activated
0.6590062253	plasma homocysteine
0.6589951425	intraperitoneal injection
0.6586363800	tumor cells
0.6586329196	carnitine transport
0.6584427998	caspase 8
0.6581373449	drug development
0.6580438044	times higher
0.6578348717	daily dose
0.6575437586	insulin release
0.6574739593	alpha 1b adrenoceptor
0.6573090346	high grade
0.6572723235	anti tumor
0.6572209071	intrinsic activity
0.6571769600	oh dpat
0.6570427571	aromatase activity
0.6568988184	striatal dopamine
0.6568177795	randomized to receive
0.6565312587	p2 receptors
0.6563005261	results suggest
0.6562294745	biological processes
0.6562252092	ligand binding domain
0.6561281563	functional significance
0.6561241995	gnrh agonists
0.6559518941	metabolic pathway
0.6558413318	neutrophil apoptosis
0.6555976481	fatty acid metabolism
0.6555790446	inhibition constants
0.6553381526	patients taking
0.6553146685	quantitative rt pcr
0.6550868877	cytotoxic effects
0.6550797184	low affinity
0.6550598790	complex iv
0.6550193312	biochemical parameters
0.6550053693	vascular endothelial
0.6548985318	urinary excretion
0.6546794073	ki values
0.6545280659	transforming growth factor beta
0.6543455330	pghs 2
0.6543350813	times daily
0.6535847483	atp binding cassette
0.6534366194	independent manner
0.6534035349	alpha linolenic acid
0.6533117486	not fully understood
0.6532521080	6 hydroxydopamine
0.6531964654	ampk activity
0.6531601679	fold increase
0.6530853873	highest affinity
0.6530783689	cerebral artery
0.6528940491	n acetylcysteine
0.6528643113	bone metabolism
0.6527948081	15d pgj2
0.6525574052	neuronal cell death
0.6524449171	self assembled
0.6521920704	vitamin k dependent
0.6521011021	cleaved caspase 3
0.6519765309	previous study
0.6516711414	pivotal role
0.6516657321	dopamine receptors
0.6515224498	cox inhibitors
0.6512733368	highest concentration
0.6511687459	renin inhibitor
0.6508931231	diaphorase activity
0.6506214714	kinetic analyses
0.6503691612	anti cancer
0.6500076119	cytochrome c oxidase
0.6499246439	monoamine oxidase inhibitors
0.6497667539	src kinase
0.6496126584	colorectal cancer cells
0.6495025645	adenosine receptors
0.6494715443	lower affinity
0.6494466605	mrna and protein
0.6493926098	controlled trial
0.6490315011	regression analysis
0.6489425397	induces apoptosis
0.6487047053	peripheral site
0.6486290630	low level
0.6482597761	beta adrenoceptor agonists
0.6478992204	rats fed
0.6477855635	il 2r alpha
0.6476897838	vascular disease
0.6476748409	° c
0.6475950535	s adenosylmethionine
0.6475868019	critical role
0.6475461577	carcinoma cells
0.6474889798	anti oxidant
0.6474072627	concentration range
0.6471768011	thyroid tumors
0.6469654548	cell differentiation
0.6468488868	penicillin binding protein
0.6468263512	nick end
0.6467310270	healthy male
0.6464956680	body temperature
0.6464884869	type 1 diabetes
0.6462254896	alpha and beta
0.6460267656	murine macrophages
0.6460187085	age related
0.6451919238	catalytic activity
0.6450566158	rate limiting step
0.6448097865	down regulated
0.6447766685	single dose
0.6445749687	β cell
0.6445422311	intravenous administration
0.6443637392	reporter gene assays
0.6442083265	inos expression
0.6441811984	protein synthesis
0.6439714659	kidney injury
0.6438603342	expressed in xenopus oocytes
0.6431330544	cyp2b6 * 6
0.6430940923	endogenous opioid
0.6430735143	times more potent
0.6429549321	oxidative metabolism
0.6429410200	n terminus
0.6428400831	kinase inhibitors
0.6428315208	anticonvulsant activity
0.6425565936	ss rats
0.6423032716	selective cox 2 inhibitors
0.6420730344	abstract truncated at
0.6418510926	mg once daily
0.6417832498	acute and chronic
0.6417082702	atp competitive
0.6415638453	adrenoceptor density
0.6414973151	c reactive protein
0.6411152064	mitochondrial complex
0.6405673777	acute pain
0.6404892668	structure activity relationship studies
0.6403510409	wild type mice
0.6401892453	mrna content
0.6400966872	adrenoceptor blockade
0.6399876755	rfrp 3
0.6398270208	n methyl d aspartate
0.6397486888	related genes
0.6397115300	alpha thrombin
0.6395668441	17 aag
0.6391298618	5 htp
0.6391241126	atp competitive inhibitors
0.6390045431	1b 1d
0.6388965938	coagulation factor
0.6388578511	v2 receptor
0.6384729401	small intestinal
0.6382198805	rat striatum
0.6381554826	follow up
0.6380521272	based approaches
0.6378346098	clinical application
0.6376786362	rs 15385 197
0.6372161770	2 epimerase
0.6368433343	based drug design
0.6366872164	group iii
0.6366323384	potency and selectivity
0.6364908766	melanoma cells
0.6363008907	hypertensive patients
0.6361563188	pancreatic β
0.6360642829	alpha 2 adrenoceptor
0.6358917445	gene silencing
0.6354208422	uvb induced
0.6351011361	chronic pain
0.6349834323	camp production
0.6349580527	reuptake inhibition
0.6344328614	cardiac muscle
0.6343319829	insulin therapy
0.6339422050	glucagon like peptide 1
0.6335075589	8 tetrachlorodibenzo p dioxin
0.6333204412	liver tissue
0.6332248489	previously published
0.6332118661	glucocorticoid receptors
0.6327783900	6 shogaol
0.6327544988	preclinical and clinical
0.6326041798	anti allergic
0.6324709518	molecular markers
0.6321893856	5 ht1f
0.6319328814	control rats
0.6319137359	sodium channels
0.6313862466	anti inflammatory effects
0.6313279636	drug design
0.6313084837	gastric cancer
0.6312507498	central nervous system
0.6311313242	neurotensin receptor
0.6310693370	mao b
0.6309718595	reporter assays
0.6308451166	ovarian cancer cells
0.6307954605	mg kg day
0.6306150150	mao inhibitors
0.6305154453	acute phase
0.6303277717	tgf β signaling
0.6302294482	provide evidence
0.6294482728	beta and gamma
0.6294354530	plasma concentrations
0.6294161277	mmp 2 and mmp 9
0.6293821844	mediated transport
0.6292072649	hf rats
0.6291763374	diabetic patients
0.6291179471	ache activity
0.6290897442	antioxidant potential
0.6290461636	previously shown
0.6289354903	expressed in chinese hamster ovary
0.6289069353	α and β
0.6289056463	pdk 1
0.6288979001	protein level
0.6287905695	6 nitrotryptophan
0.6285192635	ca2 +
0.6284671309	human embryonic kidney 293
0.6283413544	renal vascular
0.6282431204	significantly suppressed
0.6281961106	whole cell patch clamp
0.6280245562	negative breast cancer
0.6278785522	pre treatment
0.6278433664	knock out mice
0.6278226190	non hodgkin
0.6277779470	ucp 3 mrna
0.6277633966	early phase
0.6277345226	significantly lower
0.6276675838	pharmacological effects
0.6270930024	cox 1
0.6270453138	3t3 l1 cells
0.6267155877	cancer progression
0.6262285718	cell membrane
0.6262251264	ganglion cells
0.6261928775	glutamate transporter
0.6260833579	human liver
0.6258459533	site directed
0.6257448819	terminal half
0.6257357457	il 18
0.6256359231	agonists and antagonists
0.6255400426	clinically important
0.6254923372	insulin receptor
0.6253990791	p38 mitogen activated protein
0.6253702385	vegf release
0.6253555796	glomerular filtration
0.6251684040	h1 receptor
0.6250662264	cholesterol biosynthesis
0.6250440062	molecular target
0.6249997655	contractions of rat
0.6248590443	anti metastatic
0.6245907094	target gene
0.6245772112	based chemotherapy
0.6244049640	alpha 1a
0.6243068484	balb c mice
0.6237459664	micromol l
0.6233986744	clinical studies
0.6232988994	kinetic properties
0.6231735038	g csf
0.6227283532	5 methoxytryptamine
0.6220815127	transporting polypeptide
0.6220422578	protein and mrna
0.6217637199	studies demonstrated
0.6217283532	5 ht1c
0.6212229455	nuclear factor of activated t cells
0.6210477723	icam 1
0.6205700194	gene regulation
0.6204321437	human ether
0.6203883458	low and high
0.6202001816	antagonistic activity
0.6200836654	proliferation and differentiation
0.6199740373	protein expressions
0.6198402317	methods and results
0.6197576575	c ebpβ
0.6197540070	remains poorly
0.6196982886	human breast
0.6196413215	order of potency
0.6195777181	igf i
0.6189069367	p selectin
0.6188784515	oestrogen receptor
0.6188666996	and neck squamous
0.6186763328	nervous system
0.6185494778	alpha 2c
0.6185215211	positive and negative
0.6185144058	human tumor cell lines
0.6182283532	5 ht4
0.6181580703	tumor cell lines
0.6181104283	beta cell function
0.6179842405	dopamine d4 receptor
0.6179424392	potential targets
0.6179079187	parental cells
0.6175339804	steroid receptor
0.6175000069	pharmacological properties
0.6169002964	treatment option
0.6167356686	rat and human
0.6165079906	inhibitory concentration
0.6163886070	er negative
0.6162761809	beta end
0.6162254632	b raf
0.6161026773	lfa 1
0.6158160973	neuronal survival
0.6152005195	b cell lymphoma
0.6151889589	retinoic acid receptors
0.6149248284	efficacy and safety
0.6145578289	mechanistic studies
0.6145192411	positive breast cancer
0.6144017383	previous findings
0.6141545372	week old
0.6141027702	erk phosphorylation
0.6140992364	ethanol induced
0.6139318466	membrane bound
0.6139056486	mediated contractions
0.6137893745	central role
0.6136295904	carbonic anhydrase inhibitors
0.6136106209	glial cell
0.6135260094	biological activities
0.6129226315	il 2
0.6126195930	dependent and independent
0.6126004219	cox 1 and cox 2
0.6125809832	caco 2 cells
0.6125753008	proteasome inhibitor
0.6122639370	t pa
0.6122052213	fgf 7
0.6121230394	protease inhibitors
0.6119758143	glucose oxidation
0.6119464802	cell mass
0.6119307837	twice daily
0.6117212664	antioxidant and anti inflammatory
0.6116088114	de novo
0.6115564527	fold lower
0.6114144946	structural and functional
0.6113867680	penicillin binding
0.6112600414	induced apoptosis
0.6111528791	once weekly
0.6110850729	beta 2 adrenoceptor density
0.6108148870	l cystine
0.6107846106	weeks of age
0.6107807132	bone mineral
0.6107151171	adult rat
0.6099739856	beta 2 adrenoceptors
0.6099129056	post injection
0.6095805006	binding assay
0.6094899543	inhibitory effect
0.6093969222	c terminal
0.6092247564	safety and efficacy
0.6090670290	human butyrylcholinesterase
0.6089995629	three dimensional
0.6088264165	human embryonic kidney 293 cells
0.6086738572	direct interaction
0.6085317961	therapeutic potential
0.6085057678	breast cancer cell lines
0.6081525376	knockout rats
0.6080882710	pi3k inhibitor
0.6078617006	serotonin reuptake inhibitors
0.6078584191	ex vivo
0.6075696242	monoamine transporter
0.6075508253	arsenic exposure
0.6074732908	triglyceride levels
0.6073883938	kinetic studies
0.6072935140	lower concentrations
0.6063487132	5 ht
0.6058864245	up regulated
0.6052892357	kinase activity
0.6050722992	markedly suppressed
0.6050244137	negatively correlated with
0.6049774269	results in increased
0.6049660563	mouse and human
0.6046773224	mapk pathway
0.6045139706	lung epithelial cells
0.6044842539	cancer risk
0.6044434575	activated protein kinase
0.6043954587	dif 3
0.6042707316	mediated apoptosis
0.6040081260	cultured human
0.6036482297	chronic inflammatory
0.6036029793	male subjects
0.6034000290	randomly divided
0.6033964272	fmol mg protein
0.6033303047	low nanomolar
0.6029430055	chronic lymphocytic
0.6028351268	higher concentrations
0.6028079038	dose range
0.6027125131	radiation induced
0.6022288271	pancreatic beta cells
0.6021382621	culture medium
0.6020017846	genetic variants
0.6018489039	dose related
0.6018188335	cortisol levels
0.6013781516	deficient cells
0.6012555082	aromatic hydrocarbons
0.6009321447	14 3 3epsilon
0.6008055882	inflammatory response
0.6007825211	expression and activity
0.6002602322	bioactive compounds
0.5999501474	experimental data
0.5996390325	full length
0.5996316211	angiotensin ii type 1 receptor
0.5991931116	active sites
0.5990532712	synthesized and evaluated
0.5988514963	adenosine receptor
0.5988229565	development and progression
0.5986339925	human and rat
0.5986043841	clinical evidence
0.5985600134	apoptotic pathway
0.5984462615	dopamine neurons
0.5984402565	mcf 7 cells
0.5983898682	recently reported
0.5983184803	alpha 2 adrenoceptors
0.5981317585	± 0
0.5980155807	therapeutic index
0.5979965244	beta adrenergic receptors
0.5979071434	synergistic effect
0.5978764509	2 nonenal
0.5977827442	receptor agonist
0.5974514161	mechanism of action
0.5972266991	hdl c
0.5969908888	functional characteristics
0.5969005401	knock down
0.5965866252	transmission electron
0.5965490743	cancer therapy
0.5964291306	response element binding protein
0.5963652209	down regulation
0.5962862404	this article reviews
0.5959607588	once daily
0.5959079029	brs 3
0.5958877632	gene encoding
0.5956644946	potent and selective
0.5955359689	liver and kidney
0.5951880191	annexin v
0.5949161847	kainate receptors
0.5948307570	hypertensive rats
0.5947041907	95 ci
0.5946926662	findings demonstrate
0.5946438172	selective antagonists
0.5945836151	glucose dependent
0.5945351839	dopamine receptor
0.5941730511	carried out
0.5941699353	beta adrenoceptors
0.5941639722	purified recombinant
0.5940957984	receptor agonists
0.5940258986	maximal response
0.5939679026	8 oh dpat
0.5938909195	induce apoptosis
0.5937469959	data demonstrate
0.5936226639	highly selective
0.5934665058	cancer cell line
0.5933444190	free fatty acid
0.5930826507	endothelin 1
0.5930761997	studies demonstrate
0.5930629865	mda mb 231 cells
0.5929319896	potent antitumor
0.5929023012	er β
0.5928134911	mechanism based
0.5926187435	design and methods
0.5922032061	results demonstrate
0.5921359913	mg2 +
0.5921255512	cav 1
0.5921234717	cardiovascular effects
0.5917873769	plasma glucose levels
0.5917119647	fold greater
0.5908793383	microtubule associated protein
0.5908654232	nucleotide binding
0.5906872448	de pointes
0.5906016433	5 ht2c
0.5904170007	cell morphology
0.5904148791	myeloid leukemia
0.5903366083	platelet function
0.5893264277	high fat diet induced
0.5892607269	ki 67
0.5892481440	saline treated
0.5892045682	n terminal
0.5890953321	research design and
0.5890101836	pc3 cells
0.5890002462	embryonic fibroblasts
0.5889702608	glioma cell
0.5885432405	whole body
0.5884695978	cells in culture
0.5881017571	first pass
0.5875494800	side chain
0.5871711653	breast cancer cells
0.5870333307	sgc 7901 cells
0.5867977128	l glutamate
0.5865553832	tumor tissue
0.5864465140	hiv 1
0.5862446235	cos 1 cells
0.5861464694	beta cell
0.5856415317	atp sensitive
0.5854720110	acute coronary
0.5853536664	histamine h3
0.5846664841	active form
0.5845798530	play important roles
0.5842686346	induced liver injury
0.5842118471	pghs 1
0.5840216071	physiological concentrations
0.5837697202	way 100635
0.5836044750	significant differences
0.5827707124	highly specific
0.5826344254	second messengers
0.5824351703	low density
0.5822937804	omega 3
0.5822406002	ldl c
0.5822119536	bmp 7
0.5821744395	fusion proteins
0.5821455326	commercially available
0.5820558264	hepg2 cell
0.5819510945	prostaglandin synthesis
0.5818920061	c myc
0.5815133695	cellular energy
0.5814110669	growth inhibition
0.5812700531	er α
0.5811353279	weeks of treatment
0.5808777000	d3 receptors
0.5807284780	et al
0.5805998515	5 aminosalicylic acid
0.5805184451	receptor blockade
0.5804194871	well tolerated
0.5802235036	p gp and bcrp
0.5801794706	cell apoptosis
0.5801614643	antipsychotic agents
0.5800909084	mitochondrial glutathione
0.5799711473	positive control
0.5799529440	lipopolysaccharide induced
0.5797914642	experimental animals
0.5796766468	adverse drug
0.5796039807	previously demonstrated
0.5795506950	cyp2b6 activity
0.5792729432	significantly elevated
0.5790566697	il 4
0.5789340122	structure and function
0.5788797665	airway smooth
0.5785688787	target tissues
0.5783163445	dynamics simulations
0.5782041989	stable disease
0.5781257565	induced cell death
0.5780944317	performance liquid chromatography
0.5779175667	kinase domain
0.5778796440	biological activity
0.5776801761	long term treatment
0.5774933824	mao inhibitor
0.5774634876	expression and function
0.5773699692	structure based
0.5769487255	l arginine
0.5760625653	significantly inhibited
0.5760489009	epithelial cell
0.5759942842	4 thiadiazole
0.5758120631	u pa
0.5756412811	significant difference
0.5750946278	atp dependent
0.5750773992	24 hours
0.5750519403	enzyme activity
0.5750442533	experimental model
0.5750415448	in pithed rats
0.5750409908	disease causing
0.5749293298	potential role
0.5747911551	glucose and insulin
0.5747618167	selectively inhibited
0.5740505411	glutamate receptor
0.5733546173	puma g
0.5729712813	data obtained
0.5725983654	patients with relapsed
0.5725553697	the general population
0.5725198849	human prostate
0.5722545967	dose dependently inhibited
0.5721897970	downstream signaling
0.5721036165	transgenic mouse
0.5720655795	tumor tissues
0.5720283126	therapeutic efficacy
0.5720002165	5 fu
0.5718488801	antioxidant and anti
0.5718424889	second messenger
0.5715827183	targeted therapy
0.5713995244	completely inhibited
0.5713686022	stress response
0.5710846288	β cells
0.5709923623	n acetyl
0.5707660335	c terminal domain
0.5704289785	cholesterol metabolism
0.5704156093	lead compounds
0.5703467675	h1 receptor antagonist
0.5702164015	vitamin e
0.5701432633	gene transfer
0.5700244925	beta 1 adrenoceptors
0.5694354027	concentration dependent
0.5693909979	single agent
0.5692324194	markedly inhibited
0.5689794717	mutant mice
0.5689258241	dietary exposure
0.5688884869	type 2 diabetic
0.5686051881	receptor subunits
0.5685804962	hek 293
0.5680940817	rat model
0.5678019042	hek cells
0.5672847851	noradrenaline release
0.5670141931	cyclooxygenase 2
0.5667049337	alcohol dependent
0.5662489164	endogenous ligand
0.5658314339	a go go related gene
0.5658093801	c jun n terminal kinase
0.5657400383	thyroid hormone receptor
0.5655063047	biological effects
0.5654748646	synthesis and structure activity
0.5651256483	observations suggest
0.5650965937	results confirm
0.5648274573	a 381393
0.5643589418	il 5
0.5640345343	human organic anion
0.5639365461	treated cells
0.5635669361	induced cytotoxicity
0.5635392922	estrogen receptor beta
0.5633125487	anti inflammatory action
0.5629415733	insulin stimulated
0.5627785902	h1 receptor antagonists
0.5626049182	vegf expression
0.5625432536	membrane proteins
0.5624681803	zn2 +
0.5622546369	mrna and protein levels
0.5620541894	parent compound
0.5619161014	significantly diminished
0.5615924819	binding protein
0.5615102345	treatment groups
0.5613559049	intracellular reactive oxygen species
0.5613072272	cardiac function
0.5611616632	side chains
0.5611051206	fasting plasma
0.5607084642	markedly increased
0.5604630184	related factor 2
0.5604100326	primary cortical
0.5600939660	rat heart
0.5600507754	tandem mass
0.5600327205	s nitrosation
0.5599920232	protein levels
0.5594334636	human cancer cell lines
0.5592921178	inhibitory action
0.5590695355	spontaneous locomotor
0.5588282537	vascular function
0.5586159358	intracellular ca
0.5584924983	significantly enhanced
0.5584260916	lowering effect
0.5582901209	high cholesterol
0.5578569959	studies suggest
0.5577260516	physiological conditions
0.5573995804	mouse brain
0.5569363723	plasminogen activator inhibitor
0.5567673166	erk1 2 phosphorylation
0.5563969240	significantly affected
0.5563104960	prostatic hyperplasia
0.5562609390	degrees c
0.5559850234	normal subjects
0.5557001748	fatty liver
0.5554603455	nonsteroidal anti inflammatory
0.5554579573	role played by
0.5552916878	estrogenic activity
0.5547972497	rat kidney
0.5547685463	growth inhibitory
0.5545011138	binding assays
0.5544004406	il 13
0.5541968096	sert binding
0.5538058768	site specific
0.5536351878	potential therapeutic
0.5534601479	adult mice
0.5534088916	protein expression
0.5532974690	breast cancer cell line
0.5529474656	glp 2
0.5526226378	ca2 + channels
0.5524730758	cyp3a activity
0.5523843618	complex formation
0.5521332058	g protein coupled receptors
0.5521057946	d mph
0.5519871396	antiproliferative activity
0.5517367311	ligand dependent
0.5514859150	beta 1 and beta 2
0.5514249964	direct evidence
0.5512685373	300 microg kg
0.5511438743	mmol l
0.5507426648	p aminohippurate
0.5506888952	studies revealed
0.5504616068	mg twice daily
0.5504587819	positive correlation
0.5501386432	near infrared
0.5500482232	p2y12 receptor
0.5500360120	serotonin receptors
0.5500111390	key enzyme
0.5498110117	3h paroxetine
0.5497493488	binding proteins
0.5496475028	active compounds
0.5494668330	blood levels
0.5488869642	induced hepatotoxicity
0.5487832823	signal regulated kinase
0.5487629061	no significant difference
0.5486901483	stress induced
0.5484286481	fold decrease
0.5483879716	oral glucose
0.5480576576	strong evidence
0.5480325173	shp 1
0.5479653161	chemical structures
0.5478433529	key role
0.5475989875	based assays
0.5475818246	er alpha
0.5474512359	jurkat t
0.5473771346	affinity and selectivity
0.5473353084	kainate receptor
0.5472653261	5 lox
0.5472246204	actinomycin d
0.5471953496	anti oxidative
0.5471770628	smooth muscle cells
0.5468950748	protein and mrna levels
0.5468646329	nitric oxide production
0.5465809509	right ventricular
0.5464769261	intravenous injection
0.5462641435	h3 receptor
0.5460892046	ldh x
0.5460866437	× 10
0.5459434645	rat hippocampus
0.5456894866	rats received
0.5456496271	alpha 2b
0.5452740498	related compounds
0.5445110477	similar potency
0.5444630909	brain tissue
0.5443257410	2 neu
0.5442495189	cb1 receptor
0.5440182550	timp 1
0.5438936928	arginase activity
0.5436498894	g2 m
0.5434681120	molecular structure
0.5431895516	future studies
0.5428263311	high density
0.5427023384	human brain
0.5423252521	independent mechanism
0.5421340647	lymphocytic leukemia
0.5417783978	one carbon metabolism
0.5415630056	results reveal
0.5414375692	ap 1
0.5412844484	findings support
0.5409689598	therapeutic target
0.5406873996	5 ht2b
0.5405404704	l citrulline
0.5403301128	plasminogen activator inhibitor 1
0.5399006077	strongly inhibited
0.5395584510	regulatory subunit
0.5393585448	irs 1
0.5391567519	isolated rat
0.5389230153	median follow up
0.5381738252	molecular mechanism
0.5380623020	coa reductase
0.5378814918	first line
0.5378778279	insight into
0.5378451967	second generation
0.5377805982	transcript levels
0.5374697065	control diet
0.5366658774	caspase 1
0.5365056811	protein kinases
0.5363850042	mda levels
0.5363263060	mediated transactivation
0.5361557865	analysis showed
0.5359444531	e selectin
0.5355104652	living cells
0.5352360253	prevention and treatment
0.5351830063	l arg
0.5345074500	glucose tolerance test
0.5344661790	er positive
0.5342767926	first line therapy
0.5339831056	generation of reactive oxygen species
0.5339065687	receptor mediated
0.5337778363	glut 4
0.5337222550	5 ht2a and 5 ht2c
0.5336890316	higher affinity
0.5332429034	mammalian brain
0.5331323955	c57bl 6
0.5329149512	related disorders
0.5328200627	bearing mice
0.5327938457	mitogen activated
0.5327811917	bisphenol a
0.5327488608	markedly decreased
0.5326644707	low doses
0.5325214657	cyclin dependent
0.5324507252	egf induced
0.5321400310	phorbol 12
0.5321133451	fold selectivity
0.5317933553	analyses revealed
0.5317296549	d 1997
0.5316152374	β oxidation
0.5314667158	dose response
0.5314136092	neuronal activity
0.5313146893	regulated genes
0.5312692905	recently identified
0.5312596117	transplant patients
0.5309042861	ucp 3
0.5305233746	induced toxicity
0.5304826733	delta opioid
0.5303647278	l cysteine
0.5301401136	neuronal injury
0.5301181835	human gastric
0.5296003714	a special issue entitled
0.5292018729	structure based drug
0.5290814772	nadh dependent
0.5289585465	pim 1
0.5288108235	d galn
0.5286633944	gaf b
0.5285983441	drug target
0.5284304347	dose dependently increased
0.5283945692	higher dose
0.5283265342	vmat 1
0.5283248422	synthesis and biological
0.5282832979	cb1 receptors
0.5282391666	inflammatory cytokine
0.5282291667	conformational changes
0.5277483071	mechanisms involved
0.5272644519	anti inflammatory activities
0.5262603089	mg ml
0.5259574235	hormone levels
0.5259481884	scd 1
0.5259353180	sd rats
0.5258779075	chinese hamster ovary cells
0.5257205942	adrenoceptor agonists
0.5252506562	end products
0.5251660832	mediated efflux
0.5250659074	inhibitory avoidance
0.5249956156	hematopoietic cells
0.5249597183	improved survival
0.5248554208	binding characteristics
0.5247504272	self assembly
0.5246224937	receptor blocker
0.5240656367	5 meo
0.5235365820	cloned human
0.5234603576	selected compounds
0.5232752462	stat3 signaling
0.5232602815	drug administration
0.5231175460	control animals
0.5230410092	mouse liver
0.5230327705	bmp 2
0.5227859087	small cell lung cancer
0.5219859440	chemical structure
0.5217535310	patients with type 2 diabetes mellitus
0.5217486411	t lymphocytes
0.5215074574	mechanisms of action
0.5214849799	150 mg
0.5214269083	key enzymes
0.5210850865	experimental conditions
0.5207179454	human recombinant
0.5206698725	mg day
0.5202367718	significantly prolonged
0.5200389242	pancreatic β cell
0.5199355817	6 nc
0.5198090686	glucuronidation activity
0.5194964582	d2 antagonist
0.5194784644	ca2 + currents
0.5192836960	human colon cancer cells
0.5191912021	acetic acid induced
0.5189141317	signal transducer
0.5187383974	up regulation
0.5186900609	zinc binding
0.5186116270	sf 1
0.5185202982	expressed in cos
0.5183883103	non steroidal anti inflammatory
0.5181378913	ki =
0.5180439403	induced contraction
0.5174618832	fragment based
0.5173607728	erk activation
0.5171837650	cytotoxic activity
0.5170726701	cyclin e
0.5168204674	determined by measuring
0.5163881865	case control
0.5163738039	chemically induced
0.5162078687	pyridoxal 5
0.5155439355	primary cultured
0.5154017600	normal weight
0.5153834505	results support
0.5153782421	free survival
0.5147955932	sodium dependent
0.5147291783	dependent mechanism
0.5146573375	pc 3 cells
0.5146143290	regulatory proteins
0.5146098657	dose dependently reduced
0.5140453620	human breast cancer cells
0.5136072665	apoptotic cells
0.5133063992	adenocarcinoma cells
0.5132789691	highly sensitive
0.5130092312	high level
0.5130059898	regulatory element
0.5124709300	partially inhibited
0.5124178760	24 hour
0.5123705926	par 1
0.5121447415	structural basis
0.5120968011	potent anti inflammatory
0.5117932808	proximal tubule cells
0.5113287938	calcium release
0.5111371356	necrotic cell
0.5110655402	control mice
0.5105979628	plasma cholesterol
0.5103340165	d fenfluramine
0.5100126701	treated patients
0.5097714985	experimental evidence
0.5091267808	drug therapy
0.5090420055	tissues examined
0.5089585475	sup sup
0.5089116534	luciferase activity
0.5087566883	3 hydroxy 3 methylglutaryl
0.5087384645	reported previously
0.5082125341	toll like
0.5080060464	insights into
0.5077809309	serotonin receptor
0.5076075521	il 6 production
0.5073803948	photons s
0.5071213991	site of action
0.5070470396	intact cells
0.5061727655	low micromolar
0.5055382051	vitamin d receptor
0.5055314640	during pregnancy
0.5054762319	72 hours
0.5053821306	camp levels
0.5050912525	nmol l
0.5048920753	emax =
0.5048731301	mitochondrial function
0.5047379443	pmol l
0.5046470690	knock out
0.5043607942	400 mg
0.5043523784	brain gaba
0.5043025145	aged mice
0.5042075320	camp response element
0.5039265797	primary cultures
0.5036741384	differential scanning
0.5031231350	side effects
0.5030942346	mmp 2
0.5030708888	epidermal cells
0.5025114250	drug transporters
0.5022491394	drug metabolizing
0.5021425470	positive inotropic
0.5019125927	beta agonists
0.5014793246	significantly reduce
0.5013321147	gtpgammas binding
0.5009862859	chronic ethanol
0.5004128701	agonist activity
0.5003431147	hup a
0.5000978219	daily administration
0.5000417493	similar results
0.4995938607	real time
0.4993303401	year old
0.4993028900	d2 receptors
0.4992826023	airway epithelial
0.4990120329	adenosine a2a
0.4989855867	cos cells
0.4987503012	ache inhibition
0.4981370974	tissue samples
0.4981328771	cell loss
0.4979074064	marked decrease
0.4978573889	200 mg
0.4978446233	25 dihydroxyvitamin
0.4976774659	neonatal rat
0.4974392154	greater than
0.4973884474	prostate cancer cells
0.4970170007	results obtained
0.4969194773	well documented
0.4966777688	relative to placebo
0.4966760652	30 mg kg
0.4966648854	regulatory element binding protein
0.4966406361	inhibitory concentrations
0.4966038505	selective cox 2 inhibitor
0.4964965010	higher potency
0.4963294183	brain injury
0.4949281274	increased significantly
0.4947444824	molecular pathways
0.4946086101	combined treatment
0.4944036537	re uptake
0.4941769895	hl 60 cells
0.4940904647	500 mg
0.4931354408	us fda
0.4928636676	alkaline phosphatase activity
0.4927671900	highly effective
0.4927214574	mrna and protein expression
0.4926461048	inos mrna
0.4924704756	vegfr 3
0.4922942227	kidney disease
0.4922340021	substrate binding
0.4918306169	sch b
0.4917199059	caspase 3 activation
0.4916663244	once daily dosing
0.4911348116	inducible nitric oxide
0.4906285114	liver cancer
0.4906079872	previously identified
0.4903631240	caco 2 cell
0.4902912648	fgf 10
0.4901598865	gene family
0.4901465614	stimulated cyclic amp
0.4896399918	suffering from
0.4895732324	enos activity
0.4894981585	without affecting
0.4893674113	a dose dependent manner
0.4885225161	cellular functions
0.4885033810	mumol l
0.4884726181	5 lipoxygenase
0.4884115181	immune cells
0.4877557445	basal levels
0.4874220850	membrane protein
0.4872187076	showed significant
0.4868055894	decreased significantly
0.4864787288	mechanism underlying
0.4862959746	ng g
0.4862313316	third generation
0.4860676818	inside out
0.4857427885	nadph oxidase activity
0.4857184561	g gap
0.4852301658	l methionine
0.4851384173	angiotensin ii type
0.4849613227	mediated endocytosis
0.4848618404	ph dependent
0.4848610621	glutathione levels
0.4844394933	hepatic lipid
0.4842649120	dopamine release
0.4840350321	amino acid transport
0.4840000675	hepatoma cells
0.4837029164	protein kinase c
0.4837027734	so called
0.4832846977	significant correlation
0.4828537618	hepatic glucose
0.4828320499	antagonist ici
0.4821721966	cellular responses
0.4820510438	self administration
0.4818942293	600 mg
0.4814682692	annexin 1
0.4811592178	therapeutic agent
0.4808666392	potent compound
0.4805656383	frequency dependent
0.4803408970	ache inhibitors
0.4802058645	beta 2 adrenoceptor mediated
0.4801590876	compared with placebo
0.4800607491	selective inhibitors
0.4799573185	acid derivatives
0.4799472064	subjects received
0.4799410363	ganglion neurons
0.4791349623	x linked
0.4788989045	patients received
0.4788984319	patients with schizophrenia
0.4784164537	akt signaling
0.4781598358	area under
0.4778730890	20 mg kg
0.4778231890	binding of 125i
0.4775773849	mammalian cells
0.4775167556	ability to inhibit
0.4772766888	compared with vehicle
0.4766602006	single nucleotide
0.4765920796	chronic myelogenous
0.4765818953	vitamin c
0.4763081307	alpha methyl
0.4761160551	receptor binding
0.4760332505	d3 receptor
0.4758553463	phosphorylation of akt
0.4757182270	cell free
0.4754297770	pharmacological characterization
0.4751252673	divided into three groups
0.4751235271	cd4 + t cells
0.4747426899	selective agonists
0.4747315970	induced platelet aggregation
0.4745255823	non small cell lung
0.4739352956	so far
0.4738849944	case study
0.4738567704	5 lo
0.4737087717	pcr analysis
0.4734880651	synergistic effects
0.4731447192	higher concentration
0.4728565221	oxytocin receptor
0.4726945049	sub 2 sub
0.4721891208	drug resistant
0.4720720897	cancer cell proliferation
0.4718334506	glucose 6 phosphate
0.4717281873	cells stably expressing
0.4714210494	conscious rats
0.4713626317	growth factor receptor
0.4711445671	based assay
0.4707949195	mouse bone
0.4704665302	phosphodiesterase 5
0.4698215391	vegf receptor
0.4697914243	postnatal day
0.4694990547	differ significantly
0.4692670895	receptor ligand
0.4691567785	physical activity
0.4689515817	this article
0.4686473985	correlation between
0.4683302627	advanced glycation
0.4679001658	cox inhibitor
0.4677156911	3 methylglutaconic
0.4674790251	5 asa
0.4670345505	synthesized compounds
0.4670317149	assay showed
0.4668896640	il 1
0.4666269519	mu opioid
0.4665851392	breast cancer cell
0.4662592631	2d nmr
0.4660655137	present findings
0.4660179958	side effect profile
0.4657990077	glucose stimulated insulin
0.4657196006	agonist binding
0.4652315250	5 fluorouracil
0.4647151553	amphetamine induced
0.4646432098	cloned alpha
0.4644786107	focuses on
0.4644503045	plasma insulin
0.4641731474	mitogen activated protein
0.4640975209	serum insulin
0.4638225637	il 12
0.4637866101	10 mg kg
0.4637587709	camp signaling
0.4635083734	scavenging activity
0.4631318589	mmp 1
0.4630744129	dose dependent manner
0.4629871216	approximately 20
0.4627880547	cholesterol levels
0.4627048800	glutamate receptors
0.4626709997	mice exhibited
0.4622537661	interleukin 2
0.4619261280	hormone receptor
0.4617066952	binding domains
0.4612939685	small molecule inhibitors
0.4610593253	alpha beta
0.4610295638	gene mutations
0.4608180094	igfbp 2
0.4608088809	30 min
0.4600275407	signal pathway
0.4600100540	dependent pathway
0.4597047592	taken together
0.4596201321	dose and time dependent manner
0.4596150373	phase iii clinical
0.4596004339	assays showed
0.4594541685	100 microm
0.4593852206	vascular smooth
0.4591750549	approximately 50
0.4591030884	the present study
0.4590078496	patients with type 2 diabetes
0.4588048717	tissue specific
0.4586422194	positively correlated
0.4586324665	breast cancer patients
0.4580888278	phase ii clinical
0.4579411044	atp binding
0.4578244026	age dependent
0.4575855828	type 2 diabetic patients
0.4575015900	antagonist binding
0.4574381168	phosphorylation of p38
0.4571080962	irreversible inhibitor
0.4569674709	studies showed
0.4567518155	human breast cancer
0.4564206706	expressed genes
0.4563150537	rapid onset
0.4559161112	glp 1 receptor
0.4554264613	vitamin k
0.4553787365	erk1 2 activation
0.4550735148	human cancers
0.4549274125	cisplatin induced
0.4547052939	prostaglandin e
0.4542766471	mediated metabolism
0.4539411086	time points
0.4537272139	all trans
0.4537057315	akt pathway
0.4536805029	c terminus
0.4535168755	divided into
0.4531573628	duration of action
0.4526489550	glucose levels
0.4524909653	week old mice
0.4524323116	insulin levels
0.4523811354	cell signaling
0.4522329405	vesicular monoamine
0.4521016020	concentration and time dependent
0.4518169556	serum glucose
0.4513600559	greater than or equal to
0.4513235383	liver specific
0.4512444191	a lesser extent
0.4509981925	expressing cells
0.4504053513	data support
0.4501906497	mitochondrial membrane
0.4498924916	transcriptional activation
0.4496229977	anti inflammatory drugs
0.4492902407	related diseases
0.4492453576	ca2 + channel
0.4491198078	d serine
0.4486004200	human whole blood
0.4481789399	activity relationship studies
0.4481331472	fold higher than
0.4478987253	human skin
0.4478771004	1 piperazinyl
0.4472337258	expressed in chinese hamster
0.4467632133	5 alpha reductase
0.4467282755	high sensitivity
0.4466259289	these findings suggest
0.4465790971	g protein coupled
0.4464801142	binding profile
0.4461093516	sequence analysis
0.4461016798	these results suggest
0.4460642622	cyclooxygenase 1
0.4453249896	anti inflammatory effect
0.4452954799	30 minutes
0.4448166454	concentration dependent manner
0.4448056845	4 hne
0.4447019308	l cpa induced
0.4446394341	activation of ampk
0.4445690553	5 ht1b receptors
0.4445364982	specific inhibitors
0.4445205181	most common adverse
0.4443741496	lung cancer cells
0.4443159456	glucose concentrations
0.4439414543	oxidative stress related
0.4438704078	induced currents
0.4436546230	three dimensional structure
0.4435930728	ic50 =
0.4435161188	specific antibodies
0.4430914542	cox 2 expression
0.4430161871	high affinity binding
0.4430044960	cholinergic activity
0.4425645258	ligand based
0.4424067626	selective cyclooxygenase 2
0.4422538524	bcl 2 family
0.4422399490	cancer cell
0.4417536338	il 2 receptor
0.4413581879	related proteins
0.4406418124	glucose production
0.4406210121	motor activity
0.4405084012	thp 1 cells
0.4404162653	designed to evaluate
0.4403334631	l carnitine
0.4402874710	blood spots
0.4402446504	skeletal muscle cells
0.4401119458	25 hydroxyvitamin d
0.4401073062	tumor cell
0.4399478620	give rise to
0.4393009981	liver cells
0.4391049850	receptor activation
0.4390007294	100 mg kg
0.4388248510	cck 8
0.4386750478	14 days
0.4384921381	adrenoceptor mediated
0.4382321441	pi3 k
0.4380494876	estrogen receptors
0.4379441950	nf κb signaling
0.4379242683	down regulates
0.4377935702	parp 1
0.4377431172	mononuclear cells
0.4376774820	target gene expression
0.4376375947	4 hydroxyphenyl
0.4373230238	activation of nrf2
0.4370536154	in vitro
0.4368297703	acetylcholine receptors
0.4367907436	to calculate
0.4367784507	isoprenaline induced
0.4367373549	5 ht2c receptor
0.4364707231	effectively inhibited
0.4362402666	limiting enzyme
0.4360206934	good agreement
0.4358584322	nsclc cells
0.4355691219	leukemia cells
0.4355070110	high potency
0.4353807600	mol l
0.4353039824	cell number
0.4350983249	ache inhibitor
0.4344238249	results showed
0.4342960606	accounts for
0.4341891500	increased incidence
0.4341325690	channel activity
0.4338079077	protein interactions
0.4337239536	in vivo
0.4336840073	receptor type
0.4335792565	related protein
0.4334621663	cells express
0.4333950236	cultured cells
0.4333667921	commonly used
0.4333534170	alpha 2a
0.4331647136	cyclic adenosine
0.4325699648	stress related
0.4325039888	mg dose
0.4324214376	receptor antagonism
0.4319864382	l proline
0.4319051002	human serum
0.4318428153	induced seizures
0.4313841138	risk factor
0.4313177214	medical treatment
0.4311922315	low concentrations
0.4308163632	a go go
0.4307564725	whole blood
0.4306573193	x ray crystal structure of
0.4306405455	mantle cell
0.4303550007	target of rapamycin
0.4302334644	human insulin
0.4300855324	human breast cancer cell
0.4300634284	knockdown cells
0.4299277216	chronic myeloid
0.4298172534	clinical response
0.4295059345	rate limiting enzyme
0.4291591997	widely used
0.4290751799	showed higher
0.4281864771	cell type
0.4281227766	liver failure
0.4281037124	protection against
0.4280933066	diabetes induced
0.4278922265	compared with controls
0.4277157470	balb c
0.4276054140	positively correlated with
0.4275800832	l mph
0.4274840034	significant reductions
0.4273853802	brain membranes
0.4269866361	well established
0.4269638893	cross talk between
0.4269198363	tended to
0.4269118707	vitamin d
0.4262560930	a concentration dependent manner
0.4258009430	exhibited potent
0.4257972703	fed mice
0.4256294575	knowledge about
0.4252251752	serve as
0.4252006488	cancer patients treated
0.4247049064	oral doses
0.4246770873	selective estrogen
0.4246199076	induced oxidative stress
0.4244145148	ii gnrh
0.4243826293	enzyme inhibitor
0.4243795472	increased apoptosis
0.4243607285	chemical properties
0.4243353905	mediated signaling
0.4243294886	ho 1 expression
0.4240728277	delta 5
0.4237421987	owing to
0.4228730825	g feed
0.4226451357	enzyme inhibitors
0.4225636690	m2 receptor
0.4224594241	previous work
0.4223642529	human blood
0.4221980403	normal levels
0.4219697136	* 1 *
0.4214786385	cox 2 selective
0.4213277167	binding studies
0.4212572682	well defined
0.4210448753	l glutamine
0.4210412051	l name
0.4207495072	d1 receptor
0.4207316690	l phenylalanine
0.4207266442	results suggested
0.4204673735	the last decade
0.4204575955	extracellular signal
0.4204567664	enzyme inhibition
0.4204356618	calcium binding
0.4200379203	21 days
0.4198925712	antioxidant enzyme
0.4198439040	postmenopausal women with
0.4192383363	two dimensional
0.4190978356	designed to investigate
0.4188646532	d4 receptor
0.4187626028	4 yl
0.4182884334	analysis demonstrated
0.4181641873	multiple dose
0.4180505913	cell carcinomas
0.4178711351	adult brain
0.4177952883	steroid receptors
0.4177633828	dhea s
0.4177609230	hypoxia inducible
0.4176274644	raldh 1
0.4174776888	early stages
0.4172070729	mg kg per day
0.4171831006	human lung cancer
0.4171672789	human subjects
0.4170858317	significantly up regulated
0.4170578948	recent data
0.4164636241	play important
0.4164427079	human macrophages
0.4157606180	expression patterns
0.4151729684	unable to
0.4149338898	dependent apoptosis
0.4149330821	ar antagonist
0.4144314902	anti inflammatory activity
0.4143396822	histamine induced
0.4141614704	aldosterone induced
0.4137148817	n demethylation
0.4132177197	depressive disorder
0.4131560014	hormone dependent
0.4130714236	nf l
0.4129909780	resistant cells
0.4127930534	shown to possess
0.4127460563	induced pain
0.4123967133	vasopressin induced
0.4123604309	dependent fashion
0.4122511983	reductase activity
0.4120382965	cox 2 inhibitor
0.4119382555	serotonin reuptake inhibitor
0.4118985273	repeated administration
0.4117110026	transduction pathways
0.4115636881	human neuroblastoma
0.4112834726	belong to
0.4110837555	coupled receptor
0.4108077868	increased plasma
0.4107891589	human platelet
0.4107742062	c kit
0.4106685826	angiotensin ii type 1
0.4104773613	high concentration
0.4101238514	drug targets
0.4097172044	receptor stimulation
0.4096804762	l cpa
0.4095433868	times greater
0.4094734714	us food and drug administration
0.4094242938	nicotine induced
0.4093757268	inflammatory disease
0.4093244277	loss of function
0.4092109846	human kidney
0.4089203289	down regulate
0.4086065543	subjected to
0.4085205100	lung cells
0.4084364627	contributor to
0.4083209734	recent years
0.4081241817	ec50 =
0.4076691895	ranged from
0.4076534218	insulin igf
0.4076148129	experiments revealed
0.4076077646	beta cells
0.4074229682	guanosine 5
0.4071294380	these results demonstrate
0.4070096757	n terminal domain
0.4069454189	positive cells
0.4067889354	arsenic induced
0.4063807547	the mainstay
0.4063689602	muscle cells
0.4063632559	risk patients
0.4063043184	most abundant
0.4062817098	responsible for
0.4056505571	compounds showed
0.4052374357	fe s
0.4052075490	induced oxidative
0.4050941022	receptor phosphorylation
0.4048697510	protein coupled receptor
0.4048252673	cancer patients
0.4047815951	serum concentrations
0.4046722770	did not alter
0.4045932437	increased sensitivity
0.4045025647	c abl
0.4044094387	induced nephrotoxicity
0.4043960560	et 1
0.4043295375	dependent inactivation
0.4038879206	renin angiotensin system
0.4037290685	arterial blood
0.4036491148	neuronal cells
0.4032732866	glucose stimulated
0.4030167498	rat cerebral
0.4029003812	selective beta
0.4026013159	regulatory element binding
0.4022682191	decreased plasma
0.4021391528	did not differ
0.4020634416	accounted for
0.4020232303	protects against
0.4020131037	caspase 3 activity
0.4016829593	human colon cancer
0.4015517720	stress conditions
0.4014594836	recent study
0.4014260706	link between
0.4012187211	glucocorticoid induced
0.4011240951	gnrh r
0.4010971449	human peripheral blood
0.4010708790	cox 1 cox 2
0.4009586015	negative effect
0.4008533027	t cell
0.4007596332	gene expression analysis
0.4006706124	hif 1
0.4005368849	these observations suggest
0.4003719889	human nasal
0.3997355658	relevant concentrations
0.3997180363	x ray crystal
0.3996927588	basal plasma
0.3995881506	5 ht3 receptors
0.3990885937	camp dependent
0.3987413237	selective serotonin
0.3982845049	2 yl
0.3982286860	testosterone levels
0.3981566434	differences between
0.3981021337	≤ 0
0.3977070573	chronic exposure
0.3976401566	onset of action
0.3972815624	light induced
0.3972577967	chloride cotransporter
0.3971872186	derived growth factor receptor
0.3971284237	insulin induced
0.3969707383	these data suggest
0.3967626901	positive allosteric
0.3966730319	neuroprotective effect
0.3965934169	important implications
0.3962148873	recently shown
0.3960514875	significantly correlated
0.3957090260	nmda induced
0.3956863130	4 chlorophenyl
0.3955322233	cellular uptake
0.3955138954	500 mg kg
0.3954109844	mitochondria mediated
0.3946808407	the other hand
0.3945994808	10 ⁻
0.3944529259	5 ht2 receptors
0.3944213411	drug binding
0.3944121288	n methyl
0.3943024218	cellular proliferation
0.3942995714	subunit expression
0.3940785226	cardiac sodium
0.3939985688	oh bde
0.3939364587	phosphodiesterase 4
0.3939075075	± 4
0.3933685893	an open label
0.3932565569	allosteric modulator
0.3931619903	human heart
0.3930538678	selective inhibitor
0.3928437465	the concentration response
0.3928189759	cells overexpressing
0.3924456046	most frequent
0.3922944778	tyrosine phosphatase
0.3920988882	reminiscent of
0.3920652003	role in modulating
0.3918949762	stimulatory effect
0.3916521415	second line
0.3914045175	isolated compounds
0.3914038496	high doses
0.3913681466	at 37 degrees
0.3909662701	male rat
0.3909402703	did not affect
0.3908673111	elevated plasma
0.3908571498	impaired glucose
0.3907097107	study demonstrates
0.3904693171	μmol l
0.3903488708	antinociceptive effects
0.3902251520	clinically useful
0.3901679842	exhibited significant
0.3901528564	safety data
0.3899542795	25 dihydroxyvitamin d
0.3896436076	cox 2 selectivity
0.3893217046	depended on
0.3892272055	further investigation
0.3892125758	currently in phase
0.3891118833	k atpase
0.3889133827	per se
0.3885804401	fold more potent
0.3885112461	dependent signaling
0.3884625495	lower dose
0.3882638076	human cancer
0.3879617660	times higher than
0.3878620963	ci = 0
0.3874919113	functional properties
0.3873363538	5 ht2 receptor
0.3870343790	advantages over
0.3869302682	mediated responses
0.3865044498	uv b
0.3862291781	study group
0.3861087757	high performance
0.3859815825	k + channels
0.3859491661	protein aggregation
0.3857010014	urinary tract
0.3855792116	cox 2 inhibitors
0.3852078644	c met
0.3851518933	into account
0.3850649980	100 mg
0.3850534949	almost completely
0.3847279724	experimental results
0.3845352070	this paper
0.3839591412	k + channel
0.3839227723	novel object
0.3838020499	kinase signaling
0.3835731975	tested compounds
0.3834722946	alpha 1d
0.3831680235	interplay between
0.3829355038	tolerance test
0.3828622145	signaling proteins
0.3826138974	4 methylenedioxymethamphetamine
0.3821721925	rather than
0.3819663246	human bronchial
0.3818030471	gene polymorphisms
0.3817885124	raf 1
0.3814963896	plasma renin
0.3813403523	stimulation induced
0.3808707871	metastatic breast
0.3806580457	atp sensitive k
0.3806221877	potential mechanism
0.3804739411	induced obesity
0.3802948072	receptor expression
0.3799796695	mechanisms of resistance
0.3798772391	most potent
0.3796202436	human epidermal
0.3795885817	non steroidal
0.3794585021	oxidase inhibitor
0.3789120384	therapeutic concentrations
0.3788211916	plasma levels
0.3780460554	depends on
0.3778829874	antidepressant like
0.3776638019	120 mg
0.3776590717	do not
0.3773412981	inhibition studies
0.3769257008	25 hydroxyvitamin
0.3768861386	human colorectal
0.3768213042	randomly assigned to
0.3767195324	even though
0.3766777684	randomized controlled
0.3759515354	reductase inhibitor
0.3756929892	factor 1alpha
0.3753667896	ang ii induced
0.3753368223	prostate specific
0.3751645689	results provide
0.3750724337	reduced significantly
0.3745249471	plasma concentration
0.3744184991	target proteins
0.3736565709	group than in
0.3734077256	therapeutic drugs
0.3730154442	thp 1
0.3728994332	signaling molecules
0.3727520327	serves as
0.3727267110	exhibited high
0.3726948521	induced apoptotic
0.3725265508	receptor gene
0.3722864766	at least as effective
0.3721676347	receptor ligands
0.3720872801	this study examines
0.3720684028	most common
0.3719867022	receptor function
0.3719402370	cytochrome c
0.3719316414	binding of 3h
0.3714329754	an important role
0.3711639316	important role
0.3711438997	body mass
0.3710968398	8 oxo
0.3709198587	18 kda
0.3706788037	dependent enzyme
0.3702353037	activated protein kinases
0.3702096278	very low
0.3701272244	smad 3
0.3690763874	in most cases
0.3688654960	40 mg kg
0.3687954419	induced acute
0.3684935898	oxidase inhibitors
0.3684180899	the present investigation
0.3682201685	selective cyclooxygenase
0.3681184860	irrespective of
0.3676309174	protein content
0.3674083250	alpha mrna
0.3670943674	chronic obstructive
0.3665894459	dose and time dependent
0.3665894339	hyp *
0.3663027740	response element binding
0.3658834969	ii activity
0.3658548035	1 and cox 2
0.3658234721	mg min
0.3658046797	accompanied by
0.3657969858	pr b
0.3655878071	twenty four
0.3655813398	wide range of
0.3655740166	induction of apoptosis
0.3650340361	o β d
0.3648942150	dehydrogenase activity
0.3647918565	nf κb pathway
0.3643255532	specific activity
0.3642238669	direct binding
0.3641908018	for further development
0.3637584711	functional roles
0.3635244799	differential expression
0.3634467880	compared to wt
0.3633200343	whole cell
0.3628215236	intracellular signaling
0.3627358090	5 ht1a receptors
0.3625234066	5 mg kg
0.3622857679	oral dose
0.3622826212	type 1
0.3622586702	previously described
0.3622312409	high selectivity
0.3614141863	erk 1 2
0.3613679700	p less than 0
0.3613105844	receptor mrna
0.3610931902	competitive inhibitors
0.3608481123	hi 6
0.3603514021	receptor signaling
0.3603136071	insulin like growth factor 1
0.3602026716	human cancer cells
0.3600260269	focusing on
0.3598135199	to date
0.3598061287	side effect
0.3597854860	100 nm
0.3592346544	κb pathway
0.3590071379	r and s
0.3588243848	currently in clinical
0.3588017462	studies performed
0.3586425801	300 microm
0.3585939333	48 hours
0.3583669810	direct effect
0.3581739251	matrix metalloproteinase 2
0.3581033369	15 mg kg
0.3580304916	13 acetate
0.3578049130	mediated inhibition
0.3574949513	therapeutic effect
0.3574782408	cd4 + t
0.3574028023	these results support
0.3571141229	cpt 1
0.3568895408	dose and time
0.3568867536	structure function
0.3567963088	aimed at
0.3566032500	control levels
0.3565075103	alpha adrenoceptor
0.3563651185	effective in reducing
0.3562803274	these data demonstrate
0.3562551011	basal activity
0.3562481334	human colorectal cancer
0.3562312241	3 yl
0.3561079276	key roles
0.3557573106	depending on
0.3556487174	compared with control
0.3556181906	molecular basis for
0.3556072996	km =
0.3544494978	serotonin 5 ht
0.3543322550	these results provide
0.3543165704	trail induced
0.3541857795	carcinoma cell
0.3541541107	vegfr 2
0.3539368165	daily living
0.3538834566	shown to decrease
0.3538713378	treatment of hypertension
0.3538407596	inflammatory effects
0.3537269114	relationship between
0.3535110117	clinical activity
0.3534338091	demonstrated efficacy
0.3534168904	antigen induced
0.3533799019	phospholipase c
0.3527269612	greater extent
0.3526507760	regulatory protein
0.3526494736	affinity state
0.3526393029	the substantia
0.3525204177	compared to controls
0.3521141438	treatment of obesity
0.3519742801	expression levels
0.3519567857	methyl 4
0.3518916026	l serine
0.3518416362	clinically used
0.3515939881	shown to inhibit
0.3514511047	better understand
0.3509674508	48 h
0.3508706586	ht2a receptor
0.3507165138	r = 0
0.3504041442	related peptide
0.3502591914	non canonical
0.3501869204	study shows
0.3501511112	co expressing
0.3500485480	p = 0
0.3497843514	troponin c
0.3497726621	studies provide
0.3495054234	hypothalamic pituitary
0.3493388450	5 ht2c receptors
0.3492539840	apolipoprotein e
0.3490799116	design and synthesis of
0.3489903891	the presence and absence
0.3489170539	findings provide
0.3489019671	to determine
0.3488044851	10 microm
0.3486968140	group showed
0.3485545797	binding properties
0.3483956246	significantly inhibit
0.3481996508	served as
0.3479375882	increased serum
0.3479338522	these observations
0.3477424697	contribute to
0.3477040023	cyclo oxygenase 2
0.3476977847	cells transfected with
0.3472387657	diet induced
0.3472262568	protein coupled receptors
0.3471341267	blood cells
0.3467748255	non diabetic
0.3467384612	approximately 100
0.3465275464	belongs to
0.3465024333	cell activation
0.3465022159	to treat
0.3464989434	neuronal cell
0.3464799900	time and dose dependent
0.3463808232	expression profiling
0.3463770388	time course
0.3462033995	the present study aimed
0.3461563295	ed50 =
0.3460490398	significant effects
0.3458290754	pituitary adrenal
0.3457566227	account for
0.3457212516	this review
0.3456272165	dependent kinase
0.3453996424	300 mg
0.3453235424	to investigate
0.3452392229	n methyl d aspartate receptors
0.3451254217	data showed
0.3446240887	acetylcholine receptor
0.3446029233	mrna expression levels
0.3443889249	24 weeks
0.3443231110	k + current
0.3440615191	in vitro and in vivo
0.3439396110	10 fold
0.3434413122	not significantly affect
0.3434305807	term exposure
0.3433307739	obtained from
0.3433264226	compared to control
0.3423614289	induced injury
0.3417397901	active compound
0.3415809483	potential clinical
0.3410665113	similar effects
0.3405802285	transcriptional level
0.3403730668	synthase activity
0.3402318669	human prostate cancer
0.3400527865	no significant differences
0.3395961257	dependent enzymes
0.3393268723	acute liver
0.3391694725	does not
0.3391650493	sensitive sodium
0.3390758832	anion transporter
0.3390683093	led to
0.3390374684	40 week old
0.3388003972	did not correlate
0.3386110004	thought to
0.3384059217	gstp1 1
0.3383155190	chronic administration
0.3382059294	100 μm
0.3378805387	an autosomal recessive
0.3375784819	did not change
0.3374061842	insulin concentrations
0.3373065509	regulated kinase
0.3370008419	attributed to
0.3368902613	shown to exhibit
0.3367149348	14 3 3
0.3366615771	consistent with
0.3365512859	disease activity
0.3363934187	100 fold
0.3363714932	human ovarian
0.3358977334	well known
0.3356854421	p creb
0.3354987758	phosphate dehydrogenase
0.3354547597	72 h
0.3353700575	pharmacological treatment
0.3353090477	4 oxo
0.3353053755	inhibitory effect on
0.3352901659	systemic administration
0.3351445532	na +
0.3350293517	in addition
0.3346738291	cox 2 mrna
0.3345983281	appears to
0.3345792909	bcl 2 expression
0.3344558903	the current study
0.3343669643	multidrug resistance associated
0.3341942000	data provide
0.3339380360	fluorescent protein
0.3338260155	mpp +
0.3337626216	specific ligand
0.3337510051	l alanine
0.3335557754	clinical data
0.3335350822	intestinal epithelial
0.3334771809	c fos expression
0.3333101242	induced cardiac
0.3331750293	h2o2 induced
0.3331407413	effects of morphine
0.3330605229	s disease
0.3328352488	elevated levels
0.3328249003	a dose dependent increase
0.3326288581	oxidative stress induced
0.3322941044	pre treated
0.3321022441	human tissues
0.3320642697	significantly lower than
0.3310716126	12 months
0.3308993374	serum levels
0.3303715048	expression profile
0.3303237339	highly expressed
0.3303115130	differs from
0.3301867877	d amphetamine
0.3301020838	previously observed
0.3299091570	resulted in
0.3299066081	de novo synthesis
0.3296988750	metabolic effects
0.3296904968	cells exhibited
0.3291552692	significant change
0.3289354753	clinical study
0.3285260309	functional studies
0.3284138433	ph 7
0.3282645564	tissues including
0.3281325608	polymerase chain
0.3278877243	significantly affect
0.3277443845	study suggests
0.3275517986	mediated pathways
0.3275356208	existence of
0.3274485110	3h 5 ht
0.3270369124	experiments showed
0.3268018252	platelet derived
0.3267719369	glutamate induced
0.3265178001	interferes with
0.3264354108	time point
0.3260131643	injury in rats
0.3260082257	serum free
0.3259218450	adhesion molecule 1
0.3257478175	75 mg
0.3257010282	japanese patients
0.3255651004	receptor affinity
0.3253826666	hydroxy 3
0.3252575733	human plasma
0.3249443261	a time and
0.3248869751	chemotherapy induced
0.3248273538	pancreatic beta
0.3247882209	first generation
0.3247559784	relation between
0.3246958849	n methyl d aspartate receptor
0.3243783377	fed rats
0.3242866536	results revealed
0.3239858378	micro m
0.3238479831	related enzymes
0.3238432365	these findings demonstrate
0.3237933119	ranging from 0
0.3236167360	± 5
0.3236067708	leading to
0.3232189257	based design
0.3231861979	surface expression
0.3230338520	control values
0.3230269388	time and concentration
0.3230136624	moderate affinity
0.3229939828	human tumors
0.3229150148	37 degrees c
0.3228811555	renal cell
0.3228461426	a high fat diet
0.3226963545	associations between
0.3224692197	positive correlation between
0.3224384342	long term effects
0.3224343467	control cells
0.3222106881	significantly increase
0.3221572631	± 1
0.3218809358	inhibitory activity against
0.3218598933	12 weeks
0.3216664814	patients with severe
0.3216303176	the aerial
0.3215147115	20 mg
0.3214755985	200 mg kg
0.3213574034	interaction between
0.3210738213	intracellular accumulation
0.3209579677	pulmonary disease
0.3209178127	information about
0.3208884615	fat diet
0.3207141259	agonist induced
0.3204435176	high concentrations
0.3204030536	results indicate
0.3203423105	the blood brain barrier
0.3199436623	synthesis and biological evaluation of
0.3199361581	functional activity
0.3198202290	fully understood
0.3198049850	moderate affinity for
0.3196007823	glucose concentration
0.3195984496	important roles
0.3193277508	showed similar
0.3192266522	findings indicate
0.3188023290	histamine release from
0.3187895855	acid secretion
0.3185570443	non competitive
0.3185353216	drug transporter
0.3185045712	gastric acid
0.3182723625	study revealed
0.3181202513	systolic blood
0.3180552511	whole cell patch
0.3178825300	focused on
0.3178036421	long term use
0.3176624241	significantly higher than
0.3176533477	expression level
0.3176395823	inotropic effect
0.3175365568	directed against
0.3173538833	these data support
0.3172010380	cell derived
0.3171948809	chronic treatment
0.3168417653	pathways involved
0.3168398319	determine if
0.3167768605	regulated gene
0.3167397479	28 days
0.3164572504	protein protein
0.3163586491	inducing factor
0.3163284424	according to
0.3162678566	increased risk
0.3162549723	80 mg
0.3162177306	mediated mechanism
0.3161982058	phosphate dependent
0.3159787191	related adverse
0.3159318338	ii trials
0.3157539974	structural basis for
0.3154201538	effective treatment
0.3153243803	triphosphate binding
0.3151628614	did not
0.3149830236	potent anti
0.3149141136	cell based
0.3147875325	24 h
0.3147235073	cell specific
0.3144258368	factor x
0.3138489886	treatment decreased
0.3137593494	cell function
0.3135428544	mice showed
0.3134284097	50 mg kg
0.3132806329	increased intracellular
0.3130616608	ranging from
0.3125927150	study suggested
0.3125156910	15 min
0.3122979166	specific binding
0.3119409801	normal control
0.3119271163	mg protein
0.3117137682	inflammatory cells
0.3116663615	at least partly
0.3115926899	acid induced
0.3113595689	major depressive
0.3113559148	tumor necrosis
0.3113101001	potent inhibitors
0.3113082568	morphological changes
0.3105762700	competitive inhibitor
0.3104729412	emerged as
0.3103481517	compared with
0.3102137120	induced diabetic rats
0.3101849631	currently available
0.3099355241	at least in part
0.3099104558	compatible with
0.3098554032	oral glucose tolerance
0.3093338003	results highlight
0.3093146689	compared with normal
0.3092265404	compound 1
0.3091224123	mechanism involved
0.3091011576	more potent
0.3090829125	antioxidant effects
0.3089755938	play important roles in
0.3085408093	rat hippocampal
0.3079807516	results demonstrated
0.3079631251	16 mg kg
0.3078232704	significant decrease
0.3075085457	liver disease
0.3074154129	whole brain
0.3073975294	normal range
0.3073618973	fold lower than
0.3073464836	transporter expression
0.3072262108	reductase inhibitors
0.3071565470	mmp 3
0.3070730614	present study
0.3069552545	shown to induce
0.3068854270	contributes to
0.3067945082	these findings support
0.3066459388	potential target
0.3065529608	hormone receptors
0.3061884461	25 mg kg
0.3061735567	vitamin b
0.3061640844	at least
0.3061070001	to assess
0.3058153114	+ 0
0.3057521459	an update
0.3057243730	cross over
0.3054831073	uptake inhibitors
0.3054288034	enzyme linked
0.3052156297	ec 4
0.3052035471	oxidase activity
0.3051920255	patients with mild
0.3049537364	important implications for
0.3048374554	receptor alpha
0.3046329034	this study
0.3044624054	showed high
0.3039511797	acid synthase
0.3039385351	adrenergic agonist
0.3037654645	examine whether
0.3033379174	anti inflammatory drug
0.3028363735	induced cell
0.3026833402	referred to as
0.3026636368	primary human
0.3024223542	3 keto
0.3023864116	regardless of
0.3023217646	= 0
0.3023095970	modeling studies
0.3022275628	failed to
0.3019815471	no detectable
0.3018086310	early stages of
0.3017393082	replaced by
0.3015133729	classified into
0.3014940911	leukotriene receptor
0.3014320953	an attractive
0.3013880366	5 yl
0.3011736864	receptor kinase
0.3011453322	human airway
0.3008984178	not well understood
0.3008367923	non selective
0.3008168727	diastolic blood
0.3006098483	human renal
0.3004662483	synthase inhibitor
0.3003152682	dna binding activity
0.3000040629	expression profiles
0.2999482279	expression analysis
0.2998596568	capable of
0.2998571008	approximately 10
0.2997586607	levels increased
0.2993912949	the surface of
0.2993048945	hours after
0.2992189830	treatment increased
0.2991949604	non invasive
0.2991880042	cell lymphoma
0.2991507516	at high concentrations
0.2989060860	coronary heart
0.2988784504	normal cells
0.2986043605	bovine serum
0.2985220066	reduced plasma
0.2985204388	receptor blockers
0.2983828490	the growth of
0.2983239148	dependently reduced
0.2981050370	well characterized
0.2979205672	old male
0.2977787423	a wide variety of
0.2976976139	coupled receptors
0.2975254713	c src
0.2974528542	therapeutic effects
0.2972937525	mediated pathway
0.2971764882	patients with advanced
0.2970102179	study demonstrated
0.2969210388	after oral administration
0.2968251180	full agonist
0.2968124567	in vivo and in vitro
0.2968055272	protein kinase b
0.2965745627	progression free
0.2959388180	8 fold
0.2958332595	these data provide
0.2958035368	10 and 20
0.2955667203	lower incidence of
0.2953108975	p 0
0.2952887090	activated t cells
0.2947900154	streptozotocin induced
0.2947257088	much higher
0.2947141696	acidic protein
0.2946653451	c jun n terminal
0.2942021965	to evaluate
0.2939148121	o linked
0.2932210543	attributable to
0.2931768062	cd8 +
0.2929498445	androstane receptor
0.2929371175	specific inhibitor
0.2925092054	malignant cells
0.2921814694	the presence or absence
0.2920832099	a potential therapeutic target
0.2917236098	60 min
0.2916248200	cell lung cancer
0.2914590087	phosphatase activity
0.2912470401	study showed
0.2911767018	induced hepatic
0.2911083833	stimulated human
0.2909600434	selective cox 2
0.2908586676	compared with wild type
0.2907881354	does not require
0.2907284076	receptor family
0.2905288651	protein tyrosine
0.2904977910	one or more
0.2904499637	interacts with
0.2904137026	belonging to
0.2903912949	the transcription of
0.2902479065	kg day
0.2900944264	less potent
0.2897925800	controlled study
0.2895400950	ph 6
0.2895137167	stimulated camp
0.2893912949	the age of
0.2892633715	these findings
0.2890529087	s phase
0.2890085172	extracted from
0.2887638623	immediately after
0.2887584361	il 3
0.2887444593	in vivo microdialysis
0.2887227638	incorporated into
0.2885154327	protected against
0.2883912949	the decrease of
0.2882012344	beta hydroxysteroid
0.2878433214	cell carcinoma
0.2875902265	in order to
0.2875581492	fold greater than
0.2875542939	d aspartate
0.2874518718	the survival of
0.2873912949	the interactions of
0.2873912949	the process of
0.2870309712	serious adverse
0.2868127131	regarded as
0.2867791890	before and after
0.2864448663	the time of
0.2862728938	induced renal
0.2861224270	interfere with
0.2859615029	defense against
0.2855912949	the type of
0.2855784270	mice treated
0.2855507805	significant inhibition
0.2854518718	and migration of
0.2853972207	leads to
0.2850764297	time and concentration dependent
0.2850748851	ligand induced
0.2850121478	the rate limiting enzyme
0.2848453123	kidney 293 cells
0.2846896522	approximately 30
0.2843912949	the affinities of
0.2841227481	human cardiac
0.2837418180	able to
0.2837330970	these results suggested
0.2836826411	the design and
0.2835143718	in vitro and in
0.2834812309	lower than
0.2834175264	to examine
0.2830823148	in conjunction with
0.2829646845	abstract 1
0.2826826411	the affinity and
0.2826538267	receptor gene expression
0.2824974521	d glucose
0.2824706235	acts as
0.2823912949	the response of
0.2823501957	significant effect
0.2823201285	min 1
0.2819776831	nad +
0.2817525039	immune system
0.2815531513	compared to vehicle
0.2812018718	the reaction of
0.2810908905	6 months
0.2810652444	activator inhibitor
0.2807689206	l type
0.2806875500	human colon
0.2799505301	subunit gene
0.2799217529	more pronounced
0.2798460758	drug levels
0.2796738119	no obvious
0.2794529023	co administered
0.2793912949	the study of
0.2793339423	50 mg
0.2791555924	k ras
0.2791113525	cox 2 inhibition
0.2789778646	vegf d
0.2787755586	induced endothelial
0.2787615337	3 hydroxy 5
0.2787228362	kappab activation
0.2785912949	the selectivity of
0.2785140330	behaved as
0.2782871671	30 days
0.2781412949	the density of
0.2780498439	alone and in combination
0.2780408702	insulin dependent
0.2779124014	in accordance with
0.2778350352	daily dosing
0.2774175080	accounting for
0.2772217997	to compare
0.2771264120	chloro 2
0.2768902974	n =
0.2765042464	well understood
0.2763412949	the size of
0.2762643718	of mice with
0.2762160110	x 10
0.2761210510	clinical effects
0.2760110908	due to
0.2759844425	mediated effects
0.2758860727	± 6
0.2758090944	association between
0.2754957737	potent inhibition
0.2750644266	kinase akt
0.2750536385	4 methoxy
0.2749742194	antiplatelet effects of
0.2748263734	cancer treatment
0.2746909806	data indicate
0.2746090222	relatively low
0.2742860249	broad range of
0.2741706022	to obtain
0.2736612614	more effective
0.2736282234	5 ht1a receptor
0.2735733179	less than
0.2733484103	interleukin 1
0.2732056963	angiotensin ii receptor
0.2731361969	role in regulating
0.2727645451	did not modify
0.2727083073	stimulating factor
0.2726836737	present review
0.2726143404	n acetyl d
0.2724108543	to understand
0.2723430732	na + k +
0.2722813404	no synthase
0.2721582859	embryonic kidney
0.2719495339	as well as
0.2716193733	correlated with
0.2715473396	overall survival
0.2712350449	a group of
0.2711750827	correlations between
0.2710853648	h prazosin
0.2707438689	investigated whether
0.2706171334	the selective 5
0.2706105658	17 beta
0.2705806325	based on
0.2702437303	a greater extent
0.2702310922	to explore
0.2700344566	continues to
0.2698123817	nonsteroidal anti
0.2694691312	class of compounds
0.2693412949	the performance of
0.2693191801	in xenopus oocytes
0.2692886163	with and without
0.2685408727	the generation of reactive oxygen
0.2685215902	depend on
0.2684833030	day old
0.2683412949	the synthesis and
0.2683179433	in part to
0.2681412949	the field of
0.2680462842	cells showed
0.2678077604	a total of
0.2677306379	n and c
0.2676269207	in spite of
0.2674914570	the potency and
0.2673067362	devoid of
0.2672288641	compared to
0.2666309319	in order to investigate
0.2665693795	the absence and presence of
0.2661412949	the viability of
0.2655922418	basolateral membrane
0.2652887595	cat 1
0.2652643718	the outcome of
0.2650627774	90 min
0.2649657977	involved in
0.2639470985	type 2
0.2639098989	these findings provide
0.2632643718	and apoptosis of
0.2631858112	time dependent manner
0.2626557319	current study
0.2625570159	10 mg
0.2624071115	stimulated insulin secretion
0.2623312484	beta 1
0.2622643718	a study of
0.2620738720	complex i
0.2620507825	showed significantly
0.2620218950	increased blood
0.2620206546	after surgery
0.2619384577	structure activity
0.2617165394	examined whether
0.2616118630	of cells in
0.2614520743	10 mm
0.2612866405	before and during
0.2606631346	thereby reducing
0.2599831246	antagonist activity
0.2597689815	tubule cells
0.2596857916	required for
0.2595423317	terminal kinase
0.2593978861	g kg
0.2587360639	stably transfected with
0.2581833330	time and dose dependent manner
0.2580589244	to create
0.2580139595	t cells
0.2577802433	important roles in
0.2577623740	those of other
0.2574236903	dependently increased
0.2572113611	treatment of alzheimer
0.2571501814	most frequently
0.2571379050	shown to play
0.2571065882	used to treat
0.2570376454	more efficient
0.2568195556	an important
0.2563917868	30 microm
0.2560916110	induced caspase
0.2556895755	mg kg i
0.2554840635	the feasibility of
0.2554694652	activating factor
0.2554213984	t1 2
0.2553816361	t cell activation
0.2553263731	firing activity
0.2553059526	brain natriuretic
0.2551903840	key roles in
0.2551387756	still unknown
0.2549453894	the proliferation and
0.2549004654	per min
0.2548348570	activated protein
0.2547855357	20 min
0.2547088025	the functions of
0.2546158728	and differentiation of
0.2544079120	n acetyl l
0.2540126583	hydroxy 5
0.2537030746	in situ
0.2536900004	glucose 6
0.2533713636	shed light on
0.2533517872	regulated kinase 1
0.2533126843	an essential role
0.2529955567	potential anti
0.2529376474	mean age
0.2525930267	possible role
0.2524550475	composed of
0.2523773877	cox 1 cox
0.2523587472	consisting of
0.2522485126	high levels of
0.2521231716	iii trials
0.2520170771	intracellular reactive
0.2517994809	after sci
0.2517853256	cholinergic system
0.2517156538	small molecule inhibitors of
0.2514837026	high levels
0.2514265085	act as
0.2514114640	isolated from
0.2513497630	catalysed by
0.2513348061	the same
0.2513044288	g protein
0.2511934588	compensate for
0.2507960602	25 mg
0.2507476905	release of cytochrome c
0.2507032972	ectopic expression of
0.2505595221	more efficiently
0.2504523183	non peptide
0.2501382651	induced ca
0.2501338177	of mrna for
0.2499903444	the food and
0.2496805049	and tolerability of
0.2495634857	did not inhibit
0.2485406749	determine whether
0.2485234629	1 yl
0.2482301815	under investigation
0.2475539934	this study demonstrates
0.2474788922	resulting from
0.2474651472	t type
0.2467267210	receptor genes
0.2463612170	derived from
0.2459833804	the efficacy and
0.2458372362	aimed to
0.2458348929	10 μm
0.2454915822	normal human
0.2453955912	receptor dependent
0.2453920674	the basolateral membrane
0.2452609069	requirement for
0.2450693386	ca i
0.2450288060	in vivo and in
0.2449604692	treatment option for
0.2448920850	in part by
0.2448166763	urinary excretion of
0.2445582360	significant increases in
0.2444610768	most effective
0.2443583031	lower urinary
0.2440630129	3 mg kg
0.2437048747	a time and dose dependent manner
0.2434078367	levels decreased
0.2432982747	low levels of
0.2432938220	more potently
0.2428581041	inhibition of acetylcholinesterase
0.2427899513	dopamine d
0.2425367125	50 microm
0.2424166753	to determine whether
0.2416843358	able to induce
0.2416663028	lower levels
0.2412805477	specific expression
0.2411687665	phase 2
0.2411206264	incorporation into
0.2409558388	higher levels of
0.2406851253	as low as
0.2406624580	cos 1
0.2405301036	to achieve
0.2403526852	chronic treatment with
0.2399953509	protein 1
0.2398957717	+ prazosin
0.2396718469	of rats with
0.2395247245	binding activity
0.2393013290	significant decreases
0.2390320132	anti il
0.2388423438	orexin a
0.2385949349	intravenous injection of
0.2384630528	protein binding
0.2377470652	such as
0.2375722728	selective 5 ht
0.2371441808	iii clinical trials
0.2370941143	expression of mrna
0.2370643737	known about
0.2369348152	5 ht3 receptor
0.2367507227	the culture medium
0.2364820402	supported by
0.2364285444	g proteins
0.2363404794	to identify
0.2361524116	contributing to
0.2356553978	shed light
0.2355376535	human alpha
0.2353692451	t cell proliferation
0.2352882973	treatment of chronic
0.2351810882	acid residues
0.2351718686	potent inhibitor of
0.2350946985	no production
0.2350151601	a double blind
0.2345701576	with respect to
0.2344339622	pc 3
0.2342891950	decreased serum
0.2337630649	0 mg kg
0.2335292279	injury induced
0.2331147334	damage induced
0.2328462608	alpha reductase
0.2327610205	evaluate whether
0.2326667816	alone or in combination
0.2325814615	and safety of
0.2324789583	100 nmol
0.2324130396	10 and 20 mg
0.2322117666	recombinant b
0.2321374472	specific gene
0.2320221325	microtubule associated
0.2317689751	per day
0.2314890525	activated receptor
0.2312790320	protect against
0.2312560237	this finding
0.2311573215	the active site
0.2311356850	circulating levels of
0.2309293582	4 weeks
0.2308206690	inhibition of 3h
0.2306445196	receptor selective
0.2305513808	ii receptor
0.2303511220	human beta
0.2302024157	kd =
0.2299364731	after adjusting for
0.2298500314	difference between
0.2296809187	further evaluation
0.2292275634	well studied
0.2290541548	introduced into
0.2287290071	mg twice
0.2285200297	in postmenopausal women
0.2284475914	relationships between
0.2283681291	risk factor for
0.2282618066	complexed with
0.2281090770	methyl 5
0.2277925228	the gastrointestinal tract
0.2275957591	classified as
0.2274098948	followed by
0.2273861087	does not affect
0.2272542197	higher levels
0.2270724437	with or without
0.2266482449	growth factor receptors
0.2266082156	effects of
0.2261586459	hydroxy 2
0.2258486604	the molecular basis
0.2255209328	less effective
0.2249887378	± 3
0.2245392903	stimulatory effect of
0.2245260638	receptor beta
0.2243160978	mao a
0.2243114719	used clinically
0.2243022956	associated with
0.2242834069	indicative of
0.2238018059	differences among
0.2235037874	resulted in increased
0.2234390346	human cells
0.2233361707	characterized by
0.2232849389	catalyzed by
0.2231133988	kg per
0.2225978651	any significant
0.2222094986	inhibitory effects on
0.2221450784	7 hydroxy
0.2220426633	100 μg
0.2218017414	an alternative
0.2215176340	role of
0.2215041371	in contrast
0.2214689413	15 mg
0.2213991879	alpha 2
0.2212314678	glucose induced
0.2209150392	nuclear translocation of
0.2204732052	rats pretreated with
0.2203724975	firing activity of
0.2194280765	therapeutic agent for
0.2190474024	kg per day
0.2186643011	focus on
0.2185643063	synthase 1
0.2184237782	ec 1
0.2183812635	to generate
0.2181452757	allosteric modulator of
0.2179666628	significant decrease in
0.2179567670	b domain
0.2177857515	closely related to
0.2176321842	rats treated
0.2175022000	ec 3
0.2170574844	alone and in
0.2169855165	significant decreases in
0.2169155089	used to measure
0.2168418485	40 mg
0.2165242290	na k
0.2164645342	one carbon
0.2162775990	ca v
0.2159284186	oral administration of
0.2159280197	this work
0.2155357955	exposed to
0.2154035965	as monotherapy
0.2146082156	inhibition of
0.2144203910	induced increases in
0.2144173124	much less
0.2143857276	study evaluated
0.2143834602	no significant effect
0.2142646770	interactions between
0.2141306825	activator of transcription
0.2139246516	transporter gene
0.2138185435	rats exposed to
0.2136882753	higher than
0.2135749977	crystal structures of
0.2135357262	damage response
0.2131415716	released from
0.2130818322	proteins involved
0.2129443164	enzymes involved
0.2129281554	the safety and
0.2129116580	ca2 + i
0.2126056119	treatment of inflammatory
0.2120568797	acid reactive
0.2115547735	did not produce
0.2114188285	1 mg kg
0.2112730760	the control group
0.2111861718	ii induced
0.2111788848	expression of genes
0.2111016083	4 hydroxy
0.2109664428	patients treated with
0.2107279951	dose dependent increase in
0.2105526403	not clear
0.2105057145	8 weeks
0.2104492574	7 days
0.2104290779	the hypothalamic pituitary adrenal
0.2103670520	by high performance liquid chromatography
0.2103618995	across species
0.2100026406	s syndrome
0.2098316879	to analyse
0.2098259531	ic50 value
0.2096469165	patients with chronic
0.2093375387	2 pam
0.2091411953	the nucleus accumbens
0.2091394941	3 fold
0.2091004727	selective inhibition
0.2090813243	the objective of
0.2089781102	s lymphoma
0.2089778876	significantly induced
0.2089775309	methyl 1
0.2084587920	expression in human
0.2082505406	patients with acute
0.2081230936	increasing concentrations of
0.2079600276	to avoid
0.2079486015	phenyl 1
0.2074130753	ic50 values for
0.2073947912	essential for
0.2072994353	to monitor
0.2072983062	precursor protein
0.2072392597	competitive inhibitors of
0.2071318494	an animal model
0.2070781704	300 microg
0.2069904811	cox 2 protein
0.2068768684	b cell
0.2067873467	believed to
0.2058726481	to verify
0.2056988186	to address
0.2056215999	treated with
0.2054726775	ectopic expression
0.2050742159	fos expression
0.2049797951	much lower
0.2047944683	5 ht1b receptor
0.2046600008	human serotonin
0.2045719197	impact on
0.2045117057	n acetyl beta
0.2044271209	receptor positive
0.2041018793	ki = 0
0.2040209243	significantly less
0.2039302461	inhibition of cox 1
0.2036116390	a variety of
0.2034632795	at ph 7
0.2032153532	significant reduction
0.2031897228	potent inhibitors of
0.2030613016	influenced by
0.2029297588	4 fold
0.2029210757	these drugs
0.2029116712	6 phosphate dehydrogenase
0.2027321844	significant reductions in
0.2024055363	compared to wild type
0.2022986983	some cases
0.2022826010	induced neuronal
0.2022317440	patients with
0.2022188766	but not
0.2021413083	prior to
0.2019639214	induced dna damage
0.2015695681	5 ht release
0.2012144725	mg kg per
0.2009397086	half life of
0.2007527378	participate in
0.2007309855	non neuronal
0.2006903101	* 2
0.2004536761	apoptosis induced by
0.2004179629	drug induced
0.2003103354	the presence of
0.2001942766	binding protein 1
0.2000538196	non steroidal anti
0.1998227315	one patient
0.1995585266	100 mm
0.1995180654	explained by
0.1994670767	sk n
0.1994241886	mice treated with
0.1993498726	human dopamine
0.1991337648	inhibition of platelet
0.1990943941	recently described
0.1990467546	for detecting
0.1988565097	cos 7
0.1988239958	repeated administration of
0.1986831005	did not exhibit
0.1984729086	ic50 = 0
0.1984500812	dose dependent inhibition of
0.1983665724	the same extent
0.1982951652	treatment of diabetes
0.1982714496	emphasis on
0.1980710837	associated antigen
0.1980382200	very important
0.1979613748	human tumor
0.1979409173	to detect
0.1978923083	most commonly
0.1978872689	2 fold
0.1977327110	shown to
0.1977153716	brain levels
0.1977050296	by measuring
0.1976638398	caused by
0.1975484107	binding to
0.1973053455	only slightly
0.1971974372	28 day
0.1971626953	the first time
0.1971257163	new insights into
0.1971000168	t allele
0.1970795473	incubated with
0.1969918855	this issue
0.1967184372	approximately 4
0.1961548820	receptor activity
0.1959660443	effects on
0.1955691103	proteins involved in
0.1955472085	a significant decrease
0.1954560134	co administration
0.1952444891	exposure to
0.1950170718	more effective than
0.1947647378	lead to
0.1947550275	acted as
0.1947283917	vs 0
0.1944739196	chronic heart
0.1944144586	293 cells
0.1943622864	fold increase in
0.1941295045	induced by
0.1940493459	consisted of
0.1938086875	seem to
0.1937046968	vulnerable to
0.1934632089	in wild type mice
0.1932751908	effect of
0.1929990303	intraperitoneal injection of
0.1929928196	methyl 2
0.1929735557	did not prevent
0.1926223224	inhibition of cox 2
0.1926056583	blocked by
0.1926014978	1 methyl 4
0.1925574007	treatment of acute
0.1925054192	after adjustment for
0.1923079088	most promising
0.1922016565	phosphatidylinositol 3
0.1920980139	an extended
0.1919054208	ability to
0.1918858856	similar to
0.1918592749	induced pulmonary
0.1917533884	treatment of breast
0.1917332908	no difference
0.1917130510	in silico
0.1913199787	retinoid x
0.1907437510	an effective
0.1907433389	factor 1
0.1906426587	participates in
0.1906244403	to optimize
0.1903079582	exon 1
0.1902550477	30 nm
0.1899174178	in humans
0.1897378318	promising new
0.1895912210	0 mm
0.1895683215	induced phosphorylation of
0.1893642107	c peptide
0.1893122527	three times
0.1892503720	decreased expression of
0.1891978797	to elucidate
0.1891419898	more potent than
0.1890293071	modulated by
0.1890048755	peptidase 4
0.1888727258	structural changes
0.1885696843	cells in vitro
0.1884507913	oxygenase 1
0.1883051281	5 mg
0.1882884762	functional roles of
0.1882689961	this hypothesis
0.1878292306	to measure
0.1877779577	used in combination
0.1874433311	amino 2
0.1872335559	clinical use
0.1872218895	amino 3
0.1867533255	most likely
0.1866426869	intracellular accumulation of
0.1865993007	interact with
0.1864822214	most important
0.1864819701	x =
0.1864056234	inhibition of human
0.1863864379	extracellular levels of
0.1863382490	p dioxin
0.1862625615	a conformational change
0.1862042066	beneficial effects on
0.1861526270	therapeutic target for
0.1853707040	no effect on
0.1853607601	induced increase in
0.1852879404	x kg
0.1852269047	a high throughput
0.1850450093	an attempt to
0.1848039128	inotropic effects of
0.1847851443	significant reduction in
0.1845267912	the aerial parts
0.1843309967	these results indicate
0.1842791917	time dependent
0.1840512739	increased cell
0.1840501247	for 15 days
0.1840196504	17 alpha
0.1838418362	activation of caspase
0.1835979841	beta 2
0.1835869535	incubation with
0.1835564421	this effect
0.1834260146	inhibitory effects of
0.1833921175	bind to
0.1833481581	presented here
0.1832561845	ascribed to
0.1832428760	most importantly
0.1831640293	activation of
0.1830492847	to quantify
0.1823214766	1 microm
0.1822922924	high affinity for
0.1822682676	30 mg
0.1822408546	increased expression of
0.1817360462	20 microm
0.1816768164	restoration of
0.1816591522	at position
0.1815963574	kinase dependent
0.1815452954	these findings indicate
0.1814394491	in bronchoalveolar lavage
0.1814351219	the hypothalamic pituitary
0.1814205882	identification of
0.1812845545	cells from oxidative
0.1811325222	more effectively
0.1809658243	serum levels of
0.1809582910	selective over
0.1808120961	structure of human
0.1807282175	in comparison to
0.1805713447	prepared from
0.1805289416	frequently used
0.1804794975	faster than
0.1804089378	effect on
0.1802820173	fold more
0.1802425918	expression profiles of
0.1800306462	type b
0.1800278318	2 carboxylic acid
0.1795139587	apart from
0.1794494152	fold increased
0.1790974895	anti inflammatory effect of
0.1787652968	up regulation of
0.1786906166	related to
0.1784888581	superior to
0.1784691297	most active
0.1784570963	activation of nuclear factor
0.1781782290	options for
0.1780933227	h nmr
0.1780290795	chronic exposure to
0.1779363382	suitable for
0.1779136741	phase 1
0.1777256600	± 2
0.1776859180	line therapy for
0.1776265824	the entire
0.1776187945	disruption of
0.1775374240	unaffected by
0.1774569106	did not influence
0.1773975549	in 3t3 l1 adipocytes
0.1772091531	the dopamine d2 receptor
0.1771659852	significantly higher in
0.1770976413	for use in
0.1767089915	these results
0.1764461901	selective alpha
0.1763084955	an effort to
0.1762954388	effects of chronic
0.1762901303	transporter 2
0.1760867374	intravenous administration of
0.1760504077	like growth factor
0.1759904012	7 fold
0.1759230367	values of 0
0.1759008561	mimicked by
0.1758215939	a significant increase
0.1756905788	based upon
0.1755029788	inhibitor of human
0.1754304218	induced inflammatory
0.1754158461	these data
0.1753429674	this phenomenon
0.1753117560	kinase 2
0.1752874635	9 fold
0.1748981182	the ventral tegmental area
0.1748834837	factor alpha
0.1747138663	determined using
0.1746716956	implicated in
0.1746029208	these differences
0.1745910235	correlates with
0.1745353462	these agents
0.1743969666	alpha 1
0.1742974810	pretreatment with
0.1742006278	new series
0.1741796349	receptor 1
0.1739563786	by high performance liquid
0.1735776616	children with
0.1735558987	healthy control
0.1734662932	each group
0.1732463667	these data indicate
0.1730789691	in rat brain
0.1730065800	expression of
0.1728108353	methoxy 2
0.1727812095	a time and dose dependent
0.1727435768	genes involved
0.1725620239	in terms of
0.1724769017	cells exposed to
0.1724581887	transcriptional activation of
0.1724222400	against oxidative stress
0.1723062618	transporter 1
0.1723001180	higher affinity for
0.1722915807	acid metabolism
0.1722675682	significantly correlated with
0.1722514148	receptor subunit
0.1720026676	group b
0.1719181891	20 nm
0.1718905800	as follows
0.1718260063	women with
0.1718049363	4 mg kg
0.1717985830	coadministered with
0.1717938925	20 fold
0.1717937365	mediated by
0.1717755386	resulted in significant
0.1714884043	5 fold
0.1713486755	in recent years
0.1712996018	induces apoptosis in
0.1712722464	evidence indicates
0.1708966165	apoptosis in human
0.1707581207	time curve
0.1706818920	mean arterial
0.1706486499	elucidation of
0.1700930244	a significant reduction
0.1693848975	1 week
0.1693092687	abolished by
0.1692734257	10 mg kg day
0.1692078226	in xenopus laevis oocytes
0.1690243220	type 1 receptor
0.1689847521	kinase 1
0.1689198140	hydroxyl group of
0.1688378159	the rate limiting step
0.1687969126	these compounds
0.1686913056	kg 1
0.1686596718	induced diabetic
0.1684220284	structural features of
0.1683789562	cysteine s
0.1682970511	methyl 3
0.1682691018	terminal domain of
0.1682591028	5 ht receptors
0.1681094901	characterization of
0.1679687445	did not induce
0.1679323571	new insights
0.1678934066	low levels
0.1678045195	under conditions
0.1674977277	returned to
0.1674822649	role in
0.1674653490	activity toward
0.1673676275	disease associated
0.1672893498	activity in vitro
0.1668463045	different types of
0.1667722578	24 h after
0.1666903254	receptors in rat
0.1666436909	crystal structure of
0.1664623690	affinities for
0.1663667414	treatment of asthma
0.1662043752	pre treatment with
0.1661777557	in guinea pig
0.1660839277	p =
0.1659237336	increase in plasma
0.1658274389	a wide range of
0.1657727402	treatment of human
0.1656626472	increased levels of
0.1655178445	at 37 degrees c
0.1655012289	cell death through
0.1654865034	in mammalian cells
0.1654495137	determined by
0.1654454611	selective inhibition of
0.1652897096	100 microg
0.1652775005	by site directed mutagenesis
0.1650719855	mice exposed to
0.1648194441	at baseline
0.1647941872	the alpha 1a adrenoceptor
0.1645600093	no effect
0.1645388172	high affinity binding of
0.1645322144	fails to
0.1643925418	dna binding activity of
0.1643360212	25 microm
0.1642358901	the purpose of
0.1641969925	in chinese hamster ovary cells
0.1640016080	measured using
0.1639326691	four groups
0.1639005323	increased risk of
0.1636773501	mrna expression in
0.1634071997	associates with
0.1633057337	transfected into
0.1631010481	mg d
0.1628455168	with ki values
0.1627280290	a high affinity
0.1627176474	approximately 5
0.1625417068	pharmacological characterization of
0.1625351426	balance between
0.1624337497	a dominant negative
0.1623556173	these effects
0.1622033198	determined whether
0.1621406705	respond to
0.1621067518	direct inhibition of
0.1619351827	an additional
0.1618905670	divided into three
0.1618307536	regulated by
0.1617613278	this property
0.1616582634	an extremely
0.1616449013	japanese patients with
0.1612394598	along with
0.1611558393	resulting in
0.1611293012	10 min
0.1611074705	rapid onset of
0.1610754107	systemic administration of
0.1609420209	report here
0.1602448969	develop new
0.1601962431	an overview
0.1601029199	nuclear localization of
0.1599994523	the present study examined
0.1598473838	appear to
0.1597771408	highly expressed in
0.1596936747	two isoforms
0.1595534008	selectivity against
0.1594942959	encoded by
0.1594932131	each patient
0.1594931616	type i
0.1590355815	significant increase in
0.1587391840	acid binding
0.1586494812	in summary
0.1585255710	the guinea pig
0.1584142326	decreased cell
0.1582133951	95 ci =
0.1579797182	further support
0.1579473876	domain containing
0.1579208352	larger than
0.1578902321	5 methyl
0.1578761838	specific binding of
0.1578501159	susceptibility to
0.1577451053	proof of
0.1577360119	anti inflammatory effects of
0.1574901433	associate with
0.1574607234	cell death induced by
0.1571782753	30 fold
0.1571773540	relative to
0.1571488778	response to
0.1571026435	a selective cox 2 inhibitor
0.1570443234	effective against
0.1568614767	chronic administration of
0.1567904299	pharmacological profile of
0.1566609373	modulation of
0.1566551694	genes involved in
0.1566476953	binding sites for
0.1566045357	mrna expression of
0.1565019881	consists of
0.1565004634	minutes after
0.1564248788	high selectivity for
0.1563709976	analysis indicated
0.1563454417	model system
0.1563410385	2 weeks
0.1562954279	seemed to
0.1562745312	extracellular levels
0.1561917076	days after
0.1561503704	in vitro models
0.1561264586	an essential
0.1558541576	present results
0.1558419425	metalloproteinase 2
0.1556568928	the wild type
0.1556518797	acid receptors
0.1556479900	cancer cells in vitro
0.1556431467	a major role
0.1555405856	altered expression of
0.1553556093	large number of
0.1553367519	estimation of
0.1552542348	the present review
0.1551237480	genes related to
0.1550331859	rats treated with
0.1550100464	cytotoxicity against
0.1549865874	elevated levels of
0.1549380018	plasma levels of
0.1548727490	inhibited tumor
0.1548634205	an in vitro model
0.1548164514	the present studies
0.1545850876	assessed using
0.1545369920	the epidermal growth factor receptor
0.1545289102	activity in vivo
0.1542364016	induced inhibition of
0.1540778108	to clarify
0.1540775387	arteries from
0.1537167697	at steady state
0.1535406897	group 1
0.1534019312	kinase 1 2
0.1533416539	no longer
0.1527312346	1 adrenoceptor antagonist
0.1525721830	cell cycle arrest in
0.1525379978	explanation for
0.1525090232	caused by mutations
0.1524325631	linked to
0.1524245692	inhibition of tumor
0.1523121986	8 mg kg
0.1521772390	used to assess
0.1520358725	lipid accumulation in
0.1518672178	the molecular mechanism
0.1517887770	the normal range
0.1517535407	recognized as
0.1516361918	reversed by
0.1516250059	tool for
0.1515655913	synthase 2
0.1514594148	the past
0.1513993821	an increase in
0.1513288744	approximately 1
0.1512873856	high doses of
0.1511189292	at positions
0.1511085049	induced vascular
0.1510621228	the molecular mechanisms
0.1508692542	5 ht2a receptor
0.1508631362	dependent protein
0.1508123024	appeared to
0.1507770711	anti inflammatory activity of
0.1505505903	involved in cell
0.1503717974	5 ht receptor
0.1503453867	observed between
0.1503359122	differences in
0.1502011495	plasma concentrations of
0.1501985333	enzyme responsible for
0.1501698634	thus far
0.1500412974	likelihood of
0.1499968341	more than
0.1498162678	inhibited by
0.1497720717	more recently
0.1496912402	result from
0.1495723668	stimulus effects of
0.1494796165	doses of 0
0.1493422392	uptake into
0.1493269813	pathways involved in
0.1492183799	rank order of
0.1491771735	a dose dependent
0.1489813026	to delineate
0.1489794357	patients treated
0.1488923289	combination therapy with
0.1488879700	induced liver
0.1488700176	no significant
0.1488459350	the dorsal raphe
0.1486236716	supplemented with
0.1486180420	proved to
0.1485741880	the parent compound
0.1484541946	growth in vivo
0.1483222325	the plasma membrane
0.1482619875	induced apoptosis in
0.1482432619	the results showed
0.1481452881	pivotal role in
0.1481407335	serotonin 5
0.1481158759	with regard to
0.1479401226	complex 1
0.1478104807	to define
0.1477989600	localized to
0.1477895223	recovery from
0.1477015532	antagonized by
0.1476465232	the presence or absence of
0.1471064478	these same
0.1470323380	by inhibiting
0.1468718554	the norepinephrine transporter
0.1468676740	attempt to
0.1468217290	a significant role
0.1467995456	in chinese hamster ovary
0.1467342745	lower levels of
0.1466876792	a small molecule
0.1465176262	the frontal cortex
0.1464998936	in human umbilical vein endothelial cells
0.1463390227	the glucocorticoid receptor
0.1462428880	regulation of
0.1462421305	n = 11
0.1461791806	as evidenced by
0.1461665318	a high fat
0.1461428406	10 nm
0.1460477716	system y
0.1457957018	mediated induction of
0.1456697760	a single
0.1456079999	like behavior
0.1455692103	receptor gamma
0.1455204800	not affected
0.1453966687	the present work
0.1448942319	min before
0.1447172891	members of
0.1447145026	the endoplasmic reticulum
0.1446289681	delivery system
0.1445356708	no synthesis
0.1443152356	the present study investigated
0.1442723426	studied using
0.1442380979	ki values of
0.1442374267	eliminated by
0.1441355249	60 mg
0.1440457183	occurred at
0.1440370534	act through
0.1438540437	to better understand
0.1436864303	currently used
0.1436488113	as effective as
0.1436453668	adverse effects of
0.1435429274	evaluated whether
0.1434517532	prevented by
0.1433959817	ros generation and
0.1433236630	independently associated with
0.1432298690	in guinea pigs
0.1431703393	the small intestine
0.1431380213	inflammatory activities
0.1430903104	an important role in
0.1430858056	produced by
0.1430668363	in mice
0.1430038208	n = 8
0.1430012139	evaluated using
0.1429463725	the context of
0.1429098089	contributed to
0.1429066153	rescued by
0.1427735625	mg kg b
0.1427584411	5 microm
0.1427063146	a cell based
0.1426454613	ii inhibitors
0.1425038349	to predict
0.1424599219	in vitro studies
0.1423849696	the androgen receptor
0.1422336298	gene expression in
0.1420742603	to produce
0.1420450468	the sole
0.1418150717	resulted from
0.1417982668	the renin angiotensin system
0.1417185023	significant difference in
0.1417153756	b radiation
0.1416707304	these enzymes
0.1413467611	treatment of parkinson
0.1413272955	release from
0.1412381494	h post
0.1410033494	apparent k
0.1409252626	potent inhibition of
0.1409146103	the cell cycle
0.1408271612	a key role
0.1406897740	95 ci 0
0.1405375786	the cerebral cortex
0.1405218028	the dentate gyrus
0.1404439270	treatment with
0.1404040616	metabolic effects of
0.1403835049	therapeutic use
0.1403346856	oxidative stress in
0.1402205568	performed using
0.1401963329	in hippocampal slices
0.1398624906	structure activity relationships of
0.1397086140	both cell lines
0.1396542332	did not differ between
0.1396475407	2 mg kg
0.1396338754	insulin like
0.1394258470	observations indicate
0.1393711056	affinity for
0.1393691073	protective effects of
0.1393310453	+ 14
0.1390602856	5 mm
0.1389727504	1 mm
0.1388770450	significant inhibition of
0.1388613429	a series of
0.1388309291	group 2
0.1385937064	a concentration dependent
0.1385832717	glucagon like
0.1385470350	but rather
0.1385275900	replaced with
0.1384391554	both groups
0.1383902696	low affinity for
0.1381244040	further studies
0.1380883893	treatment of breast cancer
0.1380657085	6 weeks
0.1380032215	the pro apoptotic
0.1379467398	11 beta
0.1379406981	the prefrontal cortex
0.1378648227	about 20
0.1377285506	triggered by
0.1377060754	study aimed to
0.1375904611	structure activity relationship of
0.1373028620	amino 1
0.1372300483	to determine if
0.1372013693	low concentrations of
0.1371772434	currently under
0.1371053482	possible mechanisms
0.1370783898	more severe
0.1369860044	specific activity of
0.1369519632	the high affinity
0.1369355101	three groups
0.1367699209	cell cycle arrest and
0.1367663561	high degree of
0.1366138383	induced increase of
0.1366102332	located at
0.1365849317	for example
0.1364396824	important role of
0.1364067691	in vitro experiments
0.1363120978	95 ci 1
0.1363038621	a comprehensive
0.1362927718	two groups
0.1361820816	= 8
0.1358989967	l amino acid
0.1358775766	the substantia nigra
0.1357689518	high concentrations of
0.1355829825	cardiovascular system
0.1355334540	confirmed by
0.1355157997	co administration of
0.1355040285	primary cultures of
0.1354688081	five patients
0.1354139919	the spinal cord
0.1353166304	interfering with
0.1352212602	to develop
0.1351141373	3 months
0.1351102085	access to
0.1350059744	+ 2
0.1349684037	9 + 0
0.1349642052	iontophoresis of
0.1349424676	the aim of
0.1347044421	9 ±
0.1346564347	associated proteins
0.1343837224	aspects of
0.1343832722	these cells
0.1342241684	submitted to
0.1341045966	two distinct
0.1340720896	+ 1
0.1339680706	or saline
0.1339674565	significant increase of
0.1339557951	down regulation of
0.1337808763	significantly lower in
0.1337384434	needed to
0.1336936779	to characterize
0.1335961710	recognized by
0.1334293045	sensitivity to
0.1334255287	acute administration of
0.1333983475	in conclusion
0.1332869900	oral doses of
0.1331775658	induced decrease in
0.1331565399	a large number
0.1331111984	the proximal tubule
0.1330963151	mg l
0.1330673600	by decreasing
0.1329864944	in rats
0.1329541006	12 week
0.1329483282	purified from
0.1329467619	to overcome
0.1328780330	from baseline
0.1328771181	mediated inhibition of
0.1328518525	distinct from
0.1328113796	increasing concentrations
0.1327223979	weeks after
0.1326291937	correlate with
0.1325933584	4 phenyl
0.1324986086	carried out using
0.1323987668	in vitro assay
0.1323519211	brain levels of
0.1323016341	activity in human
0.1322475013	a potential role
0.1321673603	to prevent
0.1321388847	6 nm
0.1321238124	assigned to
0.1320861464	an amino acid
0.1320687674	* 6
0.1319173393	susceptible to
0.1318842895	+ 7
0.1318442470	8 nm
0.1317629694	+ 8
0.1315044837	by liquid chromatography
0.1314832047	the basis of
0.1312676156	both in vitro and in vivo
0.1310405624	all patients
0.1309507972	affected by
0.1308794593	an average
0.1308647936	activity relationships
0.1307967278	to improve
0.1307209217	broad spectrum of
0.1306326882	2 amino 1
0.1305854797	= 12
0.1305551884	the hypothesis
0.1303655927	does not appear to
0.1302631864	accounted for by
0.1301742869	did not reduce
0.1301219925	in combination with
0.1300626923	significant effect on
0.1300107103	equal to
0.1299386547	this process
0.1298880213	adrenoceptor selective
0.1298171020	more susceptible to
0.1296385461	= 9
0.1293368297	oral dose of
0.1292864998	new targets
0.1291321865	the ability of
0.1290821259	measured by
0.1290752536	direct effects of
0.1290440697	+ 3
0.1289889398	genotyped for
0.1289284774	all three
0.1288811418	to promote
0.1288347179	to form
0.1288108510	inhibitory effect of
0.1288012264	d glucuronide
0.1286851720	treatment of advanced
0.1285715638	two main
0.1285429290	2 chloro
0.1284972301	induced production of
0.1284677486	provide new
0.1283459682	considered as
0.1282189508	apoptotic cell
0.1281209513	a selective beta
0.1279521007	* 4
0.1279388113	+ 6
0.1277526678	induced reduction in
0.1277366940	experiments using
0.1276162970	to establish
0.1275379661	implications for
0.1274848028	reductions in
0.1274043604	a broad spectrum
0.1273575288	the catalytic site
0.1273449372	by western blot analysis
0.1272107215	different classes
0.1270903246	an increased risk
0.1270732598	ic50 value of
0.1270337490	a panel of
0.1268899419	2 and mmp 9
0.1266510954	approximately 2
0.1265945500	close to
0.1265498949	the enzyme
0.1265218742	the serotonin transporter
0.1260628725	binding site of
0.1258675535	to test whether
0.1258654076	significantly different from
0.1257769976	studies show
0.1257354695	about 50
0.1256623495	sufficient to
0.1256560164	little effect on
0.1256536321	majority of
0.1252916187	+ 4
0.1252567356	converted to
0.1251267736	no evidence
0.1250466379	4 months
0.1249589203	potential use
0.1249515015	induced expression of
0.1248375423	pharmacological inhibition of
0.1248223009	protein 3
0.1247916447	relatively high
0.1247234666	prevention and treatment of
0.1246739781	mg kg p
0.1244440057	bound to
0.1244163000	conformational change in
0.1243410124	in drinking water
0.1243234021	a risk factor
0.1241720393	this result
0.1239220999	low doses of
0.1237456871	a pivotal role
0.1237148487	mean =
0.1235937686	these receptors
0.1234581245	subsets of
0.1234563584	not significantly different
0.1234252687	7 microm
0.1233923132	elicited by
0.1230522474	increased phosphorylation of
0.1229006836	unrelated to
0.1227814233	9 mg
0.1227349409	receptor α
0.1226832576	a monoclonal antibody
0.1226238040	as indicated by
0.1225383483	x receptor
0.1224057386	removal of
0.1222250308	expressed in
0.1222228452	roles for
0.1222157056	resistance to
0.1221859886	evoked by
0.1221113675	the results obtained
0.1221081021	mediated via
0.1220749983	mice resulted in
0.1220263719	3 microm
0.1220042372	expression in
0.1219654199	approximately 3
0.1219561570	selectivity for
0.1219541761	mice than in
0.1217409500	activity of
0.1215134283	an ic50 value of
0.1214275865	receptor tyrosine
0.1213624312	significant effects on
0.1212788164	= 1
0.1212435886	the brain
0.1212207275	active against
0.1211502315	m cell cycle
0.1211204997	the transcription factor
0.1209622419	erk 1
0.1208495693	to estimate
0.1208098611	interaction with
0.1208042162	i o
0.1207767539	transcriptional regulation of
0.1207277365	induction of
0.1207027687	an indirect
0.1206926722	activation of nuclear
0.1206562177	+ 9
0.1205921030	concentration of 10
0.1204489793	3 hydroxy
0.1203744012	liver x
0.1202607242	response induced by
0.1201504051	positive cells in
0.1201272252	enzymes involved in
0.1199935201	4 week
0.1196784407	this report
0.1194657320	significant differences in
0.1194076218	the dopamine transporter
0.1194009239	the drug
0.1193790310	pretreated with
0.1190796761	kappa b
0.1190693296	less potent than
0.1189811569	at ph
0.1189664914	6 phosphate
0.1189274166	the positive inotropic
0.1189203166	= 7
0.1189100184	n = 12
0.1188907861	8 days
0.1187406572	this pathway
0.1186900711	in nude mice
0.1186647453	interacting with
0.1185598399	the authors
0.1185367884	45 mg
0.1184804614	to perform
0.1184567696	by western blot
0.1184191964	synthesized and evaluated for
0.1183257856	a new class of
0.1181144450	mediated activation of
0.1180350227	in conscious rats
0.1179899062	in clinical practice
0.1178830220	mediated through
0.1178777054	in breast cancer cells
0.1178019461	an allosteric
0.1177420575	as first line
0.1176909049	5 μm
0.1176875706	binding of
0.1176291072	the results suggest
0.1175730246	as expected
0.1174103645	cessation of
0.1172552485	participated in
0.1172414224	ci 0
0.1172242734	with high affinity
0.1171857038	two independent
0.1171478190	vulnerability to
0.1170114280	β d
0.1170005259	significantly more
0.1169826175	critical for
0.1169318145	the aromatase inhibitor
0.1168317282	o methyltransferase
0.1166517752	competitive inhibitor of
0.1165569483	results show
0.1164463537	than placebo
0.1164214134	an apparent
0.1163984818	compound c
0.1163867963	upregulation of
0.1163218784	addition of
0.1162791792	tools for
0.1162605071	added to
0.1162103965	3 weeks
0.1161818798	in turn
0.1160420589	the metabolic syndrome
0.1160164188	4 days
0.1160017675	or = 10
0.1159857086	major role in
0.1158665162	the treatment of
0.1158378951	marked increase in
0.1158257443	provide evidence for
0.1155173980	amino acids in
0.1155014402	2 +
0.1154101157	increase in
0.1154020876	candidate for
0.1153909467	safety profile of
0.1153592874	coexpression of
0.1153471265	values for
0.1150655134	mrna and protein expression of
0.1150633086	during development
0.1150378659	dependent effects
0.1149997815	the treatment of parkinson
0.1149655271	reported here
0.1148404611	plasma concentration of
0.1147834738	cytotoxic effects of
0.1147171063	differ between
0.1146503181	for 7 days
0.1145704154	8 week
0.1144452416	comparable to
0.1144088543	an inhibitor of
0.1142121501	this compound
0.1141980533	expression level of
0.1141858004	highly selective for
0.1139940429	molecule 1
0.1138620370	characterisation of
0.1138191528	8 microm
0.1137071923	mechanisms involved in
0.1136963162	a powerful
0.1133278703	a positive correlation
0.1132710106	growth inhibition of
0.1132209023	after 24 h
0.1131901048	contribution to
0.1131881566	coexpressed with
0.1131164222	non specific
0.1130629254	approved for
0.1130201454	the ligand binding
0.1129653150	into three groups
0.1129389525	in vivo studies
0.1128160124	the peroxisome proliferator activated receptor
0.1127765523	seems to
0.1127674808	controlled by
0.1126583235	4 methyl
0.1125640170	extracts from
0.1125532887	combined with
0.1125239397	not yet
0.1124941728	to stabilize
0.1124446717	a significant
0.1123348442	a marked increase
0.1123171933	suppressed by
0.1122827183	day 1
0.1121926823	the sodium channel
0.1121741234	portion of
0.1121356746	after intravenous
0.1120702352	kinase activity of
0.1120465989	insulin resistance in
0.1120411463	starting at
0.1119637403	mediators of
0.1118543045	evaluation of
0.1117616404	the mechanisms underlying
0.1117427326	the oxytocin receptor
0.1117329323	to induce apoptosis
0.1117312712	does not inhibit
0.1117118292	dependent upon
0.1115736400	the main
0.1115733515	the antitussive
0.1115042372	activity in
0.1114640273	+ +
0.1114257646	4 phenyl 1
0.1114231759	necessary for
0.1113546675	role for
0.1111913306	significant reduction of
0.1111097059	diet containing
0.1110256552	individuals with
0.1110239292	2 methyl
0.1110167935	to gp330
0.1109793055	determination of
0.1109187875	three doses
0.1108214497	inhibition by
0.1107610350	a competitive inhibitor
0.1106358675	each other
0.1105667970	a patient with
0.1104485672	more sensitive
0.1103321377	downregulation of
0.1102421876	a combination of
0.1102098691	binding domain of
0.1101948847	the low affinity
0.1101106817	coding for
0.1100619225	restricted to
0.1100330509	antioxidant activity of
0.1100121487	levels of
0.1100089114	binding sites in
0.1099409655	protein kinase a
0.1099407266	candidates for
0.1098611578	with ic50 values
0.1098292436	data indicated
0.1098233268	all compounds
0.1098113717	the rat
0.1098103445	activity relationships of
0.1097375578	observed in
0.1097022706	analysis of
0.1095441298	the transcriptional level
0.1094837560	binding pocket of
0.1093539526	the cell surface
0.1092557235	tyrosine phosphorylation of
0.1090691765	loss of
0.1090561779	dependent activation of
0.1089752135	+ 5
0.1089383350	add on
0.1088868479	a broad range of
0.1088359119	selective inhibitors of
0.1088210474	n = 10
0.1086821693	mrna levels of
0.1086426562	this enzyme
0.1085336224	10 nmol
0.1084584528	protective effect of
0.1084458065	n = 6
0.1083971348	in type 2 diabetic patients
0.1083841545	caused by mutations in
0.1083394916	expression levels of
0.1083278561	the alpha 1b
0.1082690707	6 mg kg
0.1082685326	also inhibited
0.1081852581	by altering
0.1081435886	in rat
0.1081108277	an endogenous
0.1080914559	cells treated with
0.1079704924	sulfation of
0.1078256374	inflammatory response in
0.1077417128	12 h
0.1077327575	all cases
0.1075377721	attached to
0.1074219450	used to evaluate
0.1073864334	abundance of
0.1072434816	evidenced by
0.1072162162	a single agent
0.1070909438	potency against
0.1070574694	achieved by
0.1068505367	50 nm
0.1067345469	this interaction
0.1067336542	much more
0.1066757663	over expression
0.1066666904	this approach
0.1066541871	the cell membrane
0.1064216378	monitored by
0.1064154383	a novel
0.1063884515	replacement of
0.1063499726	7 ±
0.1063141252	against oxidative
0.1062102404	or placebo
0.1061309758	contrary to
0.1060827983	results indicated
0.1060645122	this purpose
0.1060550353	the mineralocorticoid receptor
0.1059476977	important role in
0.1058215019	to induce
0.1057816363	characterised by
0.1057308039	to discover
0.1057244399	very similar
0.1056678566	treatment resulted in
0.1056495177	this study examined
0.1056158468	found to
0.1055336230	key role in
0.1051407524	in vitro study
0.1048409269	assessed by
0.1047732351	these models
0.1047600301	+ 20
0.1045976435	fatty acids in
0.1045387979	undertaken to
0.1044924396	blockage of
0.1042481679	3 hydroxy 3
0.1041410214	binding site for
0.1040890335	surface expression of
0.1040222355	fold higher in
0.1039679397	dose of 0
0.1039425782	reactivation of
0.1038268802	circulating levels
0.1037133503	unlikely to
0.1035205781	breakdown of
0.1034758809	the histamine h1
0.1034689724	a crucial role
0.1033592215	resistant to
0.1033377593	by means of
0.1033182286	separated by
0.1033086133	secreted by
0.1032707082	a potent
0.1032459950	15 days
0.1031815142	a significant effect
0.1031503527	predictors of
0.1031337924	toxic effects of
0.1030817229	benefit from
0.1030245469	a resolution
0.1029809736	the crystal structure
0.1026722763	overall response
0.1026416093	an anti inflammatory
0.1025649712	the first report
0.1025093030	percentage of
0.1024708335	three patients
0.1024137832	18 h
0.1023669532	n 3
0.1022350895	these diseases
0.1021543626	did not increase
0.1020781742	generated by
0.1020145547	release of
0.1019395081	a key role in
0.1019342035	used to identify
0.1019144013	assessment of
0.1018684848	a time dependent
0.1018356089	to elicit
0.1018010685	not statistically
0.1017956329	the steady state
0.1017955925	not completely
0.1017847156	a non competitive
0.1017471230	collected from
0.1017329034	a mouse model
0.1016433163	like receptors
0.1015055411	association with
0.1015008091	blood pressure in
0.1014623497	and insulin levels
0.1014518923	the treatment of advanced
0.1012508751	alteration of
0.1012393457	approved by
0.1012041636	previously shown to
0.1011765924	for treating
0.1011447367	tcdd on
0.1011139593	the first evidence
0.1011010960	insulin sensitivity in
0.1010974842	a promising
0.1010078541	gene expression of
0.1010041046	widely used as
0.1009841361	4 + 1
0.1009476580	analogous to
0.1009382504	present in
0.1008836012	= 6
0.1008768241	n = 5
0.1008116736	neuroprotective effects of
0.1007364631	the treatment of breast cancer
0.1007341466	5 days
0.1006563138	significantly increased in
0.1005502134	6 microm
0.1004471145	adverse effects on
0.1004204688	the development of
0.1003451788	challenged with
0.1002706583	identified as
0.1002615578	in human embryonic kidney
0.1001978763	also observed
0.1001967386	sequence analysis of
0.1001356966	of inflammatory cells
0.1001133414	min after
0.1000277263	a potential mechanism
0.0999734188	of hypoxia inducible factor
0.0999200709	over time
0.0998714369	these ligands
0.0998043040	8 + 0
0.0997812256	the beta 2 adrenoceptor
0.0997253873	these genes
0.0997195323	therapeutic potential for
0.0996418698	society for
0.0996177520	a potential
0.0994883096	option for
0.0994706304	of rat aorta
0.0993026991	2 toxin
0.0992732025	opioid receptors in
0.0992008914	6 mm
0.0990755141	requirements for
0.0989856969	= 24
0.0989028462	binding affinity of
0.0986947027	not affected by
0.0986914078	times more
0.0986110084	to confirm
0.0985846215	a pivotal role in
0.0985330995	in human cells
0.0984718133	ic50 values of
0.0984345572	values of 1
0.0983814286	8 oh
0.0982599152	in preventing
0.0981975503	identical to
0.0981953352	dependent increase in
0.0981918344	a single dose
0.0981899662	her 2
0.0981241074	mediated induction
0.0980980036	an additive
0.0980448695	to gain
0.0979725388	no significant effect on
0.0979600849	an efficient
0.0979364576	this disease
0.0978885956	90 mg
0.0977938781	a major
0.0976794994	most sensitive
0.0976596317	a potential target
0.0975587031	a consequence
0.0975255787	of vitamin b6
0.0974910040	adjustment for
0.0974454154	an initial
0.0974373738	induce apoptosis in
0.0974009239	a high
0.0973532447	decrease in
0.0973338192	phase i
0.0971693649	used to examine
0.0971374730	poisoning with
0.0971280009	4 amino
0.0970907429	related genes in
0.0970752216	in man
0.0970083832	mrna levels in
0.0968805680	major cause of
0.0968782759	alpha expression
0.0968639135	interference with
0.0967990499	cancer cells by
0.0967916553	ci 1
0.0966738428	the effect of
0.0966709039	treatment of
0.0965882723	reduced expression of
0.0965762841	measurement of
0.0965110283	protein expression of
0.0964680111	specific inhibitor of
0.0963843518	prepared by
0.0963405124	3 o
0.0962706199	low dose of
0.0962400722	less sensitive to
0.0962028538	by suppressing
0.0961962635	biological evaluation of
0.0961906020	present studies
0.0961470580	the anti inflammatory effects of
0.0960756866	did not show
0.0960670734	a low
0.0960646244	defined as
0.0960286158	the at1 receptor
0.0960218650	n = 7
0.0959830853	action of
0.0959748340	propensity to
0.0959575136	these actions
0.0959390189	from rat liver
0.0958081713	by modulating
0.0957951809	cd4 +
0.0956987933	potentiated by
0.0956727443	mean plasma
0.0955963912	predictor of
0.0955213620	in rat liver
0.0954204688	the role of
0.0953908028	by inducing
0.0953584293	the gene encoding
0.0953582992	at week
0.0953445363	comparison of
0.0952928586	an increased risk of
0.0952850690	this drug
0.0951546695	presence of
0.0951194214	metabolized by
0.0950100068	activity against
0.0949787337	= 15
0.0949074458	information on
0.0945963912	details of
0.0945270004	in rat kidney
0.0945159738	the pathophysiology of
0.0944020231	improvements in
0.0943334773	animal models of
0.0941091514	molecular mechanism of
0.0940509295	proposed as
0.0940448246	inhibitory activity of
0.0940071761	the effects of
0.0940042372	inhibitors of
0.0939012980	levels in
0.0938949431	the mammalian target of rapamycin
0.0938737404	these results show
0.0937514471	coupled to
0.0937379201	lack of
0.0936569761	i r
0.0936506517	compete with
0.0936434787	a transcription factor
0.0936422257	preference for
0.0936397388	induced apoptosis of
0.0936216754	beta d
0.0935193350	molecular weight of
0.0934691618	the alpha 1a
0.0934615585	a proton
0.0934597005	used to study
0.0933781072	determinants of
0.0933776415	selective inhibitor of
0.0933383966	modes of
0.0933056858	the liver
0.0933021042	affinity binding
0.0932993615	administration of
0.0932669982	+ 12
0.0932596404	starting from
0.0932262205	the mechanism underlying
0.0932003080	10 20
0.0931883138	by adding
0.0931499717	binding sites of
0.0930577293	the possibility
0.0930234781	result in
0.0930036408	self assembly of
0.0928809108	screened for
0.0928096437	binding properties of
0.0928093993	the selective beta
0.0927646986	1 μm
0.0927294695	to suppress
0.0926960548	transported by
0.0926436126	clinical trials for
0.0926347626	the beta cell
0.0926330771	development of new
0.0925687140	neuroprotective effect of
0.0925125830	a single oral
0.0925123701	determinants for
0.0924956250	the pro inflammatory
0.0924616389	these molecules
0.0924457148	transport system
0.0924245287	alpha production
0.0923420452	to analyze
0.0922945281	old mice
0.0922379116	phosphorylation of
0.0922366766	strategy for
0.0922019293	did not significantly
0.0921093873	this observation
0.0920954224	probably due to
0.0920800657	a low affinity
0.0920532964	in rodents
0.0920513015	variations in
0.0920270376	shifts in
0.0919628215	damage induced by
0.0919443023	basis for
0.0919085313	changes in
0.0919062256	the alpha 1 adrenoceptor
0.0918602665	glutathione s
0.0918591402	this study investigated
0.0918421118	data from
0.0918412004	cells resulted in
0.0918179638	found to inhibit
0.0917175863	functions as
0.0917057194	phosphoinositide 3
0.0915117211	increases in
0.0914946151	mixtures of
0.0914813665	n methyl d
0.0914801582	an inhibitory effect
0.0914267614	able to inhibit
0.0913801892	subjects with
0.0913686673	5 nmol
0.0913675836	1 31
0.0913637219	the inflammatory response
0.0913088154	h after
0.0912866572	decreased levels of
0.0912691557	difficult to
0.0911847494	insulin secretion in
0.0911634822	co treatment
0.0911188091	amounts of
0.0909945015	contribution of
0.0909609185	the molecular basis of
0.0908877684	activated by
0.0908685159	understanding of
0.0908514394	those obtained
0.0908193750	gene expression by
0.0908105478	a first line
0.0907957315	better understanding
0.0904786395	various types of
0.0903736068	to inhibit
0.0902988575	inhibitory action of
0.0902375263	enzymatic activity of
0.0899656568	the crystal structures
0.0898947356	a strong
0.0898946986	referred to
0.0898551589	the extracellular matrix
0.0897019821	the present results
0.0896974531	transcriptional activity of
0.0896551995	anticancer activity of
0.0895745963	treatment of cancer
0.0895143009	essential role in
0.0894791803	these studies
0.0894615452	also prevented
0.0893898424	functional changes
0.0893646043	fold less
0.0893270436	several genes
0.0891434573	more selective
0.0890173074	further confirmed
0.0890146300	during early
0.0888947356	a unique
0.0888820198	a novel mechanism
0.0888373754	insensitive to
0.0888073402	attenuation of
0.0887960397	7 macrophages
0.0887957565	group i
0.0887838527	quantified by
0.0887056778	located on
0.0885787570	a trend
0.0885573733	induced activation of
0.0883617288	protection from
0.0883157499	after adjusting
0.0883072580	new therapeutic
0.0882097503	to maintain
0.0881856302	with sitagliptin
0.0881510550	evaluation of novel
0.0881201364	overexpression of
0.0881099808	significantly reduced by
0.0879863061	tumor growth in
0.0879809546	a significant increase in
0.0878403567	inactivation by
0.0875881987	samples from
0.0875686995	5 hours
0.0875545810	findings show
0.0875141733	less sensitive
0.0874727768	acid receptor
0.0874534663	the major
0.0873878042	associated with greater
0.0873852189	coenzyme a
0.0871910186	in mice lacking
0.0871487617	the p gp
0.0870673117	property of
0.0870203736	point to
0.0870195020	05 vs
0.0870099925	activity relationship
0.0869295213	c type
0.0869258805	this combination
0.0869201105	5 nm
0.0869064882	management of
0.0868025062	possible mechanism
0.0867671518	n = 4
0.0867572376	a therapeutic agent
0.0867206654	transferred to
0.0867120324	used as
0.0865719292	6 fold
0.0865390805	the treatment of type 2 diabetes
0.0865382633	tolerance to
0.0865225566	cells with
0.0864826386	not only
0.0864339040	used to determine
0.0863371717	search for
0.0863370493	10 microg
0.0863283068	a dual
0.0863169135	mutations in
0.0862735058	mediation of
0.0862550980	protein expression in
0.0862516068	phosphatase 1
0.0862392437	animal model of
0.0862137270	potential role of
0.0861539758	history of
0.0860911812	a central role
0.0860863820	this investigation
0.0860594787	interactions with
0.0859773882	strategies for
0.0859533137	protein 2
0.0859288618	the catalytic
0.0859024983	the combined treatment
0.0858975316	potential target for
0.0858463297	the rate limiting
0.0857925876	defined by
0.0857838132	the male rat
0.0857827700	the outer
0.0857818846	no change
0.0857370633	at concentrations up to
0.0855946232	rationale for
0.0855906022	by increasing
0.0855203641	properties of
0.0855101275	signaling through
0.0855053022	in vitro model
0.0854912760	two genes
0.0854770062	more sensitive to
0.0854456378	formed by
0.0854280807	crucial for
0.0853752590	8 ±
0.0853229190	of endothelin 1
0.0853218908	suppression of
0.0853092499	cell death in
0.0852785659	active metabolite of
0.0851586913	the expression of
0.0850190255	receptor antagonists in
0.0848407792	driven by
0.0848378875	catalytic activity of
0.0846945198	these pathways
0.0846700306	an excellent
0.0846607132	investigate whether
0.0846606456	2 amino
0.0846100884	a specific inhibitor of
0.0843437879	or =
0.0843183239	evidence for
0.0841856400	by reducing
0.0841798287	also discussed
0.0841514769	10 days
0.0840951769	also increased
0.0840788848	1 34
0.0840592555	the final
0.0840096120	the rat brain
0.0839722606	obtained using
0.0839104614	a marked increase in
0.0838665351	protein levels in
0.0838357429	the protein level
0.0838123527	optimization of
0.0837528965	data show
0.0837342353	mouse model of
0.0837199106	the dopamine d2
0.0836778658	treatment of patients
0.0836733696	detected by
0.0836392269	a new
0.0836165914	these proteins
0.0835389974	a large
0.0834865601	effects induced by
0.0834713320	a critical role
0.0834098327	better than
0.0834063103	in patients with
0.0833996027	applied to
0.0833812507	molecular mechanisms of
0.0833765444	cells from
0.0833163377	with increasing
0.0833092542	responsiveness to
0.0832764769	known compounds
0.0832022622	in vivo anti
0.0831443702	an oral
0.0831253222	number of
0.0831171858	in relation to
0.0831073459	protein levels of
0.0831066668	activation by
0.0830508279	antibody against
0.0830373769	both wild type
0.0830205639	these mutations
0.0830163661	down regulated by
0.0828571435	antitumor activity in
0.0828461425	dependent on
0.0826751909	reduction in
0.0826639834	knockdown of
0.0825574718	roles in
0.0825529685	stimulated by
0.0825187942	decreases in
0.0824828939	to discriminate
0.0824674125	reduced by
0.0824039922	accumulation of
0.0822387577	a dramatic
0.0821403636	potent inhibitor
0.0821298569	sensitive to
0.0821173329	no differences
0.0819509460	pharmacological properties of
0.0818675222	participation of
0.0818066541	cell proliferation in
0.0815025668	binding activity of
0.0814627684	evaluated by
0.0814470990	for cancer therapy
0.0814276311	augmentation of
0.0814036595	this difference
0.0813902714	less active
0.0813593129	5 min
0.0813373322	expression of pro
0.0813125622	to study
0.0812785347	coadministration of
0.0812485921	obtained by
0.0812026251	binding site in
0.0811968164	10 ng
0.0811933263	the structure activity
0.0811870625	cell receptor
0.0811765408	also examined
0.0811563462	a novel approach
0.0811345892	involvement of
0.0811344507	related gene
0.0811110459	mechanism of
0.0810776434	death induced by
0.0810703581	a better understanding
0.0810642888	equivalent to
0.0808788216	influence on
0.0808179352	2 + 0
0.0806854421	series of
0.0806624236	cell viability in
0.0805777646	vehicle or
0.0805601826	detected in
0.0805235960	significantly decreased in
0.0805175259	kg m
0.0804699262	the mitogen activated protein
0.0804422882	in parallel with
0.0804201517	receptor expression in
0.0803853770	sufficient for
0.0803518116	5 + 0
0.0802159407	an active
0.0801740231	method for
0.0801672962	the majority
0.0801360143	assessments of
0.0801065999	study indicates
0.0798645516	significant changes
0.0798518276	dysregulation of
0.0798227701	significantly inhibited by
0.0797178084	variation in
0.0797176751	6 h
0.0796942978	analyzed by
0.0796843957	occurrence of
0.0796741085	the pathogenesis of
0.0796021172	the central nervous system
0.0794896578	amount of
0.0794118010	attenuated by
0.0793778653	spectra of
0.0793609660	analyzed using
0.0791508888	an independent
0.0791457052	mg m
0.0791392161	6 + 0
0.0791311934	for 8 weeks
0.0790556505	blockade of
0.0790406969	also studied
0.0790337076	high level of
0.0790229958	no change in
0.0790098458	this disorder
0.0788122760	acting on
0.0787497251	actions of
0.0787290897	3 x 10
0.0787168386	rat model of
0.0787041561	to select
0.0786981043	derivatives as
0.0786840123	l 2
0.0785648548	other drugs
0.0785164936	a critical role in
0.0785148378	to test
0.0784012214	16 mg
0.0783678084	cell death by
0.0783484507	an index
0.0783442971	the cerebellum
0.0781593998	antitumor activity of
0.0780062944	cytotoxic effect of
0.0779939718	more active
0.0779888221	10 weeks
0.0779672073	studies indicated
0.0778705972	exploration of
0.0777094547	a potential therapeutic
0.0776749943	1 nm
0.0776620944	about 10
0.0775900991	the pi3k akt
0.0775598642	to increase
0.0774713293	on chromosome
0.0774489532	assayed by
0.0774257808	level of
0.0774194186	present work
0.0773454143	a specific inhibitor
0.0772946680	for 4 weeks
0.0772345830	did not cause
0.0772277156	a selective
0.0772242074	a ring
0.0771788477	modification of
0.0771772280	by examining
0.0771286124	more susceptible
0.0771207711	dependent manner in
0.0771171054	developed as
0.0771023251	the generation of reactive oxygen species
0.0770085040	the high dose
0.0768833450	in vitro binding
0.0768535490	enantiomer of
0.0767767045	activities against
0.0766984004	an irreversible
0.0765579960	after injection
0.0765005682	sensitization to
0.0764956689	active form of
0.0763905129	the results of
0.0763745205	biological activities of
0.0763302159	four new
0.0762956256	up regulated by
0.0762820672	consequence of
0.0762644024	also demonstrated
0.0762514653	for 3 days
0.0762243139	observed with
0.0762014781	drugs such as
0.0761830486	ablation of
0.0761384296	+ 10
0.0760326680	studies indicate
0.0759937665	the curve
0.0759601822	enhancement of
0.0759441432	a deficiency
0.0758891206	a number of
0.0758795925	the relative
0.0756060224	degree of
0.0755384151	s 1
0.0754930826	significantly associated with
0.0754877049	sought to
0.0754204688	the absence of
0.0752314594	no significant changes
0.0750914001	a specific
0.0750832782	1 + 0
0.0748773612	beneficial effects of
0.0748754155	together with
0.0748674197	factor receptor
0.0748177507	the nucleus
0.0748159929	examined using
0.0748128438	apoptosis through
0.0747664405	different classes of
0.0747478607	1 nmol
0.0746856656	signaling pathway in
0.0746799398	0 mg
0.0746679647	concentration of
0.0746444047	m phase
0.0745390752	all subjects
0.0744799887	= 17
0.0744712878	actions on
0.0743993093	the inhibitory effect
0.0743857998	classes of
0.0743565440	apoptosis via
0.0742519129	this mechanism
0.0742372020	an increase
0.0742094426	after incubation
0.0742007987	3 + 0
0.0739287739	the potential
0.0738662912	more important
0.0738235484	to investigate whether
0.0737543010	action on
0.0737243994	the first study
0.0737238463	a decrease in
0.0736586119	the x ray
0.0735996332	2 adrenoceptor agonist
0.0735910642	comparison with
0.0735751671	an effect
0.0735715837	doses of
0.0735369270	in brain tissue
0.0735241661	signs of
0.0734978886	a key
0.0734648828	on days
0.0734431502	performed on
0.0733891641	significantly reduced in
0.0733733696	a novel class of
0.0733733596	a simple
0.0733396922	= 11
0.0732727276	mol of
0.0732442192	the striatum
0.0732251027	degradation by
0.0731845876	the patent
0.0731845115	increased by
0.0730999144	therapy for
0.0730984580	biological activity of
0.0730404151	contributions of
0.0729581365	development of
0.0729570942	copies of
0.0728483076	a similar
0.0727936062	the genes encoding
0.0727587309	pharmacodynamics of
0.0726964126	induced changes in
0.0726889373	three new
0.0726856768	further evidence
0.0726630538	signaling pathways in
0.0725968183	identified by
0.0725569984	in patients treated
0.0725227905	the cytosol
0.0725107941	markers of
0.0724635660	central role in
0.0723845448	extent than
0.0723014226	diversity of
0.0722879905	for 5 days
0.0722365598	three different
0.0721823224	absent in
0.0721751075	inhibitor of
0.0721144664	adjusting for
0.0720789865	located in
0.0720727872	the cytoplasm
0.0720022593	homozygous for
0.0719895193	cloned from
0.0719615284	coupled with
0.0719311301	an aqueous
0.0719122612	for studying
0.0718713083	novel approach
0.0717804006	effective than
0.0717803943	better understanding of
0.0717622962	adsorption of
0.0716968287	to enhance
0.0716800231	the side chain
0.0716739907	1 year
0.0716320708	to confer
0.0716250853	this class
0.0715676462	an antibody
0.0714784124	dose of
0.0714423547	a marked
0.0713651288	the estrogen receptor
0.0712509787	the existence of
0.0712292312	the full length
0.0711897649	by radioimmunoassay
0.0711742654	also showed
0.0711056885	at least two
0.0710681500	overexpressed in
0.0710578255	the formation of
0.0710485055	infusions of
0.0709678771	ingestion of
0.0709463165	processing of
0.0709208424	known to
0.0708906281	set of
0.0708406697	day 5
0.0708346499	regulator of
0.0707520165	many studies
0.0707325891	the plasma concentration
0.0707097711	k +
0.0707072730	the selective alpha
0.0706751294	5 x 10
0.0706173202	men with
0.0706108362	reduction of
0.0705864741	observed after
0.0705743580	useful for
0.0705371976	fall in
0.0705309746	a rat model
0.0704847340	a rare
0.0704587761	new drugs
0.0704298650	occurs at
0.0704095626	consumption of
0.0703578027	at 37
0.0702970963	sensitivity of
0.0702923121	studies on
0.0702610142	the market
0.0702604509	incorporation of
0.0702081365	activities of
0.0701250711	for 30 min
0.0701178959	dissociation of
0.0701142868	stimulation of
0.0700511723	biology of
0.0700144497	cell lines with
0.0699972436	no association
0.0699243336	amplitude of
0.0698346313	structure of
0.0698017767	by activating
0.0697792204	of activated t cells
0.0697458452	the anti inflammatory effect
0.0697430605	3 day
0.0697370966	phosphorylation at
0.0697324256	elevation in
0.0696830598	treatment of various
0.0696715823	disorders such as
0.0696438057	results from
0.0696268001	effective at
0.0696219052	risk of
0.0695098106	kg b
0.0694797995	in patients with acute
0.0694163951	very high
0.0693116478	approach to
0.0693077671	a small
0.0693014226	manipulation of
0.0692522002	assay using
0.0692508886	important for
0.0691771608	inflammatory activity
0.0690954787	a minimum
0.0690178501	treatment for
0.0690066367	a critical
0.0689251105	at doses
0.0688889229	injected with
0.0688635750	a potential target for
0.0687752440	segment of
0.0687171176	= 25
0.0686546942	diseases such as
0.0686516989	used to investigate
0.0685271366	delivery of
0.0684976437	also determined
0.0684027727	and time dependent manner
0.0683726571	7 nm
0.0683108971	treatment of patients with
0.0681806485	proposed to
0.0681228805	an inhibitory
0.0681206252	the activity of
0.0681120017	this case
0.0680155919	1 mg
0.0679945109	a non selective
0.0679147560	verified by
0.0679053908	study indicated
0.0678969830	investigated using
0.0678303612	the present
0.0678139802	a valuable
0.0676693615	the uterus
0.0676491521	the fact
0.0676460426	upregulated by
0.0675351650	combinations of
0.0674858498	targets for
0.0674408151	a weak
0.0674281193	associated with increased
0.0674146755	any effect on
0.0673860391	+ t cells
0.0673538036	version of
0.0672489267	2 selective inhibitors
0.0671995407	increased in
0.0671781203	this model
0.0671072190	the literature
0.0670734249	a new target
0.0670578255	in response to
0.0670386625	the molecular
0.0669926135	none of
0.0669460811	at 250
0.0668765755	2 months
0.0668461060	the inhibition of
0.0668425790	act on
0.0668346313	domain of
0.0668034971	aspect of
0.0667132406	in vitro activity
0.0666351027	region of
0.0666177284	relevance to
0.0663455040	to reduce
0.0662441067	significant role in
0.0661244797	cell proliferation by
0.0661206252	the levels of
0.0661183948	source of
0.0661104260	a common
0.0660924422	liver injury in
0.0660231136	2 nm
0.0660010921	in mammals
0.0659854985	to regulate
0.0659562818	safety and efficacy of
0.0659498146	generated from
0.0659026542	expressed at
0.0658715173	a novel mechanism of action
0.0658209351	3 mm
0.0658198506	at 300
0.0657977140	alterations in
0.0657067496	= 5
0.0656935827	detoxification of
0.0656377684	prevention of
0.0656095236	designed to
0.0655712696	detection of
0.0655594050	or = 1
0.0655474600	deletion of
0.0655462073	curves for
0.0655181830	6 mg
0.0655173457	n 2
0.0655015776	the production of
0.0654892917	the parent
0.0654119535	by combining
0.0653894391	4 microm
0.0653549924	in patients with advanced
0.0653367319	also investigated
0.0653132310	but did not affect
0.0652796499	modifications of
0.0652565524	the circadian
0.0652505876	the importance of
0.0652409938	preincubation with
0.0651683478	quantification of
0.0651568258	independent of
0.0650856024	two additional
0.0650832967	a truncated
0.0650805659	potentiation of
0.0649687608	accuracy of
0.0648622527	determinant of
0.0648078302	at least one
0.0648029466	model of
0.0647511278	3 nm
0.0647348553	a suitable
0.0647089209	a role in
0.0646527661	over expression of
0.0646217080	three compounds
0.0646023894	also suppressed
0.0645982716	advances in
0.0645943088	and well tolerated
0.0645072218	dependent inhibition of
0.0645036094	different mechanisms
0.0644025809	concentrations of
0.0643932870	measured as
0.0643872690	modulation by
0.0643561741	as shown by
0.0642418103	binds to
0.0642094492	by blocking
0.0641934388	0 + 0
0.0641650603	regulators of
0.0640476571	all tissues
0.0640012980	formation of
0.0639243714	site at
0.0639219406	several mechanisms
0.0638954657	complexes with
0.0638811941	the stimulatory effect
0.0638688441	either alone or
0.0638562151	prediction of
0.0638461060	the activation of
0.0638334828	not significantly
0.0638073787	h before
0.0637738841	expression and activity of
0.0636493849	high affinity to
0.0635891646	agonists at
0.0635610464	the dose response
0.0635420150	the results
0.0635283385	n = 3
0.0635228030	an anti
0.0634811426	facilitated by
0.0633001562	this method
0.0632858273	potential for
0.0632469522	to deliver
0.0631821916	an antidepressant
0.0631206252	the regulation of
0.0631113004	expected to
0.0631048620	2 years
0.0631000120	needs to
0.0630925758	activity by
0.0630696132	uptake of
0.0629783386	more likely to
0.0629696918	to disrupt
0.0628872565	profile of
0.0628868994	the stomach
0.0628276320	for 12 weeks
0.0627996830	form of
0.0627364536	to provide
0.0627211252	affinity than
0.0627157381	application of
0.0627107268	or in combination with other
0.0627004299	enhanced by
0.0625810385	4 hours
0.0625351340	to yield
0.0625228030	an enzyme
0.0625223114	agreement with
0.0624769127	a broad spectrum of
0.0624526016	both types of
0.0624192810	risk for
0.0624135078	a range of
0.0624029676	development of novel
0.0623699145	also known as
0.0623325085	death through
0.0623318591	delay in
0.0622885719	distribution of
0.0622809551	human t
0.0622671161	the latter
0.0622443358	an essential role in
0.0622147332	agent for
0.0621984957	a result of
0.0621735509	the alpha
0.0621732518	1 methyl
0.0621625439	potency than
0.0621476522	the binding of
0.0621353251	reported to
0.0620879024	the use of
0.0620759747	a complete
0.0620271863	acting as
0.0619916588	sensitive k
0.0619526339	the c terminus of
0.0619083263	efficacy of
0.0619020834	classification of
0.0618960102	considered to
0.0618795526	analysed by
0.0617211399	spectrum of
0.0616214547	atherosclerosis in
0.0616027713	abrogated by
0.0615610624	the exact
0.0615544109	a major role in
0.0614126247	mechanism for
0.0614074682	stages of
0.0613420850	overview of
0.0612637638	approach for
0.0612364536	to block
0.0612195562	predicted to
0.0611595833	new target
0.0611124306	the hypothalamus
0.0611102414	selective for
0.0610222828	drugs used
0.0610148903	cleavage of
0.0609346285	in addition to
0.0608796344	location of
0.0608633226	a direct
0.0608241553	appearance of
0.0605959867	regions of
0.0605871448	independently of
0.0605573167	promise for
0.0605372962	observed during
0.0605288239	defective in
0.0605096620	a significant decrease in
0.0605028860	downregulated by
0.0605015776	the amount of
0.0604976571	other tissues
0.0604923675	h +
0.0604636548	effects via
0.0604460522	without effect
0.0604410883	remains to
0.0604234722	among patients
0.0604185747	decreased by
0.0603946672	absence of
0.0603639694	expression and function of
0.0603501298	the cytotoxic effects
0.0602926786	factor 2
0.0602217628	5 ±
0.0602134037	an activator of
0.0601998619	target for
0.0601633097	knowledge of
0.0601419817	mechanisms of
0.0600883410	a novel series of
0.0600876632	on days 1
0.0600403102	novel mechanism of action
0.0599991181	marker for
0.0599608454	a crucial role in
0.0599081740	played by
0.0598795897	antagonism of
0.0598663816	showed only
0.0598349109	a reduction in
0.0597907063	after adjustment
0.0597872919	the mechanism of
0.0597632767	the alpha 2
0.0597291368	injection of
0.0596786352	the duodenum
0.0596139114	also reduced
0.0596014737	a prospective
0.0594897123	initiated by
0.0594671514	the goal of
0.0594562264	state of
0.0594554974	after oral
0.0594537896	non small
0.0594114645	biotransformation of
0.0593890649	elevation of
0.0593082271	an overview of
0.0592998318	two different
0.0592323468	the number of
0.0591828655	these interactions
0.0591801106	novel drug
0.0591250622	the cytotoxic effect of
0.0591200966	displacement of
0.0591155416	clinical use of
0.0590853560	measured in
0.0590184727	this study aimed to
0.0590108207	concentration time
0.0589847156	evaluated as
0.0589321609	after incubation with
0.0589112558	flux of
0.0588857176	these factors
0.0588783849	feature of
0.0588401284	new compounds
0.0587838559	the first
0.0587090034	did not result in
0.0586674243	not observed
0.0586420628	desensitization of
0.0585779761	this molecule
0.0585754918	forms of
0.0585560835	alone or in combination with
0.0585036245	12 mg
0.0585015776	the influence of
0.0584495298	regulation by
0.0584238395	reversal of
0.0583164540	tumors with
0.0582948012	member of
0.0582785692	a pyrene
0.0582166928	autophagy in
0.0582024765	both drugs
0.0580879024	the level of
0.0580826385	proportion of
0.0580013845	the beginning of
0.0579686385	impact of
0.0579567262	increased after
0.0579527341	variety of
0.0578954448	measured at
0.0578761087	concentrations up to
0.0578545526	assayed for
0.0578341679	subject to
0.0578109962	decline in
0.0577431950	these results indicated
0.0576752883	at concentrations
0.0575992618	proven to
0.0575974772	in vitro and in vivo studies
0.0575727194	homology to
0.0575438367	5 years
0.0575015776	the affinity of
0.0575015776	the interaction of
0.0574729908	the world
0.0574510931	a dose and time dependent
0.0573319191	further confirmed by
0.0572805447	configuration of
0.0572549836	expression system
0.0572465020	a potent inhibitor
0.0571154847	by immunohistochemistry
0.0571032650	to support
0.0571000447	aim of
0.0570480235	evaluated for
0.0570443345	a case
0.0570344692	moderate to
0.0569750614	mechanisms of action of
0.0569279466	production of
0.0569040396	231 cells
0.0569016441	phosphorylation on
0.0568963333	an increase of
0.0568130074	carriers of
0.0567425745	= 4
0.0565968822	antagonist at
0.0565915774	with placebo
0.0565536124	a rapid
0.0565132767	the alpha 1
0.0565026132	the data suggest
0.0564983063	the hippocampus
0.0564879166	different concentrations
0.0563569770	in contrast to
0.0563287611	a significant role in
0.0562632121	significantly different
0.0562575864	knowledge on
0.0562510025	a large number of
0.0562481838	residues in
0.0562465747	tested for
0.0562255603	rise to
0.0561165798	an open
0.0561127378	once daily for
0.0560963857	active site of
0.0560806754	the last
0.0560668646	rates of
0.0560546548	metabolized to
0.0560247740	a rational
0.0559897429	the predominant
0.0559783852	show here
0.0559540351	modified by
0.0559355060	in rats treated
0.0559315284	injections of
0.0559248485	to protect
0.0558949482	relation to
0.0557844230	to correlate
0.0557820052	rate of
0.0557290272	the distal
0.0557138020	an intact
0.0557017319	therapeutic potential of
0.0556891519	widely used to
0.0556748673	synthesized by
0.0556709025	as compared to
0.0556204006	6 mice
0.0556109770	these experiments
0.0556053625	a candidate
0.0555758026	conversion of
0.0555034009	discovery of
0.0554974405	activity than
0.0554638934	nm for
0.0554296750	not fully
0.0554072414	the upper
0.0553742304	to reverse
0.0553591679	termination of
0.0553402459	an estrogen
0.0552941695	component of
0.0552736657	effects against
0.0552706507	a role for
0.0551861521	complexity of
0.0551632728	provided by
0.0551547784	events associated with
0.0551206426	inactivation of
0.0550650499	3 h
0.0549858499	measures of
0.0549454866	respect to
0.0549381501	uptake by
0.0548472710	by preventing
0.0547159265	the treatment of diabetes
0.0546895584	regard to
0.0546728811	8 h
0.0546569428	down regulated in
0.0546431072	a subset of
0.0546139114	also decreased
0.0545579173	values of
0.0545376986	prevalence of
0.0545282605	significant changes in
0.0545247508	apoptosis in
0.0545052115	the occurrence of
0.0544660724	after administration
0.0544409957	a progressive
0.0544207335	a rat model of
0.0542152997	a central role in
0.0541765532	these parameters
0.0541534232	observed for
0.0541460923	1 h
0.0541331565	the discovery of
0.0540409082	to synthesize
0.0540372438	any effect
0.0540117669	selected for
0.0539511036	not altered
0.0539042448	4 h
0.0538489645	defect in
0.0538218179	c terminus of
0.0537954205	assay for
0.0537661621	not known
0.0537264131	some patients
0.0537226653	suppression by
0.0537019148	indicator of
0.0536620406	3 days
0.0536377873	terminus of
0.0536185720	variability in
0.0535492423	2 h
0.0535233342	less well
0.0535184261	significance of
0.0534829157	widely used in
0.0534525633	methods for
0.0533870370	toxic to
0.0533537056	effects through
0.0533211005	neurons in
0.0532911380	administered to
0.0532191701	as evidenced
0.0531876913	potential of
0.0531861521	expansion of
0.0531831069	a model
0.0531544279	progress in
0.0531305271	2 mm
0.0530417968	degradation of
0.0530273886	components of
0.0529399402	= 2
0.0529127156	change in
0.0528775755	microm for
0.0528698665	on day
0.0528431576	increased during
0.0528138158	expression through
0.0527341483	not detected
0.0527324684	receptors in
0.0526628037	the risk of
0.0526156634	does not appear
0.0525088569	for predicting
0.0524799131	choice for
0.0524664898	a dose of
0.0524044563	a wide
0.0523766425	a better understanding of
0.0523413834	effectiveness of
0.0523272024	compound for
0.0523190474	relaxation of
0.0523066354	exception of
0.0523004553	attempts to
0.0523000726	not altered by
0.0522671065	efficacy and safety of
0.0522211266	a new therapeutic
0.0522191181	prolongation of
0.0522067535	limited by
0.0521511994	improvement in
0.0521155191	other proteins
0.0520940299	the treatment of chronic
0.0520894180	transformation of
0.0520728080	this series
0.0520451144	than previously
0.0519342979	required to
0.0517934467	extract from
0.0517886713	numbers of
0.0517523185	model for
0.0517520300	or vehicle
0.0517346971	production by
0.0516463809	limited to
0.0516422513	to modify
0.0515616630	characteristics of
0.0515339945	correlated to
0.0515317186	need to
0.0515256962	activity at
0.0515042273	a member of
0.0514427494	pattern of
0.0514054103	up regulated in
0.0513856518	complex with
0.0513631148	1 phosphate
0.0513586080	a single dose of
0.0513451153	status of
0.0513326858	these responses
0.0512986166	trained to
0.0512968077	the treatment of asthma
0.0512496718	at 24 h
0.0511876913	metabolism of
0.0511786995	to stimulate
0.0511086024	both proteins
0.0510580069	only 10
0.0510540974	emergence of
0.0510540512	the absence or
0.0510098120	any other
0.0510070270	a biomarker
0.0509614635	4 nm
0.0509390872	also measured
0.0509122674	also attenuated
0.0508966842	for 24 h
0.0508446706	the current
0.0507872919	the involvement of
0.0507680192	aims to
0.0507284589	but not by
0.0506818937	function of
0.0506333263	interaction of
0.0505977751	immunoreactivity in
0.0505892661	assembly of
0.0505871834	the beta 2
0.0505367725	to modulate
0.0505178118	evolution of
0.0505082402	acetylation of
0.0504723686	the active site of
0.0504500380	not directly
0.0504333191	secretion by
0.0504311084	neurotransmission in
0.0503135082	the active
0.0503028198	two types of
0.0502865795	mechanism of action of
0.0500694169	impairment of
0.0500283691	fold for
0.0500024056	by regulating
0.0499912046	constants for
0.0499873872	even more
0.0499813987	hyperglycemia in
0.0499734084	little or
0.0499724311	characteristic of
0.0499625422	to undergo
0.0499197107	the percentage of
0.0498545095	used to
0.0498461060	the release of
0.0498212458	likely to
0.0497872919	the control of
0.0497648617	consequences of
0.0496977751	relaxation in
0.0496113754	diet for
0.0495967628	3 ±
0.0495734683	investigation of
0.0494255832	more complex
0.0493994451	by comparing
0.0493925786	a down regulation of
0.0493453076	no treatment
0.0493234440	utilized to
0.0493101163	active than
0.0492826959	both enzymes
0.0492557116	iop in
0.0492339220	potency for
0.0490136731	a natural
0.0489843696	inflammatory effect of
0.0489520038	a novel target
0.0489333191	stimulation by
0.0489292312	the design of
0.0489099695	stabilization of
0.0488510582	to activate
0.0488068026	correlation with
0.0487996248	employed to
0.0487837662	n = 1
0.0487732741	characterized as
0.0487692730	m +
0.0487461515	kinase b
0.0487322312	cells via
0.0487145125	studies using
0.0486666122	measured with
0.0486389067	the metabolism of
0.0486106294	agents such as
0.0485729817	also detected
0.0485031226	but did
0.0484509781	the emergence of
0.0483831115	alteration in
0.0483680893	potential as
0.0483323815	not significantly different from
0.0482982583	features of
0.0482613927	an experimental
0.0482414940	a hydrophobic
0.0481488917	to receive
0.0481377423	to demonstrate
0.0481331565	the impact of
0.0481258802	also evaluated
0.0481016584	effect against
0.0480907563	defects in
0.0480696664	strategy to
0.0480515532	also assessed
0.0480446072	except for
0.0480170440	as determined
0.0480011049	further investigated
0.0479822312	cells through
0.0479425851	3 mg
0.0479331176	a general
0.0479328466	act by
0.0478757333	up to
0.0478547215	the potency of
0.0478506244	mean +
0.0478274421	these conditions
0.0477505760	examination of
0.0477402778	organization of
0.0477078604	family of
0.0477039227	to protect against
0.0476048097	place in
0.0475907563	composition of
0.0475717307	parts of
0.0475036337	several studies
0.0474904177	the cytotoxicity of
0.0474760364	the precise
0.0473967322	administered at
0.0473902796	to explain
0.0473467489	monitoring of
0.0472872584	synthesis of
0.0472823812	transfected with
0.0472753204	retention of
0.0472256853	defect of
0.0472227850	maturation of
0.0471931200	the extent of
0.0471739891	promoted by
0.0471720778	function after
0.0471544279	aid in
0.0471299478	on platelets
0.0471267707	expression via
0.0471037975	n = 2
0.0470361838	people with
0.0470219011	light on
0.0469493887	protected by
0.0469345774	day 7
0.0468786601	the time course of
0.0468236859	an intravenous
0.0468169752	specificity for
0.0468041882	the combination of
0.0467872919	the addition of
0.0467744083	class of
0.0467565537	the rate of
0.0467416058	a prominent
0.0467247988	a poor
0.0467188814	= 3
0.0465695454	mutation in
0.0465321941	observed at
0.0465218028	repression of
0.0464970178	following exposure
0.0464904691	evaluated in
0.0464716145	many patients
0.0464411154	depletion of
0.0463996925	biomarker for
0.0463950381	n terminus of
0.0463846926	effective in
0.0463452873	but also
0.0463175739	healing of
0.0463175739	availability of
0.0462333263	secretion of
0.0461633033	critical role in
0.0461347158	relevant to
0.0460989572	higher in
0.0460615290	10 m
0.0460396181	subset of
0.0460316495	the concept
0.0460275286	transport of
0.0460169618	infusion of
0.0460023899	incidence of
0.0459986172	the potential to
0.0459787274	metastasis in
0.0459234695	agonist at
0.0458190788	this agent
0.0458139129	to conclude
0.0458037037	arrest in
0.0457895193	a significant reduction in
0.0457753204	occupancy of
0.0457382811	two enzymes
0.0457374045	alternative to
0.0457284589	the accumulation of
0.0457260260	recommended for
0.0457044794	the increase in
0.0456652976	exposure on
0.0455972963	obtained with
0.0455942458	the human 5
0.0455781196	inflammatory effects of
0.0455619589	not detected in
0.0455238971	with ki values of
0.0454766813	roles of
0.0454045592	the availability of
0.0454027502	fraction of
0.0453376802	new drug
0.0453273085	using in vitro
0.0453092306	compared with other
0.0452901628	influence of
0.0452881214	quality of
0.0452255727	corresponding to
0.0451862271	an early
0.0451784487	accumulation in
0.0451454278	but does
0.0450896685	an association between
0.0450863793	many other
0.0450712445	the majority of
0.0450290177	pocket of
0.0450031492	novel series of
0.0449842077	a potent inhibitor of
0.0449610493	the synthesis of
0.0449571861	the induction of apoptosis
0.0448896053	these changes
0.0448570368	relevant for
0.0448516513	kinetics of
0.0447872919	the efficacy of
0.0447695130	abundant in
0.0447496574	3 phosphate
0.0447458458	report on
0.0447436104	the action of
0.0447350768	the central
0.0446963983	incubation of
0.0446662360	activators of
0.0446411344	even at
0.0446266206	the mechanism of action of
0.0446028257	without effect on
0.0445268552	identity to
0.0445022961	found in
0.0444948981	suggested by
0.0444769117	detected at
0.0444404283	suggested to
0.0444348285	the potential role
0.0444346382	3 hours
0.0444144004	a result
0.0444068031	mode of action of
0.0443819242	reflected in
0.0443751754	remain to
0.0443674032	as determined by
0.0442318289	severity of
0.0441566363	secondary to
0.0440694013	production in
0.0440407402	the down regulation of
0.0440117077	in patients with chronic
0.0439952074	responsive to
0.0439830301	part of
0.0439053236	manifestations of
0.0438929527	both compounds
0.0438666182	vs 1
0.0437860377	to mimic
0.0437853082	attachment of
0.0437436104	the concentration of
0.0437321916	by enhancing
0.0437294146	effective as
0.0437223358	approved in
0.0436943516	= 50
0.0436831092	this polymorphism
0.0436520146	grown in
0.0436438876	a high degree of
0.0436279241	the structure of
0.0436153514	treatments for
0.0436003140	the treatment of alzheimer
0.0435595871	abundance in
0.0435526937	a remarkable
0.0434240896	dosage of
0.0433833558	a partial
0.0433623511	remodeling in
0.0432508148	substrate for
0.0432215690	addition to
0.0432141690	substitution of
0.0431768250	1 x 10
0.0431647240	3 d
0.0431578512	a useful
0.0431569455	possible role of
0.0431464466	these data show
0.0431428725	8 mg
0.0430586083	combination with
0.0430284986	using in vivo
0.0430248810	or = 0
0.0430015247	1 ng
0.0429960620	validation of
0.0429703704	hydrolysis of
0.0428952981	the control
0.0428828888	collected for
0.0428667670	to control
0.0428294805	demonstrated to
0.0428038591	affinity of
0.0427761320	the crystal structure of
0.0427548580	an animal
0.0427340432	the appearance of
0.0427126168	needed for
0.0427125568	to mediate
0.0426420294	also blocked
0.0426418683	toxicity of
0.0426313061	cultures of
0.0426055494	a substantial
0.0425900549	transport by
0.0425766368	testosterone to
0.0425441239	a broad
0.0425006344	for clinical use
0.0424615072	benefits of
0.0424389191	distributed in
0.0424349627	as measured by
0.0424082115	inhibitors such as
0.0424065631	different concentrations of
0.0423380503	metabolism in
0.0422933549	efficacy in
0.0422557258	affinity at
0.0422438426	developed by
0.0422155300	as assessed by
0.0421984683	types of
0.0421271306	with type 2 diabetes
0.0421010119	x receptors
0.0420483656	as inhibitors of
0.0420357205	3 times
0.0420196241	studied in
0.0420193604	a modest
0.0419390838	comprised of
0.0419080880	obtained at
0.0418705625	a lack of
0.0418605053	in vertebrates
0.0418345178	panel of
0.0418271759	sites on
0.0418234586	to facilitate
0.0418022355	purification of
0.0417980895	efficiency of
0.0417888158	activity via
0.0417830705	significantly associated
0.0417784583	nm at
0.0417436104	the phosphorylation of
0.0417318233	to occur
0.0417205224	the association of
0.0417152575	adults with
0.0417016513	oxidation of
0.0416700032	success of
0.0416654402	a novel therapeutic
0.0416149426	induced changes
0.0416134490	stability of
0.0416055011	pharmacology of
0.0415340818	μm for
0.0415217922	associated with decreased
0.0415040936	expressed as
0.0414166844	the inhibitory effects of
0.0413553696	established by
0.0413444173	block by
0.0413435689	the inhibitory effect of
0.0413343181	in animal models of
0.0413211005	proliferation of
0.0412955987	a double
0.0412854382	found between
0.0412413027	a selective inhibitor
0.0412296074	capacity to
0.0412242237	goal of
0.0411812037	orientation of
0.0411747876	a major cause of
0.0411522727	following exposure to
0.0411486532	after treatment with
0.0411471516	the expression of genes
0.0411378047	dependence on
0.0411279241	the potential of
0.0411211005	site of
0.0411002929	intensity of
0.0410814035	like effects
0.0410667299	comparable with
0.0410542312	after administration of
0.0410385003	to help
0.0410199504	nature of
0.0409790893	a review of
0.0409732344	compounds such as
0.0409569428	or in combination
0.0409550753	two drugs
0.0408515538	mode of
0.0408461060	the identification of
0.0408433671	both wild type and
0.0408418288	measure of
0.0408196662	livers of
0.0408038591	ratio of
0.0407937944	investigated in
0.0407376190	fibrosis in
0.0406782434	function in
0.0406770577	association of
0.0406740278	increased from
0.0405953911	all four
0.0405849489	recruitment of
0.0405805479	use of
0.0405062367	the degree of
0.0404143572	to give
0.0404021143	in mediating
0.0403904737	more than one
0.0403444085	tissue from
0.0403380503	lower in
0.0403102771	the reduction of
0.0401652904	upregulated in
0.0401311633	developed to
0.0400970858	profiles of
0.0400661735	new class
0.0400449045	mutagenesis of
0.0400317242	metabolized in
0.0400272641	stress in
0.0399790893	the exception of
0.0399511103	a decrease of
0.0398530462	possibility of
0.0398513235	the inhibitory
0.0398367408	difference in
0.0398276687	content of
0.0398099750	other than
0.0398083249	two compounds
0.0397846715	control of
0.0397565537	the activities of
0.0397016740	the expression levels
0.0396678511	utility of
0.0396645598	product of
0.0396626971	tool to
0.0396418683	toxicity in
0.0396055011	recovery of
0.0395758265	a dose
0.0395681914	the antiplatelet
0.0395394209	potency of
0.0395372492	to bind
0.0395046285	to possess
0.0394860429	the question
0.0394742240	amplification of
0.0394316876	for treatment of
0.0394125422	a representative
0.0394110020	performed in
0.0394026048	even after
0.0393849844	to screen
0.0393775231	a dose and time
0.0393722717	discussed in
0.0393478697	pairs of
0.0393395700	a model of
0.0393055733	the lack of
0.0393029563	the aim
0.0392447814	means to
0.0392238175	secretion from
0.0391028935	movement of
0.0390915783	to affect
0.0390710600	advantage of
0.0390576035	a favorable
0.0390513381	target of
0.0390350651	used for
0.0390070403	the same time
0.0390003694	decreased in
0.0389986238	conformation of
0.0389954240	also tested
0.0389505530	also enhanced
0.0389363927	the end of
0.0388705753	capacity for
0.0388612575	the induction of
0.0388049497	to restore
0.0387967746	this end
0.0387962529	ligands for
0.0387896577	several other
0.0387645075	a low dose of
0.0387515259	to take
0.0386009762	a set of
0.0385938263	the corresponding
0.0385755769	h after treatment
0.0385022719	the beneficial effects of
0.0384894421	but does not
0.0384423668	refractory to
0.0383034174	a nonselective
0.0382921561	bioavailability of
0.0382885189	magnitude of
0.0382634294	by monitoring
0.0382622742	reduced in
0.0382026700	localization of
0.0381790417	an association
0.0381684319	these values
0.0381308357	localized in
0.0381215075	therapies for
0.0380642283	associated protein
0.0380451989	bound with
0.0380448814	obtained for
0.0380173750	homologous to
0.0380100848	developed for
0.0379941799	unchanged in
0.0379620165	binding at
0.0379599252	end of
0.0379539842	importance of
0.0379345388	the catalytic site of
0.0379152981	the mechanisms
0.0379065318	a period of
0.0378879167	release by
0.0378189715	models of
0.0378063668	discontinuation of
0.0377761320	in subjects with
0.0377615767	identified in
0.0377005892	transfection of
0.0376768957	a concentration
0.0376745185	the introduction of
0.0376293413	support for
0.0376154750	deposition of
0.0375343903	the in vivo effects
0.0375265402	and activator of transcription
0.0375114242	a marker of
0.0374635366	search of
0.0374374700	improved by
0.0374275308	therapeutic use of
0.0373871967	exists in
0.0373690692	limitations of
0.0373664258	by determining
0.0373595811	7 cells
0.0373218425	the pathophysiology
0.0373118335	studied by
0.0372476878	examined in
0.0372433035	conducted to
0.0372421033	start of
0.0372239422	maintained in
0.0372210934	formed in
0.0372090314	stimulated with
0.0371906974	altered by
0.0371817438	demonstrated by
0.0371652904	diagnosis of
0.0371606752	the decrease in
0.0371008578	to find
0.0370794660	determined in
0.0370497981	investigated as
0.0370202467	r =
0.0369956389	the onset of
0.0369862812	therapy with
0.0368865765	means of
0.0368830961	= 10
0.0368801323	strength of
0.0368597188	the well known
0.0368490303	by about
0.0367734822	also significantly
0.0367132809	2 x 10
0.0366863955	formulation of
0.0366535168	markers for
0.0366269458	concept of
0.0365883563	heterogeneity of
0.0365788003	a selective inhibitor of
0.0365558265	the number
0.0365329811	selection of
0.0365295171	in comparison with
0.0365294239	supplementation with
0.0364997215	a well known
0.0364496857	with ic50 values of
0.0364440270	patterns of
0.0364100861	only one
0.0363840615	but did not
0.0363746503	but not in
0.0363556788	occurred in
0.0363444890	cohort of
0.0363133135	site on
0.0362595108	the presence
0.0362484766	duration of
0.0362463211	the two drugs
0.0362208284	new class of
0.0362082565	mechanism by
0.0361958115	shift in
0.0361802397	the mechanism
0.0361625422	a systematic
0.0361254895	detectable in
0.0360909429	an appropriate
0.0360115767	reported in
0.0359820074	a monoclonal
0.0359160226	the result of
0.0359140074	a competitive inhibitor of
0.0359090934	pathway in
0.0358643419	the induction
0.0358539323	administered by
0.0358433178	the gut
0.0357922452	genes associated with
0.0357791869	extract of
0.0357582540	important to
0.0357301838	the capacity of
0.0357141705	period of
0.0357120336	determined at
0.0356538716	after exposure to
0.0356311953	event in
0.0356083839	the clinic
0.0356041390	separation of
0.0355894668	presented with
0.0355538933	these tissues
0.0355100325	substrates for
0.0355070700	an inhibitor
0.0354929740	alone did not
0.0354167191	to respond to
0.0354058125	to decrease
0.0353656284	tissues from
0.0353475714	known as
0.0353243718	rich in
0.0352705581	performed to
0.0352532197	in patients with type 2 diabetes
0.0352415873	analyzed in
0.0352378501	decline of
0.0351639871	acquisition of
0.0351639445	order of
0.0351431313	the loss of
0.0351309327	expressions of
0.0351223633	the role
0.0350054051	array of
0.0350035348	primarily by
0.0349488735	pretreatment of
0.0348004397	secretion in
0.0347455353	a competitive
0.0347237301	conducted in
0.0347130826	modulator of
0.0346636516	a typical
0.0346165505	preparation of
0.0345888095	design of
0.0345845548	kg i
0.0345783928	demonstrated for
0.0344738542	dependence of
0.0343614295	a link between
0.0343534830	the protective
0.0343404577	capability of
0.0342869521	improvement of
0.0342056838	maintenance of
0.0342037629	evidence from
0.0341970189	novel class of
0.0341463135	first time
0.0341173966	estimated to
0.0340943604	a classical
0.0340840494	the management of
0.0340691303	a robust
0.0340635172	the possibility of
0.0340285732	occur in
0.0339349220	as demonstrated by
0.0339288754	rise in
0.0338547215	the function of
0.0338357409	proposed for
0.0337421225	no changes in
0.0337193705	balance of
0.0337081195	b inhibitor
0.0336725010	deamination of
0.0336367005	an overall
0.0335888095	cultured in
0.0335809922	at doses of
0.0335507394	the livers of
0.0335307977	enriched in
0.0334860583	a consequence of
0.0334492314	the structures of
0.0333890353	the proliferation of
0.0333766924	novel mechanism of
0.0333643490	coupling of
0.0332390141	the ability
0.0332283728	library of
0.0332237700	different from
0.0332144716	an established
0.0331766778	critical to
0.0331763253	structures of
0.0331733687	mediator of
0.0331626971	subgroup of
0.0331576792	extent of
0.0331109929	the mechanism of action
0.0330995970	a concomitant
0.0330893889	the progression of
0.0330749206	regulated in
0.0330749206	cytotoxicity of
0.0330577582	a good
0.0330227465	inflammation in
0.0330166690	via activation of
0.0330009012	the therapeutic potential of
0.0329652672	a special
0.0329443516	* 1
0.0329182586	combination of
0.0328412263	through inhibition of
0.0328197455	but only
0.0327812964	the mechanisms by
0.0327810156	transmission in
0.0327759955	the degree
0.0327387932	the mechanisms of
0.0327237301	conserved in
0.0326985355	seen in
0.0326840417	polymerization of
0.0326814413	specific for
0.0326247045	the treatment of patients
0.0326196920	the mechanism by
0.0325858938	investigated by
0.0324994011	route of
0.0324982157	steps in
0.0324175119	and in combination
0.0324128685	revealed by
0.0323391677	episodes of
0.0323296927	the mechanisms of action
0.0322895134	cells against
0.0322672511	purpose of
0.0322482711	to express
0.0322024513	the beginning
0.0321936334	inducer of
0.0321674004	the mrna levels of
0.0321362939	to alter
0.0321260038	to exert
0.0321035075	as well
0.0320944968	a mixture of
0.0320849366	modeling of
0.0320810211	increase of
0.0320781988	at least as
0.0320652672	a lesser
0.0320244058	as assessed
0.0319886591	also observed in
0.0319574658	identity of
0.0319081561	introduction of
0.0319015247	to attenuate
0.0318058288	ineffective in
0.0317729808	terms of
0.0317317806	an inhibition of
0.0317145977	used in
0.0316767671	in rats with
0.0316717515	initiation of
0.0316547375	administered with
0.0316147804	function as
0.0316028120	mainly due to
0.0315916557	the kinetics of
0.0315849038	provide further
0.0315663106	a history of
0.0315100668	an interaction
0.0315062367	the prevention of
0.0314646820	a profound
0.0314581973	orders of
0.0314476389	the absence
0.0314185013	to play
0.0313868258	range of
0.0313663103	the prevalence
0.0313393679	the modulation of
0.0313387174	day after
0.0312532985	mechanisms by
0.0312414987	in agreement with
0.0311674004	the protective effects of
0.0311386552	excretion of
0.0311374972	a major cause
0.0311115161	some other
0.0310749206	greater in
0.0310663106	the treatment of patients with
0.0310561900	the relationship between
0.0310467937	the discovery
0.0310170949	useful as
0.0310097421	observed by
0.0309743618	essential to
0.0309445067	the need for
0.0309025157	resistance in
0.0308882532	confirmed in
0.0308407609	frequency of
0.0308135172	the effectiveness of
0.0308017144	generation of
0.0307779373	a clear
0.0307759955	the pathogenesis
0.0307536094	2 hours
0.0307336024	an antagonist
0.0307188652	recognition of
0.0306760392	daily for
0.0306402724	isolation of
0.0306196920	the roles of
0.0306084664	truncated at
0.0305979555	value of
0.0305713133	pharmacokinetics of
0.0305616774	to interact
0.0305062367	the conversion of
0.0304476479	basis of
0.0304423814	clearance of
0.0304228711	to lead
0.0303902137	observed on
0.0303110247	a risk factor for
0.0302370891	other forms of
0.0301006909	marker of
0.0300905851	benefit in
0.0299935798	an intracellular
0.0299404972	the former
0.0298992515	mixture of
0.0298340243	performed with
0.0298163153	tested in
0.0298043321	necessary to
0.0296786201	the transport of
0.0296750736	obtained in
0.0296706987	a host
0.0296419329	the hydrolysis of
0.0296294152	kg day of
0.0296254230	binds with
0.0295587775	tested by
0.0295182987	occurs in
0.0294810266	the contribution of
0.0294662307	the reduction in
0.0294386198	noted in
0.0294140992	to exhibit
0.0293685091	expressed on
0.0293316876	the sensitivity of
0.0293079764	excess of
0.0292863124	a role
0.0292103373	specificity of
0.0290225127	as part of
0.0289982297	3 +
0.0289283623	modulators of
0.0289142292	elimination of
0.0288823850	in mice with
0.0288598549	not prevent
0.0288406086	a target for
0.0287743100	capacity of
0.0287526014	by mutations in
0.0287373390	the protective effect of
0.0287160517	that inhibition of
0.0286903074	exist in
0.0286858704	well tolerated in
0.0286183042	included in
0.0286011076	a second
0.0285987852	ability of
0.0285191764	randomized to
0.0284810638	assessed in
0.0284762008	need for
0.0284591189	a rise in
0.0284546646	this system
0.0284445908	the potential for
0.0283271358	relevance of
0.0282860886	this class of
0.0282183178	the vasculature
0.0281953123	the frequency of
0.0281674004	in rats treated with
0.0281606752	the administration of
0.0281290558	pathogenesis of
0.0281260038	a dominant
0.0280438191	if not
0.0279948341	a mouse model of
0.0279884451	achieved with
0.0279857615	as compared with
0.0279853015	5 +
0.0279514850	step in
0.0279450149	associated with reduced
0.0278571473	sites for
0.0278464865	as well as on
0.0278434338	the increase of
0.0278359616	alone or
0.0278251468	a high affinity for
0.0278118969	the biological activity of
0.0277751765	not associated with
0.0277526014	2 expression in
0.0276984235	also found
0.0276762202	seen with
0.0276634444	translocation of
0.0276576428	useful in
0.0276093725	performed by
0.0275670681	downstream of
0.0275139340	a potent and selective
0.0273831314	investigated for
0.0273192955	alone or in
0.0272755036	expressed by
0.0272457697	elevated in
0.0272075818	different between
0.0270452956	a *
0.0270383287	death in
0.0270259065	the order of
0.0270096577	but not to
0.0269990758	the pharmacokinetics of
0.0269593852	biosynthesis of
0.0269575146	the crystal
0.0269053894	the exception
0.0268862566	activity through
0.0266570998	metabolite of
0.0266474801	not result in
0.0265474100	abnormalities in
0.0265123228	disposition of
0.0265078518	in primary cultures of
0.0265072752	the case of
0.0264467494	= 20
0.0264457975	also shown
0.0264317536	case of
0.0264273584	the urinary excretion of
0.0264061945	for binding to
0.0262270055	activator of
0.0261897935	examined for
0.0261736539	time course of
0.0261150461	the development of new
0.0259676389	the identification
0.0259565215	no changes
0.0259459740	to make
0.0259023576	contrast to
0.0257909709	reported for
0.0256862683	of genes involved in
0.0256625120	the prevention and
0.0255670333	shown by
0.0255653074	sample of
0.0255263244	by treatment with
0.0254685013	an alpha
0.0254515009	with high affinity to
0.0253772116	but without
0.0253715907	this study provides
0.0253701763	the translocation of
0.0253513084	the clearance of
0.0253403898	no significant changes in
0.0253126506	treated for
0.0252930797	the magnitude of
0.0252785115	the relevance of
0.0251674004	the expression levels of
0.0251489893	the toxicity of
0.0251455636	system for
0.0251158981	the duration of
0.0250895824	determined for
0.0250547549	a crucial
0.0249363468	examined by
0.0249206600	a family of
0.0249094071	the liver of
0.0248796577	that treatment with
0.0248721741	day treatment
0.0248719383	the molecular mechanism of
0.0248706771	to become
0.0248340670	the conformation of
0.0247412455	the crystal structures of
0.0246807305	not induce
0.0245663106	the potential role of
0.0244989564	pronounced in
0.0244530311	the catalytic activity of
0.0244259439	and protein expression of
0.0244245470	to allow
0.0244094071	the brain of
0.0243701763	the content of
0.0243628084	the mode of action of
0.0243481288	the specificity of
0.0243470933	help to
0.0243241992	no evidence of
0.0242737132	the cardiovascular system
0.0242110641	a model for
0.0242081844	to interfere with
0.0241427412	a possible
0.0239671764	a mutation in
0.0239349068	third of
0.0238020187	this effect of
0.0237554819	in vitro by
0.0237082267	factor for
0.0236786201	the site of
0.0236176389	a review
0.0235875536	to act
0.0235501339	that treatment of
0.0235123228	limit of
0.0234094071	the inactivation of
0.0233813679	also associated with
0.0233340670	in vivo effects of
0.0233127688	1 microg
0.0232988010	to bind to
0.0232523165	also activated
0.0231974880	the dose of
0.0231777465	the proportion
0.0229349068	the need
0.0228295174	a component of
0.0227998833	a rapid and
0.0227640884	no differences in
0.0227035097	in patients treated with
0.0226617200	gain of
0.0226287670	use for
0.0225437956	available for
0.0225424998	6 ±
0.0225010279	novel target
0.0224492314	in complex with
0.0224294071	the effects on
0.0223906708	in individuals with
0.0223613787	the stability of
0.0223481288	the proportion of
0.0222668220	described as
0.0222538798	result of
0.0222427404	the analysis of
0.0222314436	changes at
0.0221124720	3 vs
0.0221077395	the occurrence
0.0221054971	the association between
0.0220809027	an antagonist of
0.0219744722	onset of
0.0219511680	the rank order of
0.0218732679	the percentage
0.0217464355	the time course
0.0216998100	in combination with other
0.0216882246	the balance between
0.0216604736	the area under
0.0215592914	these effects of
0.0215390365	two novel
0.0215119534	the mrna expression of
0.0214745249	4 x
0.0214168403	the interaction with
0.0213901763	and inflammation in
0.0213352813	cause of
0.0212427404	the changes in
0.0212206247	possible mechanism of
0.0212202464	value for
0.0211834672	that activation of
0.0210451926	the utility of
0.0210245432	the pharmacological properties of
0.0209874535	via inhibition of
0.0209668006	in rats by
0.0207751539	or absence of
0.0207322751	a brief
0.0206830328	the interaction between
0.0206786201	the secretion of
0.0206548740	not produce
0.0206521344	the cells with
0.0205811043	to cause
0.0205092772	the mode of
0.0204971796	no difference in
0.0204904270	but not for
0.0204245470	made by
0.0204094071	the rates of
0.0204094071	the blockade of
0.0203892201	both in vitro and
0.0203887025	a novel mechanism of
0.0203363392	during treatment with
0.0203232001	to interact with
0.0203049689	a few
0.0202256173	for up to
0.0202027555	and in vivo studies
0.0201455636	found with
0.0201298000	not due to
0.0201057371	used with
0.0201054956	the neuroprotective effect of
0.0201019767	progression of
0.0200015215	to respond
0.0200007337	the disposition of
0.0199847656	the top
0.0199787359	as well as by
0.0198431050	to act as
0.0198258899	the generation of
0.0197970193	a third
0.0197274763	also shown to
0.0197160859	the immune system
0.0197116023	made to
0.0196982115	known for
0.0194765648	an important role of
0.0194168403	the results from
0.0194135332	described for
0.0193701763	of cells with
0.0193479098	for determination of
0.0193205549	the quality of
0.0192988010	the delivery of
0.0192888304	the range of
0.0192760738	the elevation of
0.0192124701	way to
0.0192052716	the course of
0.0192005925	an ic50 of
0.0190942591	but not with
0.0190760738	the downregulation of
0.0190196016	the recognition of
0.0190027064	to show
0.0189968665	to describe
0.0189332166	the removal of
0.0189322897	a regulator of
0.0188340670	a change in
0.0188183884	in children with
0.0185638779	the severity of
0.0185150461	through activation of
0.0184662307	the uptake of
0.0184312547	the incidence of
0.0184168403	the characterization of
0.0183901763	and progression of
0.0183787355	made in
0.0183701763	the detection of
0.0183613787	a comparison of
0.0183613787	the maintenance of
0.0183215407	an ic50
0.0183059883	and then
0.0182185216	a function of
0.0181459488	the development of novel
0.0180456982	the antitumor activity of
0.0180384695	the participation of
0.0180357630	the results show
0.0180178180	the suppression of
0.0180007337	the isolation of
0.0179332166	the measurement of
0.0178939859	the hippocampus of
0.0178480239	not required for
0.0177998833	the investigation of
0.0177811470	by pretreatment with
0.0177005766	in association with
0.0176786201	the distribution of
0.0176218867	interest in
0.0175334672	as well as in
0.0174788969	found for
0.0174590620	of tcdd on
0.0174380214	use as
0.0174331264	or in combination with
0.0174094071	the upregulation of
0.0173671536	the response to
0.0173489564	an effect on
0.0172289457	a source of
0.0171613787	the oxidation of
0.0170760738	and secretion of
0.0170571858	all other
0.0170196016	the nature of
0.0169487870	no significant differences in
0.0169332166	and maintenance of
0.0169312431	in adults with
0.0169139859	and pharmacokinetics of
0.0168255488	possible to
0.0168090549	the degradation of
0.0167461900	both in vitro and in
0.0167415423	not required
0.0167039336	the interactions between
0.0166961417	the first report of
0.0166786201	the actions of
0.0166786201	the determination of
0.0166521344	the concentrations of
0.0165961417	an accumulation of
0.0165739999	described in
0.0164978137	the difference between
0.0164591352	or even
0.0163215407	a mixture
0.0161974880	the stimulation of
0.0161916974	indicated by
0.0161786201	a loss of
0.0161219383	at concentrations of
0.0160760738	the ability to
0.0160368430	the incorporation of
0.0160061322	the ratio of
0.0159406498	the evaluation of
0.0159332166	the application of
0.0159139859	the characteristics of
0.0158114640	the efficacy and safety of
0.0158090549	the difference in
0.0157998833	the enhancement of
0.0156912099	the consequences of
0.0156690397	a substrate for
0.0156440784	mainly by
0.0155827583	and biological evaluation of
0.0155100457	mild to
0.0155007337	the initiation of
0.0154356894	associated to
0.0154094071	the understanding of
0.0153113365	and perhaps
0.0152451861	course of
0.0152289457	in men with
0.0152185216	the expressions of
0.0152035097	a role of
0.0151811234	to near
0.0148939859	the first to
0.0148939859	and toxicity of
0.0148340670	the significance of
0.0147265648	an interaction with
0.0146912099	and duration of
0.0146912099	the prevalence of
0.0146912099	the selection of
0.0146877379	2 adrenergic
0.0146877379	an activator
0.0146521344	the assessment of
0.0146489564	the efficiency of
0.0146294298	to account for
0.0145100457	approaches to
0.0143671536	the properties of
0.0143489564	the biosynthesis of
0.0142289457	with selectivity for
0.0141532166	the form of
0.0141489564	the recruitment of
0.0139401600	by binding to
0.0138950523	more potent in
0.0137804842	made of
0.0136912099	the diagnosis of
0.0136489564	the basis for
0.0134773192	a concentration of
0.0134412099	the active metabolite of
0.0133188010	the overexpression of
0.0130179751	a reduction of
0.0129194855	indicated for
0.0127289457	the results indicated
0.0097023656	not well
0.0086162534	given to
